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Abstract 
Fragment synthesis: pharmacophore and diversity-oriented approaches 
By Andrew James Peter North 
This thesis explores two approaches to fragment-based drug discovery. First, protein target 
CK2 was chosen due to its importance in the cancer phenotype. A literature fragment, 
NMR154L, proved to be a promising compound for fragment development, due to its binding 
at the interface site of the protein rather than the highly conserved ATP pocket. Analogues 
were synthesised of this fragment leading to a candidate with a better IC50. Additionally, 
computer modelling of the interface site suggested that a series of spirocyclic compounds 
would inhibit this protein. These were synthesised and tested in vitro. Results from these tests 
were analysed and informed the synthesis of new inhibitors with the aid of crystal structures 
and computer modelling. 
Secondly, to address the lack of spirocyclic scaffolds in fragment screening libraries a number 
of diversity-orientated synthetic campaigns were undertaken. The first of these utilised 
glycine as starting material. Two terminal alkenes were installed. The alkenes were linked and 
the amino and acidic residues cyclised. This allowed for the formation of a diverse range of 
spirocyclic scaffolds from this one starting material.  
Having established chemistry for linking amino and acidic residues a campaign with 
dehydroalanine was under taken. This would allow for the installation of the second ring by 
pericyclic chemistry as well as using chemistry previously established. 
This pericyclic chemistry was also applied to synthesising spirocycles from rings with 
exocyclic double bonds. These being readily installed from Wittig chemistry, this allowed 
utilisation of starting materials which contained a cyclic ketone. Of these azetidinone was a 
good candidate due to the fact it was a commercially available building block and allowed 
access to spirocycles containing a 4-membered ring; an underrepresented ring size. 
Finally, computation analysis was carried out on the library to assess it diversity and any 
potential biological targets which these fragments may inhibit. 
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Chapter 1 
1. Introduction
1.1. Drug Discovery 
1.1.1. The drug discovery pipeline 
Of marketable products, pharmaceuticals are one of the most expensive to produce, time 
consuming to make, and heavily regulated. There is a huge burden on the drug discovery 
process to ensure that the drugs which are brought to market are safe and effective.1 To this 
end, the drug discovery process is broken down into multiple stages: a pre-clinical stage, 
which sees the creation of biological agents (small molecules, proteins, antibodies, etc.) to 
affect a medical condition, and a clinical stage where these agents are tested in man to assess 
their safety and efficacy (Figure 1.1). 
 
Figure 1.1 A graphic representing the drug discovery process separating out both the pre-clinical and clinical 
stages of the process.  
Pre-clinical stage: 
Unmet need: The identification of a disease for which there is little or no treatment or it is 
believed the treatment could be improved. 
Target identification and validation: Research is carried out to identify which macromolecules 
are involved in a particular disease process such that their modulation will cause the desired 
therapeutic response.  For validation, different strategies involving a wide variety of areas can 
be applied such as genetics, cellular or in vivo and in vitro modelling.2  
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Hit identification: A range of compound screening assays are used to identify compounds with 
the desired activity. This can cover a wide range of techniques from the modification of 
natural products with known biological effects, to screening of compound libraries to discover 
novel biological antagonists (this usually takes the form of high throughput screening or 
fragment-based drug discover, discussed later on in this introduction). 
Hit development and lead optimisation: Intensive Structure-Activity Relationship (SAR) studies 
are conducted around each core structure. Potency and selectivity are assessed as well as 
detailed profiling of physico-chemical and in vitro absorption, distribution, metabolism, and 
excretion (ADME) properties.3 
Clinical stage: 
Pre-clinical trials: The clinical candidate is first tested in animals to collect information 
pertinent to the safety of the compound. The species chosen will have the most similar traits 
to humans in the part of the body which the drug is affecting. 
Phase I, II & III: During these stages, the clinical candidate is tested in humans, with testing 
split into three phases. Phase I is the ‘first-in-man’ study. Usually, healthy volunteers are given 
the compound in increasing doses to assess the appropriate dose-range before adverse side-
effects are seen. Phase II is the first time the compound is tested in humans with the disease, 
and as such provides the first proof-of-concept, demonstrating whether the desired clinical 
outcome has been achieved, whilst also continuing to monitor safety and side effects. Phase 
III tests the drug therapeutic effect on a larger cohort of patients over a significantly longer 
time frame, often years.4 
Drug approval: The gathered data is presented to a country’s licencing authority which 
determines whether the compound can be marketed and sold as a drug for the treatment of a 
specified illness. 
Market: This time is also known as Phase IV as the long-term health impacts of the drug are 
continually monitored and assessed. A drug can be withdrawn from the market by the 
licencing authority if there are questions about its safety. 
This process is protracted and costly. From a compound being identified as a potential 
therapeutic for a disease (hit identification in Figure 1.1) to a marketable drug, 10–15 years 
usually elapse.5 Additionally, while it is difficult to provide a reliable estimate of the costs due 
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to differences in accounting practices and industry confidentiality,6 recent research has put 
the cost of bringing a drug through the discovery pipeline at $1.4 billion.7 
This astronomical figure can be mostly ascribed to the expense of carrying out Phase I, II, and 
III clinical trials.8,9 The clinical phase alone can cost researchers in excess of $100 million.5 
Failed drugs also contribute to the large cost of drug discovery, with no possibility of 
recouping the cost of development upon failure.10 Studies have suggested that fewer than one 
in five drugs progress from Phase II to Phase III, and those in Phase III only have a 50% 
probability of making it to the market.11–13 Reasons for these failures are mostly attributed to 
the lack of safety and lack of efficacy of clinical candidates. About a third of drugs fail at Phase 
I for lack of safety and Phase II and III failure rates are 42% and 54% respectively for lack of 
efficacy.14 
Therefore, there is a huge pressure on licensed and marketed pharmaceuticals to recoup the 
development costs of both successful and failed drugs. This is difficult for several reasons. 
The purchasers of the drugs, in most cases national governments, insurance companies, and 
clinics, have scarce resources.15 On top of this is the limited life span of patents which give the 
producer a monopoly on the exploitation of their invention. To prohibit competitors from 
operating in the same areas, most compounds are patented early in the drug discovery 
pipeline (usually around the ‘hit-to-lead’ stage). However, given the life span of a patent is 
typically 20 years,16 this limits the length of time for which the patent remains in place once 
the compound reaches the market. This significantly diminishes the time the producer has to 
recoup the approximately $1 billion expenditure from the drug’s development. Once the 
patent expires, generic pharmaceutical companies can produce the same compound at a 
fraction of the price as they do not have to cover the large research and development costs.  
Consequently, pharmaceutical companies, and researchers more generally, are searching for 
ways to cut down on the time and money in drug development.  
1.1.2. Attrition rates and new chemical entities 
The high attrition rates in the drug discovery process are an obvious place for researchers to 
look for a way to cut costs. If the compounds entering the clinic are more likely to succeed, 
costly and unsuccessful clinical trials can be avoided.  
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Despite advances in research methods and technology,17 attrition rates across drug discovery 
have remained high,11–14,18 and as a result, research has been carried out looking to link 
chemical properties with the success (or otherwise) of potential lead compounds in the clinic. 
One of the first and most famous of these studies was by Lipinski et al. who performed a 
detailed study into the physico-chemical properties of orally bioavailable drugs. Their 
research found that:  
[P]oor absorption or permeation are more likely when: There are more than 5 H-
bond donors (expressed as the sum of OHs and NHs); The MWT is over 500; The 
Log P is over 5 (or MLogP is over 4.15); There are more than 10 H-bond acceptors 
(expressed as the sum of Ns and Os) Compound classes that are substrates for 
biological transporters are exceptions to the rule.19 
This was the first statement of Lipinski’s ‘Rule of Five’ (RO5), and it has since developed as a 
ubiquitous rule-of-thumb in drug development and discovery.20 Additionally, others have 
added to the list of physico-chemical properties which should be considered when assessing 
the likely oral bioavailability of a compound. 
The number of rotatable bonds and the polar surface area (the surface area of all the polar 
atoms) were found to also be strong indicators of the oral bioavailability in rats. A rotatable 
bond count of less than 10 and a polar surface area of less than 140 Å2 were more reliable than 
the molecular weight cut-off of 500 gmol–1 as a predictor of this property.21 Consequently, 
these two metrics have been added to the list of properties considered within the Rule of Five 
(Table 1.1).22 
Table 1.1 Lipinski’s Rule of Five. 
Property Rule of Five 
Molecular Weight (gmol–1) < 500 
clogP ≤ 5 
Polar Surface Area (Å2) ≤ 140 
H-Bond Acceptors ≤ 10 
H-Bond Donors ≤ 5 
Rotatable Bond Count ≤ 10 
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The advantage of physico-chemical descriptors as a metric for assessing the likely attrition of 
a compound is that they are easily measurable before synthesis of the compound has even 
taken place. Thus, chemists can plan and direct their effort to maximise the chance of 
compounds succeeding in the clinic. In addition, physico-chemical properties are easy to 
analyse en masse from drugs and failed clinical candidates to produce helpful predictive data. 
Analysis of compounds at Pfizer found that compounds with a clogP < 3 and a PSA >75 Å2 
were 2.5 times less likely to be toxic at 10 μM.23 This is known as the ‘3/75 rule’. An additional 
Pfizer study has suggested that a compound with a predicted human efficacious total plasma 
concentration of < 250 nM was more likely to pass toxicology screening.24 
One interesting result from meta-analysis of attrition in four major pharmaceutical companies 
is that molecules with a high fraction of sp3 (Fsp3) atoms are more likely to become marketed 
drugs.25,26 This tallies with a corresponding decrease in the aromatic ring count also giving a 
compound greater success in making it to market.27 
Indeed, one failing of the Rule of Five is that, although it adequately acknowledges the 
physico-chemical characteristics of a molecule, it makes no reference to its spatial qualities. In 
this way a set of compounds can obey the RO5 with a diverse set of data, but all have a very 
similar shape. Thus, the chance that they are going to probe a large area of chemical space is 
small. Research by Lovering et al. agrees with the above observation. They showed there was 
a statistically significant increase in the Fsp3 from lead candidates entering the clinic to the 
marketed drug coming out (0.36 to 0.47). In addition, the number of compounds with 
stereocentres increased from 53% entering the clinic to 64% coming out. They hypothesise that 
these 3D molecules are more adapted to the inherently 3D shape of biological targets as well 
as conveying beneficial physical properties like increased solubility and decreased melting 
point, which have been shown to aid oral bioavailability.25,28,29 
Physico-chemical descriptors are only one factor which determines a drug’s success in the 
clinic. In fact, the early drug discovery process is similarly afflicted with challenges. 
1.2. Established Methods of Drug Discovery 
1.2.1. High Throughput Screening 
One of the most common and powerful methods in drug discovery has been High 
Throughput Screening (HTS).30–32 This method aimed to combine the vast improvement in 
biological assay technologies over the past 20 years33,34 with expansive compound libraries 
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accrued by the pharmaceutical industry. Robots were designed and programmed to conduct 
millions of experiments between these libraries and biological assays in microplates of 
thousands of wells. The results could be quickly analysed by heat maps of the wells (Figure 
1.2). The compounds which showed promise were modified in a combinatorial-type approach 
to improve their properties and selectivity. When these were believed to be optimal, they 
would progress to clinical trials. 
 
Figure 1.2 Diagram depicting an HTS method of testing a compound library against a target and assessing the 
outcome of the experiment. (Figure ref 35)  
The driving force for industry to investigate HTS was the ‘brute force’ and ‘enhanced 
serendipity’ of this method. Many targets have unknown structures or ligands making a 
‘rational’ design difficult. However, the chances that at least one molecule of the millions 
tested would bind to a given target was presumed reasonably high. Thus pharmaceutical 
companies could put their compound collection to new uses by seeing if the chemicals would 
bind to targets that would not have been predicted.31 
This technique has not been unsuccessful. In the period 1991–2008, of 58 drugs for which the 
starting compound was known, 19 owe their existence to an HTS campaign (e.g. Figure 
1.3).30,36  
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Figure 1.3 Example of a hit from HTS, UK-107,543, leading to a marketed drug, Maraviroc, used in the 
treatment of HIV. The red scaffold in Maraviroc shows the features maintained from the initial HTS hit.37 1 2 
However, HTS has faced criticism for its failure to produce more drugs from such an 
unprecedented number of experiments.30,31,38,39  This has been put down to weakness in the 
two most important factors of an HTS experiment: the nature of the compound library and 
the quality of the biological assays used. 
Macarron et al. attributed the problems with the biological aspect of HTS to ‘poorly validated 
targets,… highly artificial and non-physiological assay systems,…a severe lack of appropriate 
animal models, [and] unpredictable toxicities.’30 From a chemistry perspective, libraries 
consisted mostly of large, impure compounds.40 Even when the emphasis changed to single, 
pure-compound screening libraries, a distinct lack chemical diversity hampered the degree of 
chemical space which was being probed.30,31 
One of the biggest wake-up calls for the effectiveness of HTS was the GlaxoSmithKline 7-year 
antibiotic discovery programme. In the face of the growing threat of antibiotic resistance,41 
SmithKline Beecham (SB) and subsequently GlaxoSmithKline (GSK) embarked on a program 
to test their entire compound collection for novel antibiotic activity. In total, 70 HTS were 
carried out using over 500,000 compounds. Only 16 hits were identified and of these only 5 
became leads. Synthetic modification of these leads failed to generate any compounds to meet 
the desired criteria. This was incredibly disappointing considering the time and money (>$70 
million) spent on the project. Analysis of the program demonstrated that the lack of chemical 
diversity in the compound collection inhibited the power of the screen, with many of the 
molecules within the same or similar areas of chemical space.  
GSK were not alone in their failure to detect new antimicrobials from HTS. Between 1996 and 
2004 more than 125 screens were carried out, none of which resulted in drug candidates.42 
HTS, although a powerful tool in drug discovery, still relies on serendipity and one of the best 
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ways to increase the chances of success is to screen as diverse a range of compounds as 
possible. An industry focus on combinatorial synthesis is partly to blame in this regard.43 
1.2.2. Target-based drug discovery 
Another prominent paradigm in drug discovery since the 90s has been target based drug 
discovery (TBDD).17,44,45 It was hypothesised that with sufficient information regarding a 
disease and its mode of action, databases could be searched or drugs could be rationally 
designed which block its mode of action and therefore treat the disease.17,46 
Although superficially very rational, several real-world limitations have shown this method 
to be less successful than first hoped. This treatment of biological systems as simple flowcharts 
may aid understanding in some respects, however much of the complex reality is missed. 
Ignoring these secondary effects at an early stage in the drug discovery process can lead to 
off-target activity further down the line and hence attrition.45 
Additionally, understanding of underlying biological systems is no guarantee of success or 
failure in drug discovery. Effective drugs have reached the market with little understanding 
about their mode of action (e.g. clozapine);17 for others, understanding has been gained during 
development (e.g. lyrica).47 Conversely, despite some understanding of their mode of action,  
many drugs have failed to reach or pass clinical trials (e.g. beta-amyloid targeting in the 
treatment for Alzheimer’s disease).17 Overemphasis on this bottom-up approach has not lead 
to a breakthrough in drug discovery nor a lowering in attrition.17,45  
1.3. Fragment-based drug discovery 
1.3.1. Chemical space 
The main challenge facing medicinal chemists is the identification of chemical entities as 
potential hits and developing those compounds to form the best clinical candidates. This is a 
vast and non-trivial problem, a contributing factor of which is the extent of chemical space 
(the total possible number of molecules), which is so large as to be infinite for practical 
purposes. 
Given that medicinal chemists focus on organic ‘drug-like’ molecules, the size of chemical 
space can be limited and therefore estimated. Most commonly, medicinally-relevant chemical 
space is restricted to thirty non-H atoms chosen from the most common elements found in 
organic chemistry (C, N, O, S) which puts the estimate at 1063 molecules.48 
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It is not possible to synthesise even a meaningful percentage of this space to assess their 
pharmaceutical potential. Therefore, a strategy must be developed to effectively probe those 
areas of chemical space which are most likely to yield useful drugs. 
Chemical space increases exponentially as the number of atoms in the molecule increases; 
therefore, decreasing the complexity of molecules reduces chemical space to a more 
manageable size. Computational research into the enumeration of smaller molecules (up to 
seventeen atoms of C, N, O, S, and halogens) has found the chemical space much more 
manageable at 166.4 billion molecules.49 
Therefore, restricting synthesis and screening to smaller molecules allows a greater area of 
chemical space to be explored more efficiently. These small molecules could be regarded as 
‘fragments’ of drugs which could be combined to form a potent lead ‘drug-like’ molecule.50 
1.3.2. What is fragment based drug discovery? 
Fragment based drug discovery (FBDD)a is a technique used to aid the discovery of potential 
drugs. It capitalises on restricting screening libraries to fragments (discussed in section 1.3.3) 
and screening these fragments against biological targets.51 The result of these screens is both 
physical measurements of how well the fragment inhibits the protein (usually expressed as 
the half maximal inhibitory concentration, IC50 or dissociation constant, Kd) and crystal 
structures to assess the structure-activity relationship (SAR).52 From these results, fragments 
are modified, grown, and linked to produce a more drug-like molecule (Figure 1.4).53 These 
fragment modifications use the best available interactions with the protein as determined by 
SAR data, and the success of the modifications are measured by falling IC50s.  
                                                     
a The term fragment-based lead discovery (FBLD) has also been used for the same process. This is 
because the output of this process is a lead compound for inhibiting a specific biological target. The 
final ‘drug’ being discovered after lengthy optimisation to a pre-clinical candidate, followed by clinical 
trials.52 However, because this technique is used primarily as an aid to the discovery of new drugs, the 
term FBDD is used in this thesis. 
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Figure 1.4 A cartoon representation of the fragment-based drug discovery process.a) A library of fragments 
is screened against a biological target or targets (usually a protein). b) Data is obtained from the screen of 
those compounds which bind. This includes physical measurement of the Kd and IC50, binding modes and 
structure-activity relationships. c) Fragments are linked, grown, and merged to create larger molecules which 
should have superior biological activity and improved substrate specificity. These are then screened against 
the target. d) A lead compound is found and can be further optimised or taken through to the next stages of 
the drug discovery process.  
As summarised in Figure 1.4, FBDD follows a rational framework. Firstly, a fragment library 
is assembled or designed (this process will be discussed in more detail in section 1.3.3). This 
library, typically in the region of 102–103 molecules, is then screened against a biological target. 
Unlike HTS, only a weak binding affinity c. 0.1–10 mM would be expected to be observed due 
to the small size of the fragments; however, they are found to produce better quality hits and 
fewer false-positive aggregations (organic molecules forming colloids in buffer solution which 
denature proteins and therefore causes non-specific inhibition).53,54 A variety of techniques 
can be employed to assess the nature and quality of any binding found during a screen: NMR 
spectroscopy55 and Mass Spectroscopy56,57 are quick qualitative methods for gaging whether 
there is binding between a protein and a fragment. Fluorescence Polarisation (FP)58 assays and 
Isothermal titration calorimetry (ITC)59 are employed to gain important quantitative data 
about how well a fragment binds (usually as an IC50 or Kd respectively). Finally, X-ray 
crystallography gives vital structural information about where on the target the fragment 
binds and what non-covalent interaction(s) it utilises.60 
Using the data gained in the screen, the most promising fragment hits are elaborated using 
structural data obtained from an X-ray structure. Fragment elaboration usually occurs by 
three methods: linking, growing, and merging. Linking is most often employed when two 
fragments have bound to a target at two separate sites. These fragments are then linked by a 
tether to produce a lead-like molecule with enhanced physico-chemical properties. Although 
this technique has been employed successfully in the past,61,62 it is the most difficult strategy 
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within fragment elaboration due to the difficulty in optimising the length and rigidity of the 
tether and the limited scope for further elaboration.53,63 
Fragment merging is most readily employed where two or more fragments have been found 
to occupy the same or proximal space, but structural analysis has found they interrogate 
different aspects of the target. In this case, structural features of the fragments are merged to 
give a new lead-like molecule which hopefully utilises all of the previous interactions.64 This 
has been employed successfully in several cases of drug discovery.65–67 
Finally, fragment growing is used to produce leads. This is the most common strategy and is 
used when only one fragment is found to have bound to a target. Using the crystal structure 
as a guide the fragment is grown along several vectors to explore additional interactions with 
the target. This gives rise to an iterative cycle where a number of compounds are screened and 
the resulting crystal structures used to direct further development and elaboration (Figure 
1.5).53,68,69 
 
Figure 1.5 Diagram visualising the three strategies of fragment elaboration in hit-to-lead optimisation in 
fragment-based drug discovery.  
The first example of a systematic fragment-based approach to protein inhibition was reported 
in 1996 by Shuker et al. They had discovered a method of determining the structure-activity 
relationship (SAR) between a ligand and a protein using NMR. A low molecular weight 
library was screened against a protein, FKBP, to establish which molecules, if any, would bind. 
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These molecules were then modified to increase their binding affinity. Finally, they were 
linked to give a molecule which bound to FKBP with a Kd of 19 nM (Figure 1.6).62 
 
Figure 1.6 Summary of Shuker’s work.A fragment library was screened against protein FKBP. Two sites of the 
protein were found where molecules bound. The molecules with the lowest dissociation constant (Kd) for 
each site were linked at various points and using a variety of tethers. This resulted in the discovery of a new 
compound which bound to FKBP with a Kd of 19 nM. 3 4 5  
FBDD aids drug discovery in a number of ways. Firstly, it allows the thermodynamics of the 
ligand-protein interaction to be broken down in several steps. The free energy of a ligand-
protein interaction is determined by the Gibbs free energy equation (1.1): 
∆G = ∆H − T∆S (1.1) 
The dissociation constant (Kd) is related to the Gibbs free energy by the isotherm equation 
(1.2): 
∆G = RTln(Kd) (1.2) 
Thus, a small Kd, and hence large negative ΔG, will be determined by how exothermically the 
ligand binds to the protein (large negative ΔH) and how much entropy is lost upon binding 
(small positive ΔS). 
Applying these principles to FBDD shows how growing, linking, and merging fragments can 
yield drug candidates with low Kds.50  
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Figure 1.7 A representation of the enthalpy and entropy of molecules A, B, and AB binding to a target.  
When two fragments, A and B, bind to a protein, their Kds are determined independently of 
one another and are a function of their respective ΔH and ΔS (Figure 1.7). However, when A 
and B are combined the enthalpy of their binding will be approximately equal to the sum of 
the enthalpy of the binding of A and B respectively, as they are both utilising the same 
interactions to bind to the protein (1.3). 
∆HAB ≈ ∆HA + ∆HB (1.3) 
Yet, the entropy penalty of AB is much less than the entropy penalty of A and B binding 
separately. Although there will be a greater penalty for the more complex molecule in the 
form of restriction on rotating and bending modes, these pale in significance compared to the 
reduction in entropy required for two separate entities to leave solution and bind with a 
protein. Thus: 
∆SAB ≈ ∆SA ≈ ∆SB ≪ ∆SA + ∆SB (1.4) 
Therefore, when combining fragments to make a large drug-like molecule, the favourable 
enthalpic terms combine but the unfavourable entropic terms stay approximately the same. 
This is extremely powerful because, as detailed in equation 1.2, ΔG and Kd are related 
exponentially. Every time ΔG doubles, Kd is squared. This gives FBDD an advantage over 
HTS of large molecules which require nanomolar binding to be considered good enough for 
a lead, whereas fragments only need to exhibit a weaker millimolar binding as fragment 
development can yield high binding drugs. 
Secondly, FBDD rigorously employs X-ray crystallography as well as several other techniques 
to ensure that the structure-activity relationships (SARs) between fragments and the target 
are understood. This gives FBDD fragment elaboration a rational aspect to the design of leads 
molecules, which can give greater success in the clinic. 
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Thirdly, fragments are less ‘complex’ than larger molecules. Complexity is desirable in drug 
candidates and medicines as it conveys selectivity to the target in question and minimises off-
target activity which is likely to lead to increased toxicity. However, to probe biologically 
active chemical space it is best to have simple molecules which probe only certain interactions; 
an overly complex molecule is more likely to possess groups which inhibit binding (Figure 
1.8). Therefore, it is possible that fragments are more promiscuous than lead-like molecules. 
However, the process of fragment elaboration should increase selectivity. 
 
Figure 1.8 A complex molecule versus simple fragments binding on a protein.The complex molecule, although 
it contains groups which would interact with the target, is prohibited from doing so because of its complexity. 
The fragments, containing only one or two functional groups are perfectly suited to probe the target’s biologic 
space. (Image taken from ref 53)  
This proposition of less complexity leading to more biological hits has been validated 
statistically.70 Hann et al. showed that the probability of a molecule matching a target 
decreases exponentially as complexity increases (Figure 1.9). 
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Figure 1.9 A graph showing the probability of a ligand matching a biological target compared with its 
complexity. The complexity was measured computationally from the length and pattern of the molecule’s 
features. (Image adapted from ref 70)  
1.3.3. Identifying fragments 
Limiting chemical space to fragments can only become a reality when there is an appropriate 
definition to direct synthetic research. Lipinski’s “Rule of Five” (RO5) (see section 1.1.2) was 
already well-established for highlighting the typical properties of orally bioavailable drug 
candidates when FBDD was first established. Since then, a number of studies have resulted in 
the development of similar “rules” to apply to ideal fragments. 
Inspired by the RO5, Congreve et al. analysed the fragments used in FBDD and discovered 
that a ‘Rule of Three’ (RO3) might be a useful tool in guiding the construction of fragment 
libraries. Based on the criteria used by the RO5, they suggested that: 
[M]olecular weight is <300, the number of hydrogen bond donors is ≤3, the 
number of hydrogen bond acceptors is ≤3 and ClogP is ≤3. In addition, the results 
suggested NROT [number of rotatable bonds] (≤3) and PSA (≤60) might also be 
useful criteria for fragment selection.71 
More recently, pharmaceutical company Astex published its internal guide for fragment 
synthesis. These have further restrictions compared to the RO3 and focus on other details 
regarding the property of fragments, including spatial and synthetic properties which are an 
important addition to the field of fragment synthesis.72 Astex’s rules are compared to the RO5 
and RO3 in Table 1.2: 
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Table 1.2 Comparison of the RO5 with the RO3 and Astex’s in-house fragment rules. 
Property Rule of Five19 Rule of Three71 Astex’s Rules72 
Molecular Weight (gmol–1) < 500 < 300 140–230 
clogP ≤ 5 ≤ 3 0.0–2.0 
Polar Surface Area (Å2) ≤ 140 ≤ 60 — 
H-Bond Acceptors ≤ 10 ≤ 3 — 
H-Bond Donors ≤ 5 ≤ 3 — 
Rotatable Bond Count ≤ 10 ≤ 3 0–3 
 
Astex also highlight additional properties which would be beneficial for fragments:72 
• Diverse polar groups for protein binding 
• Multiple elaboration vectors for 3D growth 
• Aqueous solubility, stability, and solution and avoidance of highly reactive groups or 
groups which cause aggregation 
• Easy to synthesise 50–100 mg in ≤ 4 steps from commercial starting materials 
• A variety of 3D scaffolds 
• 0–2 chiral centres 
All these suggestions should be taken as good rules of thumb to aid in the design and 
functionality of fragment libraries. 
1.3.4. Success of FBDD 
Clearly the FBDD process has some notable advantages over previous drug discovery 
paradigms including HTS and TBDD.  
More efficient sampling of chemical space: both HTS and FBDD rely on serendipity to discover 
novel chemical leads. However, the chances of this happening are slim unless the HTS 
screening libraries sample an appropriately high volume of chemical space. Given HTS 
chemical space, this is likely to be in the order of 1063 molecules. Sampling a millionth of this 
space would require the synthesis and screening of 1057 molecules; an impossible task. 
However, fragment space is considerably smaller at around 1011 molecules. A millionth of this 
space is only 100,000 molecules; a very achievable target. In addition, advances in 
computational technology mean that in silico screening can be readily employed to aid in the 
synthesis of fragments. TBDD does not rely on serendipity to find leads. However, over- 
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reliance on focusing on one biological system could see molecules which may inhibit other 
systems not being utilised to their full advantage. 
Greater chances of a compound binding: Another advantage which the use of fragments gives 
FBDD is the molecules are less complex with fewer skeletal appendages. This allows 
functional groups to more efficiently probe biological space, with a lower chance of steric or 
electron clash related to more complex molecules. 
Hit-to-lead optimisation improved: Fragments would ideally consist of multiple vectors of 
elaboration. This means that chemists could easily modify fragments with a hit in most spatial 
directions, hopefully allowing for almost any hit to be improved. The late stage nature of HTS 
libraries mean the number of vectors is less and elaboration would be a more laborious task. 
FBDD has been successful over the past twenty years of drug discovery. Erlanson et al. 
identified 32 compounds in clinical trials which are known to have been identified from 
FBDD. Figure 1.10 shows two marketed drugs derived from FBDD.73 Due to this success, this 
thesis focuses on the synthesis of fragments for potential use in drug discovery.  
 
Figure 1.10 Vemurafenib and Venetoclax with the initial fragment hits highlighted.67
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Chapter 2 
2.  Fragment inhibitors of CK2 
 
2.1. Introduction 
2.1.1. FBDD in targeting PPIs 
Biological interactions are largely governed by the interactions between proteins, called 
protein-protein interactions (PPIs). They modulate many key pathways in health and disease 
with an estimated 400,000 biological processes regulated by PPIs. Thus, they are an important 
target in drug discovery.74,75 However, the often large and shallow nature of the PPI pockets 
has given them the reputation of being ‘undruggable’.76–78 Recently, work has begun to 
overcome this challenge using small molecule approaches to drug discovery which has led to 
PPI being examined as a potential target for discovery programmes.79  
PPI inhibitors can be broadly sub-divided into two categories: orthosteric inhibitors, which 
block the interaction site between the two proteins, and allosteric inhibitors, which bind to a 
different site on the protein but in doing so change the shape of the protein binding site, thus 
inhibiting the PPI (Figure 2.1). 
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Figure 2.1 Diagram showing the mode of action for ortho- and allosteric inhibitors of PPIs.(Image take from 
ref 75).  
Whilst traditional screening methods with larger molecules often fail to sufficiently bind these 
shallow pockets, the smaller nature of fragments allows them to probe these sites. This 
provides a way of identifying initial hits to kickstart a PPI inhibitor discovery process. Indeed, 
FBDD has been successful in discovering a new anticancer drug: Navitoclax was discovered 
from a FBDD campaign and offers potent treatment of small-cell lung cancer and chronic 
lymphocytic leukæmia.80 Two fragments, a biaryl and a tetrahydronaphthalene, were 
discovered that bound in the PPI site and a campaign of linking and growing produced 
Navitoclax,80,81 which entered the clinic in 2009 and was licenced in 2017.82,83 Due to the highly 
specific nature of PPI sites, this treatment lacked the off-target effects of the previous 
treatment, Obatoclax, and reduced negative side-effects (Figure 2.2).84 
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Figure 2.2 The initial fragment hits which led to the discovery of Navitoclax.8910  
With the role FBDD can play in the discovery of PPI inhibitors in mind, the rest of this section 
will focus on a specific PPI interaction and how its inhibition could produce potent anti-cancer 
therapies. 
2.1.2. Casein Kinase 2 
Protein kinases were discovered serendipitously in 1954 when Kennedy and Burnett reported 
an enzyme catalysing the transfer of a phosphate from ATP to a protein.85 Although the 
physiological significance of the discovery was not initially realised, the following six decades 
brought considerable knowledge and understanding to the field of protein kinases. 
Since then, discoveries have demonstrated the importance of Casein Kinase 2 (CK2) in human 
biology. Recent research on a database of almost 11,000 naturally-occurring phosphorylated 
sites revealed that the unique acidic marker that identifies CK2 has been found on 2275 (>20%) 
of them.86 
The pivotal role CK2 plays in controlling many other kinases and cell death has led to some 
calling CK2 the ‘master kinase’. Indeed, the vast number of targets of CK2 signifies that almost 
all cellular activity is regulated in some way by CK2. The most notable of these include: stress 
stimulus mediation, gene expression regulation, protein synthesis and degradation, 
regulation of the circadian rhythm, viral infection, and counteracting apoptosis.87 
2.1.3. Structure and activity of CK2 
CK2 is a tetramer consisting of two of CK2α and CK2α’ subunits and two CK2β subunits. 
Thorough crystallographic and structural analysis has been carried out on CK2. This has 
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shown that the α subunit is the catalytic subunit, the β subunit is the regulator subunit, and 
these form the tetrameric holoenzyme of α2β2, αα’β2, or α’2β2 (Figure 2.3). 
 
Figure 2.3 CK2 protein with the structure α2β2 (PDB: 1JWH, Image from ref 88).  
The three heterotetrameric forms of CK2 have displayed no differences in activity from one 
another. Analysis of the CK2α and CK2α’ has shown that CK2α’ lacks the C-terminal amino 
acids 330–391. In addition, comparison of the 1–329 sequence of CK2α and CK2α’ has shown 
an 86% homology. However, they exhibit the same activity.89 
CK2 is involved in many key cellular processes. Yet, there are two signalling pathways of 
particular interest especially if focus is concentrated on CK2 tumorogenisis. These are the Wnt 
pathway and the NF-B pathway, two signal transduction pathways that regulate important 
cell development events and play a role in some cancers.90 
The CK2α subunit is always in the active conformation and possesses the key ATP binding 
site which is responsible for the biological activity. The CK2β subunit is a regulatory subunit. 
The activity of this subunit is dependent on the substrate. CK2β is also found to increase the 
proteolytic and thermodynamic stability of CK2α as well as providing sites for substrates to 
dock.91 
2.1.4. CK2 and Cancer 
As a protein kinase, CK2 phosphorylates a great many substrates involved in cell growth.89 
Being a ubiquitous protein kinase, CK2 is overexpressed in a large range of cancers.92 
Importantly, it is not mutations of CK2 which are carcinogenic, but unnaturally high 
quantities of CK2 and its associated activity have been observed in many tumours. In 
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comparison with normal cells, which sees CK2 diffused in the various cellular compartments, 
tumours have high levels of CK2 around the nucleus and in neoplasia and CK2 is elevated 
beyond what is expected for normal cells.93 CK2, as well as being involved in cell proliferation 
and growth, also suppresses apoptosis, linking CK2 to the cancer phenotype.94 
CK2 is up-regulated during cell proliferation however it readily returns to normal after 
proliferation has finished. Yet in cancerous cells it finds homoeostasis at this level and remains 
high.95 In addition, studies on prostate cancer—forms which are both androgen sensitive and 
androgen independent—showed CK2 to be functional irrespective of the growth factor.96 
Having identified CK2 as an important target, is it a viable target for cancer therapy? One 
reason why CK2 inhibition may be a particularly effective form of treatment is the pivotal and 
indispensable role it plays in the cell. If inhibited below the high critical threshold, the 
cancerous cell would no longer be malignant as there are no alternative signalling pathways, 
which could by-pass the need for CK2. Due to the role of CK2 in cell growth, proliferation, 
and apoptosis, its down regulation could be particularly catastrophic to cancer cells, as such 
down regulation of protein kinases has been researched on previous occasions.97 
2.1.5. CK2 Inhibition 
Being a protein kinase, it is not surprising that initial research into inhibiting CK2 was directed 
at finding competitive inhibitors at the ATP binding site of the protein. One of the challenges 
this presented was selectivity issues when targeting the ATP pocket due to the fact that the 
pocket is highly conserved among kinases. There are in excess of 500 protein kinases in the 
human genome, with those in the same family sharing similar structural features. Thus, 
finding a compound which can selectively bind in the ATP site of CK2 without affecting other 
protein kinases would be challenging. Another issue with targeting an ATP site is that the 
inhibitor in question would have to compete with the high concentration (~1–10 mM) of ATP 
within the cell. However, this is less of an issue when the protein in question is in an inactive 
form.98 
This is not prohibitive, since there are some ATP inhibitors in clinical trials which are not 
completely selective.99 A study in 2008 involving 317 kinases (over half the human kinome) 
showed that of the 38 kinase inhibitors tested, none were selective within the range Kd < 3 
μM. Even the most selective ATP inhibitors, GW-2580 (primary target CSF1R, not yet in 
clinical trial) and lapatinib (primary target EGFR and ERBB2, approved for HER breast cancer) 
exhibited binding to three different kinases (Figure 2.4).100 Therefore, when seeking an ATP 
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inhibitor for CK2, total selectivity may not be necessary (which may be impossible). Instead 
sufficient selectivity to avoid inhibiting other kinases and therefore avoid adverse side effects. 
 
Figure 2.4 GW-2580 and Lapatinib, the most selective ATP inhibitors in the study by Karaman et al. 11 12  
The first example of an ATP based CK2 inhibitor was found in 1986 when a compound called 
DRB (Figure 2.5) inhibited CK2 with an IC50 of 15 μM.101 However, it was also found four years 
later that this compound also inhibits other kinases with similar IC50 values.102 
 
Figure 2.5 CK2 inhibitors, all Ki values are expressed in μM. 13141516171819 
DRB also inspired a series of derivatives (Figure 2.5) to improve the potency of the original. 
To improve the hydrophobic interactions, all the positions on the benzene moiety were 
brominated and the appendant sugar was removed to form TBI. The triazole equivalent gave 
TBB and a diethyl amino substituted TBI produced DMAT. All of these were substantial 
improvements on DRB (DMAT being the most promising with a Ki of 0.040 μM compared to 
DRB’s 4.50 μM).103 
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A range of natural products were also tested against this target. Emodin was found to be both 
unselective and lacking in potency. However, two unnatural analogues, MNX and MNA, 
where found to be an improvement on emodin.104 Flavonoids were found to bind better than 
DRB, yet they lacked selectivity.105 
The most progress made towards a drug which could inhibit CK2 through binding at the ATP 
site is a compound called CX4945 from Cylene Pharmaceuticals (Figure 2.6). This has been 
subjected to phase I clinical trials and was tested against BT-474 breast cancer cells and BxPC-
3 pancreatic cells with overexpressed growth factors. It was found to suppress the PI3K/Akt 
signalling pathway in the cell. 
 
Figure 2.6 CX4945 with an image of the crystal structure of it binding in the ATP pocket of CK2 (PDB: 3PE1). 
20 
When administered orally in vivo, BT-474 cancer cells showed up to 97% TGI, with just over 
20% showing 50% reduction in tumour size. For BxPC-3 93% TGI with about 30% showing no 
tumour after treatment.106 However, due to CX4945’s activity on the ATP pocket, its activity 
against other protein kinases may lead to adverse side effects. Studies have shown CX4945 to 
be a promiscuous molecule, even targeting another protein, CLK2, more potently than CK2. 
Indeed it targets 13 other proteins with nanomolar activity, which could present a problem in 
its progress through the clinic.107 
Targeting the ATP site is not the only way to inhibit protein kinases. Research has also been 
directed to non-ATP competitive inhibitors which can overcome some of the disadvantages 
of the ATP inhibitors. Namely, they are more likely to be protein specific as there is more 
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variety in the shape of pockets outside the ATP site. Furthermore, because it does not have to 
compete with ATP for binding, they can be administered in concentrations closer to the Ki. 
The most commonly targeted non-ATP site in kinases is the substrate binding site.  
Both small molecules and peptides have been used to bind this site.108 Additionally, 
compounds have been developed which bind to both the ATP site and the substrate site 
simulateously.109 Unfortunately, peptide-based inhibitors come with their own set of 
problems: low potency, difficult uptake, and intracellular instability. However, recent 
developments in drug discovery are attempting to overcome these limitations.110 In addition, 
there may be other sites on the protein which can also be exploited for inhibition. As shall be 
seen, this is the case for CK2 at the interface of the protein-protein interaction (PPI) between 
the α and β subunits. 
Some progress has been made in finding an inhibitor of CK2 which does not act on the ATP 
binding site. When a crystal structure of DRB binding in CK2 was obtained, it was noted that 
a second molecule of DRB bound to the interface of the α-β subunits111 and that it has an 
inhibitory effect on CK2. However, when a peptide of the C-terminal 181–203 of CK2β was 
exposed to CK2α, it had a stimulatory effect on CK2α phosphorylation, yetr this was less than 
CK2β itself.112 Continued exploration of peptide-based inhibitors of CK2 found that a cyclic 
peptide of CK2β 186–193 also bound in the PPI site, inhibiting the CK2 tetramer assembly.113 
In addition to this, a molecule identified as W16—as part of wider research into 
podophyllotoxine indolo-analogues in CK2 PPI inhibition—was found to have an IC50 of 20 
μM (Figure 2.7).114 
 
Figure 2.7 Compound W16. 21  
Recent research on a di(naphthalene) diazene core has identified a number of new compounds 
which exhibited inhibition of CK2. Of the 23 compounds based on this scaffold, five showed 
inhibition of CK2 (Figure 2.8). Of these compounds, compound 26 showed the lowest IC50 of 
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0.4 μM and analysis showed that it was inhibiting in both the ATP and PPI sites of CK2. It was 
further shown that against U373 cell line (cells from an aggressive form of brain tumour) 
compounds 24 and 26 both stopped the cell cycle and inhibited colony growth formation.115 
 
Figure 2.8 Di(naphthalene) diazene series of compounds 2223242526 
From all these examples, it seems that the field is developing for insights into inhibiting CK2; 
not just via the ATP pocket but also via allosteric inhibition of the PPI. Due to the higher 
specificity of a PPI inhibitor over an ATP inhibitor, the more the field of compounds is 
widened, the discovery of a molecule which could one day be used in a clinical setting 
becomes closer. 
2.2. Outline of this work 
Capitalising on the fact that CK2 consists of a catalytic subunit, CK2α, and a regulatory 
subunit, CK2β, inhibition of the protein-protein interaction may lead to molecules which 
selectively inhibit CK2.116 
This is not a new strategy. Three molecules and a cyclic peptide have been identified as 
inhibiting CK2 at the α-β interface pocket.117 One of these molecules, DRB (13), a fragment, 
exhibited off-target activity by binding in the ATP pocket of CK2.111 The two other molecules, 
W16 (21) and a diazo compound (26), are large drug-like molecules with some undesirable 
physico-chemical properties, and lack crystal structure data to prove binding at the interface 
pocket (Figure 2.9).68,114,115 
Fragment inhibitors of CK2 
28 
 
 
Figure 2.9 Structures of inhibitors of CK2α in the interface pocket. 
A recent screen of a compound collection library produced by the Abell Group at the 
University of Cambridge found NMR154 (27), which bound in the interface pocket of CK2α 
(Figure 2.10).118 
 
Figure 2.10 The structure of NMR154 alongside the crystal structure of NMR154 bound at the interface pocket 
of CK2α (image taken from ref. 118).  
NMR154 had two drawbacks. Firstly, it also bound in the ATP pocket of CK2α and secondly, 
it had a relatively high IC50 of 900 μM. The Abell Group made analogues of NMR154 to 
improve selectivity and inhibition. Of these, only one, NMR154L (28, Figure 2.11), showed an 
improved inhibition of 700 μM. However, it still bound in the ATP pocket.68 
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Figure 2.11 Structure of NMR154L. 
Despite these failings, NMR154L has ideal features for it to be the basis of further fragment 
development. Firstly, its properties were well within the Rule of Three, meaning further 
fragment development was likely to exhibit good physico-chemical properties (Table 2.1). 
Secondly, NMR154L has plenty of vectors to grow and elaborate the fragment; off the aromatic 
ring or amine group, for example. Thirdly, the existence of a crystal structure of the molecule 
binding in the interface pocket allows for design of new inhibitors based on known 
interactions (especially that of the electrostatic interaction between the primary amine on 
NMR154 and Asp37, see Figure 2.10). 
Table 2.1 Table comparing the physico-chemical properties of NMR154 and NMR154L with the Rule of Three. 
a MW: molecular weight in gmol−1, clogP: calculated log of the partition coefficient, PSA: polar surface area in 
Å2, HBA: hydrogen-bond acceptors, HBD: hydrogen-bond donors, RBC: rotatable bond count, CC: chiral 
centres. 
Propertya Ideal Fragment 
Range (RO3)71 
NMR154 NMR154L 
MW < 300 176.05 190.07 
clogP ≤ 3 1.88 2.31 
PSA ≤ 60 26.02 26.02 
HBA ≤ 3 1 1 
HBD ≤ 3 1 1 
RBC ≤ 3 1 2 
CC 0–1 0 0 
 
This chapter will explore developments of NMR154 analogues through elaboration of the 
aromatic ring and the generation of a new series of fragments to inhibit the interface pocket 
developed by computer modelling. 
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2.3. NMR154(L) analogues 
2.3.1. Vectors of elaboration 
Previous work has seen attempted optimisation of the methylene bridge and amino group on 
NMR154 to improve out-of-pocket binding interactions (Figure 2.12).  
 
Figure 2.12 Elaboration of NMR154.Elaboration from the amino group was investigated (blue box) as well as 
substitution of the methylamine group (red box).  
Unfortunately, varying the methylamine group only led to improved binding in one case, that 
of the ethyl amino group (discussed previously as NMR154L). The other functional groups 
evaluated: alcohol, amide, carboxylic acid, aldehyde, carbamate, and dihydroimidazole 
showed no improvement on NMR154(L) (Figure 2.12, red box).68 
Thus, the methylamine group was maintained (as it was synthetically easier to synthesize 
than the ethyl derivative and displayed interaction with Asp37) and additional groups were 
grown from it. A range of functionalities were explored with the view of picking up additional 
electrostatic interactions outside the pocket (Figure 2.12, blue box). Again, none of these 
showed improvement on NMR154L.68 
As a result, elaboration of the benzene core of NMR154 was next to be explored. The shape 
and structure of the α-β interaction pocket was investigated in silico using the computer 
program Maestro 10.2. As can be seen (Figure 2.13), the pocket is reasonably deep but narrow. 
The key to increasing the binding interactions into this pocket would be to utilise the two 
2.3 NMR154(L) analogues 
31 
 
aspartate residues at the top of the pocket. Suitable positioning of ammonium moieties could 
allow for hydrogen bonding. In addition, the breath of the pocket can also be explored. 
Additionally, fragments could be synthesised elaborating at the ortho position of the benzene 
ring with regards to the ethylamino moiety on NMR154L (Figure 2.13). 
 
Figure 2.13 NMR154L with the elaboration vector next to the interface pocket showing the Asp residues. 
The first elaboration tested was the addition of another ethyl amino group (fragment 29) to 
try and mimic the success of the original ethyl amino in binding to an Asp residue. Modelling 
predicted that this modification would show improved binding at the interface pocket. The 
Maestro 10.2 program assigns a ‘docking score’ to aid in the prediction of how well fragments 
will bind. The more negative the score, better binding is predicted. NMR154L was given a 
docking score of –6.1 and the proposed fragment 29 was awarded a docking score of –7.0, 
giving a good degree of confidence in its binding (Figure 2.14). 
 
Figure 2.14 Maestro 10.2’s prediction of how the proposed fragment (29) would bind at the interface site.This 
interaction was awarded a ‘docking score’ of –7.0 compared to NMR154L’s –6.1.  
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2.3.2. Synthesis of fragment 29 
Due to the plane of symmetry in fragment 29 a straightforward synthesis could be proposed 
as all disconnections and functional group interconversions do not need to have as high a 
degree of regioselectivity. Looking at 29 it seemed easiest to begin from a starting material 
which had the dichloro functionality already present. All that would be required was an 
appropriate synthetic handle on the opposite side of the ring. Thus, the readily available 4,5-
dichlorophthalic acid (33) was chosen as an ideal starting material. 
The retrosynthetic plan firstly involved the primary amines being revealed from nitriles via 
reduction (Scheme 2.1). Nitriles may be added by SN2 displacement of an appropriate leaving 
group. This is obtained from the alcohol, itself revealed from a dicarboxylic acid. 
 
Scheme 2.1 Retrosynthetic analysis of 2,2'-(4,5-dichloro-1,2-phenylene)bis(ethan-1-amine) (29) from 
commercially available 4,5-dichlorophthalic acid (33). 29 30 31 32 33  
Despite having literature precedent,119 the product of the diacid reduction with borane in THF 
(Scheme 2.2) did not yield the desired product by NMR (only displaying one peak). One 
possible explanation of this could be that the anhydride was formed. Although borane should 
be strong enough to further reduce the anhydride, it could be possible that the reagent might 
have degraded. The reaction was repeated yielding the same results. The reduction was then 
attempted with lithium aluminium hydride (Scheme 2.2)—a much stronger reducing agent—
which should have easily converted the carboxylic acid (33) to the alcohol (32). However, this 
also yielded the same, undesired, product by NMR. It would be extremely unlikely for the 
lithium aluminium hydride to stop reduction at the anhydride. As this strategy did not yield 
the desired diol, a different strategy was approached.  
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Scheme 2.2 Attempted direct reduction of 33 using borane in THF (left) and lithium aluminium hydride in THF 
(right).  
To overcome this issue, it was postulated that direct reduction of a methyl ester would not 
present such a problem. The diacid was methylated by treatment with thionyl chloride in 
methanol (Scheme 2.3). This readily produced the diester (34) in good yields which was 
submitted straight for reduction with lithium aluminium hydride. The pure diol (32) was 
afforded in good yield. 
 
Scheme 2.3 Synthesis of fragment 29. 
With this in hand, diol 32 was submitted for bromination under phosphorous tribromide 
conditions. This achieved the desired effect of producing the dibromide 31. An SN2 reaction 
using sodium cyanide in refluxing ethanol transformed the dibromide into the dinitrile 30. 
Finally, all that was required was reduction of the nitriles with lithium aluminium hydride. 
Unfortunately, this did not produce the desired product 29. Examination of the literature 
showed that on a similar system (4-bromo-1,2-benzenediacetonitrile) access to the diamine 
was not achieved directly but via a Boc-protected intermediate.120 Thus, a nickel (II) and 
sodium borohydride mediated reduction was performed in the presence of Boc-anhydride. 
This successfully produced two mono-Boc protected amines 35. The product was carried 
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straight through to remove the Boc with 4M HCl/dioxane. This furnished 29 as the pure 
bis(HCl) salt (Scheme 2.3). 
2.3.3. Biological testing of 29 
Compound 29 was submitted to a fluorescence polarisation (FP) assay.b These assays work 
through CK2α being soaked with a fluorescence labelled peptide which mimics the part of 
CK2β that binds to CK2α. If a compound binds at this interface the tumbling of the protein 
would be different, and this would affect the degree of polarisation of the light. In this way, 
the half- maximum inhibitory concentration (IC50) of the compound could be measured. 
The results of the experiment showed that compound 29 bound to the interface of CK2α with 
an IC50 of 250 μM (cf NMR154L IC50 of 700 μM). The crystal structure of CK2α with 29 bound 
at the interface was obtained to examine the nature of the binding and further inform design 
to improve the inhibition (Figure 2.15). 
 
Figure 2.15 Compound 29 in interface pocket showing two binding modes. 
The crystal structure confirmed the model's predictions about the nature of the binding in the 
pocket. Interestingly, one of the binding modes did show one of the ethylammonium moieties 
facing away from the aspartate residue. 
                                                     
b All biological work was carried out by Dr Paul Brear, Department of Biochemistry, University of Cambridge. 
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2.3.4. Methyl analogue of 29 
Due to the similarity in binding between NMR154 and NMR154L, it was investigated whether 
a dimethylamine analogue of 29 (fragment 38) would display similar biological properties to 
29. If 38 could be more easily synthesised than 29 and display comparable properties, this 
could aid further fragment elaboration if both alkyl amino groups wish to be kept on the 
fragment. 
Fragment 38 was readily synthesised in two steps from commercially available 1,2-dichloro-
4,5-dicyanobenzene (36). This was submitted to the same nickel (II) mediated reduction-Boc 
protection to afford Boc-protected diamine 37, which was deprotected by 4M HCl/dioxane to 
afford the bis(HCl) salt 38.2HCl (Scheme 2.4). 
 
Scheme 2.4 Synthesis of 38.  36 37 38  
This was submitted to the same FP assay experiment as compound 29 but showed >1 mM IC50 
meaning it was not an improvement on NMR154. 
2.4. Bicyclic series 
2.4.1. Exploring the pocket width 
With the improvement in binding from the ethylamine moiety in mind, it was explored 
whether growing the benzene core of NMR154L into a fused bicyclic core would fill more of 
the width of the pocket and thus aid binding by anchoring the fragment in the pocket. In this 
way, naphthalene-based fragment 39 was conceived (Figure 2.16). 
 
Figure 2.16 Growth of fragment NMR154L to incorporate a naphthalene core 39.  
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2.4.3. Synthesis of 39 
Synthesis of this naphthalene derivative started from commercially available 1-
chloronaphthalene (40) which was subjected to a Friedel-Crafts acetylation. The electronics of 
the 1-chloro substituent directs the acetyl group para to the chlorine (41).121 Subjecting this to 
the iodoform reaction converted the acetyl group into a carboxylic acid (42).121 Reduction then 
gave alcohol 43, followed by bromination  which afforded a bromomethyl species, 44.122 This 
was ripe for SN2 displacement with cyanide to yield nitrile 45.120 Reduction gave 39 as the HCl 
salt (Scheme 2.5).  
 
Scheme 2.5 Synthesis of naphthalene derivative 39 from commercially available starting material 1-
chloronaphthalene 40.  
2.4.4. Testing of 39 
Naphthalene derivative 39 was submitted to the same fluorescence polarisation assay as 
previous fragments. This showed an inhibition of >500 μM, not showing an improvement.  
A crystal structure was also obtained of 39 binding in the interface pocket. This was interesting 
as it displayed a binding mode than had not been expected (Figure 2.17).  
Looking at the crystal structure of NMR154L, it was predicted that the naphthalene core 
would straddle the length of the pocket with the chlorine protruding into the depth of the 
pocket and the ethylamine making electrostatic interactions with Asp37.  
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However, compound 39 has turned on its side to bind into the pocket. The unsubstituted ring 
of the naphthalene core now explores the depth of the pocket. This leaves the ethylamine to 
bind with Asp37, as predicted, and the chlorine pointing into the length of the pocket (Figure 
2.17). This suggests that the pocket may be able to accommodate a larger molecule into its 
depths as well as its length. 
 
Figure 2.17 Crystal structure of compound 39 in the interface pocket of CK2α. 
2.5. Expanding bis(ethylamino) fragments 
2.5.1. Synthesis of precursors 
With the success of adding a second ethyl amino group to NMR154L, it was investigated 
whether adding additional alkylamine groups to other fragments, such as naphthalene 39, 
would also lead to improved binding. 
This presented a challenge due to the lack of an appropriate synthetic handle on the 
naphthalene scaffold. A C-H activation paper by Giri and Yu offered a way of selectively 
installing a carboxylic acid group ortho to a pre-existing carboxylic acid using Pd catalysis and 
a CO atmosphere (Scheme 2.6).123 
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Scheme 2.6 Summary of Giri and Yu’s work to install a carboxylic acid group ortho to a pre-existing carboxylic 
acid.4647  
The advantage of using this work is that with the two carboxylic acids installed, the same 
chemistry to synthesise 29 can be followed. 
Additionally, it was decided to pursue this methodology in tandem with further elaborations 
at the ortho position. If an acetylene moiety could be installed there, then its pluripotent 
functionality could be further transformed into a number of different groups. 
It was hoped that the acetylene functionality could be easily installed through a Sonogashira 
cross coupling. The synthesis began with commercially available 2-bromo-4-chlorobenzoic 
acid (48) which was readily esterified to give methyl ester 49 for the cross-coupling. The 
acetylene was installed after experimenting with a few conditions. The conditions previously 
used by the authors did not afford the desired product (Table 2.2, Entry 1).124 When the 
reaction was repeated under reflux and double concentration, the reaction proceeded with 
only a 5% yield (Table 2.2, Entry 2). A literature procedure from Thorand and Krause was 
then tried. These conditions used similar reagents to the previous one, however less base and 
CuI were employed, five-times the amount of Pd(PPh3)2Cl2 used, a catalytic amount of PPh3 
added, and it was performed at a slightly higher concentration.125 This unfortunately only 
returned starting material (Table 2.2, Entry 3). However, repeating the reaction under reflux 
gave the desired product, 50, in good yield (Table 2.2, Entry 4).  
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Table 2.2 Screen of conditions to install TMS acetylene on benzene core. 
 
Entry Conditions Yield 
1 NEt3 (8 eq), CuI (10 mol%), Pd(PPh3)2Cl2 (1 mol%), THF 
(0.1M), 130 °C124 
SM Returned 
2 NEt3 (8 eq), CuI (10 mol%), Pd(PPh3)2Cl2 (1 mol%), THF 
(0.2M), reflux124 
5% 
3 NEt3 (1.5 eq), CuI (1.2 mol%), Pd(PPh3)2Cl2 (5 mol%), 
PPh3 (2.5 mol%), THF (0.25M), RT125 
SM Returned 
4 NEt3 (1.5 eq), CuI (1.2 mol%), Pd(PPh3)2Cl2 (5 mol%), 
PPh3 (2.5 mol%), THF (0.25M), reflux125 
79% 
 
Ester hydrolysis and TMS deprotection were then carried out simultaneously to yield the 
desired 4-chloro-2-ethynylbenzoic acid (51, Scheme 2.7). 
 
Scheme 2.7 Simultaneous ester hydrolysis and TMS deprotection to yield acid 51. 
With both 42 (chloronaphtholic acid precursor of 39 in Scheme 2.5) and 51 in hand, these were 
subjected to Giri and Yu’s ortho carboxylation conditions (Table 2.3). 
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Table 2.3 Table summarising attempted ortho carboxylation of 51 and 42.  52 53  
 
Entry Conditions Yield 
1 
Pd(OAc)2 (10 mol%), Ag2CO3 (2 eq), NaOAc (2 eq), CO (1 atm), 
1,4-dioxane, 130 °C, 18h 
SM 
Returned 
2 
Pd(OAc)2 (10 mol%), Ag2CO3 (2 eq), NaOAc (2 eq), CO (1 atm), 
1,4-dioxane, 130 °C, 18h, sealed tube 
Complex 
mixture 
 
Despite several attempts to affect the conversion using the conditions outlined above, no pure 
product was isolated. Thinking this could be down to the difficulties with isolating vicinal 
diacids, the crude reaction mixture from the sealed tube experiment was submitted straight 
to methylation conditions in an attempt to form the di(methylester) which could be easier to 
separate. Unfortunately, the desired product was not isolated from the complex mixture that 
was returned (Scheme 2.8). 
 
Scheme 2.8 Attempted isolation of diacid via diester.  54  
2.5.2. Docking Studies 
To assess qualitatively whether biaryl analogues of NMR154L would be good leads, a brief 
docking study was conducted with the structure of CK2. In this study, CK2β and residual 
water molecules were removed leaving just the CK2α subunit before energy minimisation 
was carried out. 
From this result, a docking grid was placed over the interface site of the protein showing the 
area in which docking should take place. Into this model a variety of analogues of NMR154L 
and 39 were entered. These were transformed into 3D structures and their energy minimised. 
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With both the protein and compounds in hand, an SP docking glide was carried out and the 
program was asked to return the top 80% of hits. Each compound was returned with a 
‘docking score’ shown in Figure 2.18. While these numbers holds little value in themselves, 
they can be used qualitatively against compounds known to dock to assess whether they may 
be worth making. As can be seen, all but compound 39 returned numbers similar to that of 
NMR154L. 
 
Figure 2.18 Series of molecules based on NMR154L with docking scores shown.  55 56 57 58 59 60  
Interestingly, compound 39 was predicted not to bind by the computer. The reason in this 
case for the prediction of 39 not binding could be because the model predicted all the bicycles 
occupying the width of the pocket and did not explore its depth. In this way, the amine on 39 
would not be able to bind with Asp37. The model perhaps underestimates the protein with 
regards to pocket depth or its flexibility to accommodate deeper ligands (Figure 2.19). 
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Figure 2.19 Example of how Maestro 10.2 predicted the bicycles would bind in the interface pocket (in this 
case compound 55).  
The bicycles with two ethyl amino groups proposed present more of a synthetic challenge 
than 29. This is down to several factors: first of all, those compounds lack the symmetry seen 
in 29, thus requiring a more regioselective synthesis. Secondly, due to the unusual substitution 
pattern of these bicycles, finding appropriate starting materials would be difficult. Thirdly, 
for the sake of atom economy and efficiency, a synthesis that could feature a late stage 
divergence to make all the structures would be desirable. However, a shorter synthesis of one 
compound could be achieved to test the validity of the model before embarking on a larger 
synthetic effort. 
For the divergent synthesis, a cross-coupling reaction was the easiest to effectively introduce 
pyridine (for fragments 57 and 58) and cyclopentene (for fragments 59 and 60) into the 
scaffold. In this way, if a common disconnection could be found between all the structures, a 
common synthesis may be proposed. Work by Mamane et al. showed that similar aromatic 
systems could be synthesised by a indium (III) mediated cyclisation.126 The reaction also has 
the benefit of positioning the chlorine at the desired position (Scheme 2.9). This worked by the 
indium coordinating to the alkyne, activating it for 6-endo-dig attack of the adjacent aromatic 
ring. 
2.5 Expanding bis(ethylamino) fragments 
43 
 
 
Scheme 2.9 Example of work from Mamane. Chloroacetlyene 61 is transformed into phenanthrene scaffold 
62.126 
For our system, this would require synthesising an enyne with a pendant phenyl ring and 
groups which could be used later to produce the ethylamine functionality. There are 
established literature procedures for the synthesis of a chloroalkyne moiety from an aldehyde, 
and an α,β-unsaturated aldehyde from the corresponding unsaturated TBS protected 
alcohol.126 
This leaves an obvious sp2–sp2 disconnection between the alkene and phenyl. Not only is this 
easily achieved through a Suzuki reaction, but it allows other rings to be added at this stage, 
including pyridine and furan, which form the basis for the other bicyclic systems that are to 
be investigated. 
This leaves the key intermediate; an alkene with a bromine, methyl TBS-protected alcohol, 
and two groups which can be later functionalised into ethylamines (Scheme 2.10). 
 
Scheme 2.10 Retrosynthesis of 66 to common intermediate. 63 64 65 66  
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The main challenge in synthesising this alkene is selectivity in the bond geometry. However, 
research from Wei-Jun et al. may provide an answer.127 They showed that a cyclopropyl group 
at one end of an alkene may be selectively opened to install both a bromine and a tosyl- 
protected ethylamine in a single step (Scheme 2.11). In terms of selectivity, it was found that 
the bromine preferentially adds to the same side as the bulkiest substituent. The methyl TBS-
protected alcohol is bulkier than a nitrile and so this should give the desired selectivity. 
 
Scheme 2.11 Example of cyclopropane being opened to reveal bromine and tosyl protected ethylamine 
moieties. 67 68  
This leaves a rather facile alkene to synthesise. The cyclopropane could be added via a Wittig 
reaction. Finally, this gives a ketone for which there is literature precedence that it can be 
made from a molybdenum (0) catalysed opening of an isoxazole. The total forward synthesis 
is summarised in Scheme 2.12. 
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Scheme 2.12 General proposed scheme for the synthesis of the bicyclic series. 69 70 71 72 73 74 75 76 77 78 
79 80 81 82 83 84 
Forays were made into this synthesis to test its viability (Scheme 2.13). TBS protection of 
propargylic alcohol 71 is a standard procedure and proceeded without issues. 2-Oxoacetic 
acid (69) condensation with hydroxylamine followed by dropwise addition of elemental 
bromine, which led to the formation of dibromoformaldoxime, 70. In the presence of base, the 
formaldoxime performed a 1,3-dipolar cycloaddition with the protected of propargylic 
alcohol to yield the bromoisoazole, 73. Despite one example in the literature of this ring being 
opened with molybdenum (0), this methodology did not produce the desired result instead 
yielding a complex and inseparable mixture.128 
At this point, another strand of research in the Spring Group discovered CAM187. This was 
derived from NMR154 and represents the best fragment inhibitor of the CK2 interface pocket 
with an IC50 of 44 μM (see Appendix D for the publication regarding this discovery).68  
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Scheme 2.13 Steps towards the synthesis of 74. 
2.6. Spirocyclic fragment series  
2.6.1. Computer modelling 
Work in the group had also been directed towards developing a new series of fragments based 
upon computer models of the interface pocket of CK2. To direct the synthesis of compounds 
likely to bind at this site, another member of the Spring Group, Dr Qingzhong Hu, created an 
in silico pharmacophore model. 
Hu conducted the study of the pharmacophore in Molecular Operating Environment (MOE) 
2014 version. In this model, the redundant protein copies in the crystal structure of CK2 holo-
enzyme comprising CK2α and CK2β were removed. The CK2β subunit and water molecules 
were also removed. After the Amber10 force field was designated to the structure, hydrogens 
and partial charges were added via the Protonate3D module in MOE. A pharmocophore 
model was subsequently established via the structure-based approach. Employing this 
prepared structure followed the standard protocol with default parameters being adapted, 
which was followed by empirical manual modifications on the locations and confines of some 
pharmacophores. The virtual screening of the ZINC database129 employing this 
pharmocophore model was performed using MOE with pharmocophores F1 and F2 being set 
as essential, and a spirocyclic compound 85 was identified as a hit. To further verify this hit, 
Hu docked compound 85 back into the prepared CK2α crystal structure with GOLD after 
being built and energy minimized in the Amber10 force field with MOE. The function of 
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automatic active site detection was switched on although amino acids composing the interface 
were also manually designated as the binding site, the radius of the active site was set to 19 Å 
and β4β5-loop was set to be flexible. The ligand was docked in 50 independent genetic 
algorithm (GA) iterations for each of the three GOLD-docking runs. Moreover, the GOLD 
score parameters were exploited, and the GA default parameters were set. The results were 
subsequently ranked according to fitness and compound 85 achieve a fitness score of 38.85. It 
was further evaluated with the LigX module in MOE and illustrated in contrast to the 
previously-identified fragment NMR154L as shown in Figure 2.20. 
 
Figure 2.20 Compound 85 (in magenta) in α-β PPI pocket with previously known hit NMR154L (in cyan).  
Based on the pharmacophore model producing a hit for spirocyclic compound 85, a further 
library of spirocyclic compounds and fused ring compounds were proposed by Hu to see if 
these compounds validated the model. Through this, an inhibitor for CK2 was found (Figure 
2.21). 
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Figure 2.21 Products of the pharmacophore model.  85 86 87 88 89 90  
2.6.2. Synthesis of compound 85 
Synthesis of spirocycle 85 followed the work of Zhu.130 Bis(ethylchloro)ammonium chloride, 
91, was initially Boc protected (Scheme 2.14) to give 92 which could be used in the synthesis 
of three spirocyclic compounds in the series. 
Initially, 2-(2-bromophenyl)acetonitrile, 93, was reacted with sodium hydride. When 
compound 92 was added to the reaction this was expected to perform two SN2 reactions at the 
methylene position forming a piperidine ring. Several attempts failed to yield the desired 
product, 94 (Scheme 2.14), returning the starting materials. 
 
Scheme 2.14 Attempted reaction using a bromophenyl sequence. 
The above procedure was repeated with the fluoro analogue, 95. Again, base was added 
followed by bis(chloroethyl)amine 92 (Scheme 2.15). This formed a Boc-protected piperidine 
ring substituted at the 4-position with a nitrile and an ortho-fluorophenyl, 96, which was 
deprotected to give 97. In the presence of lithium aluminium hydride, the nitrile was reduced 
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to an amide anion, which performed an internal SNAr at the fluorinated position, leading in 
one step to the formation of the indoline system and the spirocyclic centre, 85. 
 
Scheme 2.15 Synthesis of compound 85.  
2.6.3. Synthesis of indane spirocycle 86 
The synthetic techniques of 85 could be employed for the synthesis of 86. A benzyl protecting 
group was used on the bis(ethylchloro) amine as it was thought this could be removed in the 
same step as the hydrogenation of the double bond of the indene. The bis(ethylchloro)amine 
91 was protected with a benzyl group to give 98 (Scheme 2.16). This was reacted with indene 
(99) using LHMDS in THF. The resulting spirocycle 100 was subjected to hydrogenating 
conditions of palladium on carbon in a hydrogen atmosphere. The alkene in the indene ring 
system was successfully reduced, however the benzyl remained, giving compound 101. 
 
Scheme 2.16 Synthesis of benzyl protected spirocycle 101.  
Although desirable to simultaneously remove the protecting group and reduce the alkene, 
Boc-removal is a reliable reaction and this extra step could easily be used to reveal the desired 
product. Therefore 92 was reacted with indene in the presence of LHMDS to produce the Boc-
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protected piperidine-indene spirocycle 102 (Scheme 2.17). Boc deprotection, giving 103, 
followed in a facile and high yielding manner. Finally, 103 was hydrogenated using palladium 
on carbon to give 86 as the HCl salt.131 
 
Scheme 2.17 Synthesis of 86.HCl.  
2.6.4. Synthesis toward spirocyclic amide 87 
Compound 87 has the spirocentre α to an amide. It was thought that this position could be 
sufficiently acidic to broadly follow the same procedure described above using two 
equivalents of base with 92. To test this theory dihydroquinolone, 104, was Boc protected, 
giving 105, prior to being reacted with 92 and LHMDS. This reaction only returned starting 
material. Considering LHMDS may not be a strong enough base, the reaction was repeated 
with LDA made in situ. A product was isolated from this reaction. However, it was the 
dihydroquinolone dimer linked by a diethylamine moiety, 106. It seems the tertiary centre 
was either too sterically hindered to be deprotonated or to perform the internal SN2 (Scheme 
2.18). 
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Scheme 2.18 Attempt to synthesise 87 from hydroquinolone. 107 
A different strategy was employed to synthesise 87. This was based on a patent by Bristol-
Myers Squibb. To begin with, ethyl piperidine-4-carboxylate 108 was Boc-protected to give 
109 (Scheme 2.19), which was then subjected to deprotonation at the tertiary centre. 2-
Nitrobenzyl bromide 110 was added to this anion and an SN2 occurred displacing the bromine, 
giving nitro-ester 111. Hydrogenation was attempted to reduce the nitro to aniline 112. Boc-
deprotection with 4M HCl/dioxane proved to be messy, despite several attempts. Therefore, 
synthesis of this compound was put on hold subject to biological results from 85 and 86. 
 
Scheme 2.19 Synthesis of 87. 113 
2.6.5. Initial Biological Results 
Compounds 85 and 86 were submitted to a fluorescence polarisation assay. Unfortunately, 
neither compounds 85 nor 86 exhibited any inhibition of CK2α. 
With these results in mind, work done by Dr Hu was re-evaluated. It was noted that the 
known hit NMR154L had a chlorine moiety protruding into the pocket. It was postulated that 
Fragment inhibitors of CK2 
52 
 
this would increase the hydrophobic interactions and therefore aid in binding. Thus, a 
chlorine analogue of spiroindane 86 was designed (because this core was the most convenient 
out of 85, 86, and 87 to make). Additionally, instead of indole 89 a chlorine analogue of that 
indole was be made. It was decided not to pursue compounds 88, 89, or 90. 
2.6.6. Synthesis of chlorine analogue of 86 
Commercially available 6-chloroindanone 114 was easily reduced to give 6-chloroindene 115 
(Scheme 2.20).132 This was achieved by reacting 6-chloroindanone 114 with sodium 
borohydride, then taking the crude alcohol and heating it to reflux with p-toluenesulfonic 
acid. With chloroindene 115 in hand, the same procedure as the synthesis of 86 was used. The 
spirocyclic centre was formed with 92 to produce spirocycle 116. The Boc group was removed 
to give salt 117, and the alkene was reduced by hydrogenation, yielding the final chlorine 
analogue 118. 
 
Scheme 2.20 Synthesis of 118.  
2.6.7. Synthesis of chlorine analogue of 89 
Finally, a tricyclic indole was synthesised. This was easily done via the Fischer indole synthesis 
between (4-chlorophenyl)hydrazine 119 and ethyl 4-oxopiperidine-1-carboxylate 120. This 
produced indole 121, which left only the removal of the ethyl ester by heating to reflux in base 
to give the desired product, 122 in two steps (Scheme 2.21).133 
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Scheme 2.21 Synthesis of 122. 
Compounds 118 and 122 were submitted to the fluorescence polarisation assay with CK2α. 
Unfortunately, like compounds 85 and 86, they exhibited no binding on the interface site. 
2.7. Conclusions 
2.7.1. In silico modelling 
This project produced three spirocycles and one tricycle from an in silico pharmacophore 
model. However, none of these compounds bound to the interface pocket of CK2. The model 
predicted that the aromatic core would anchor in the pocket while the piperidine would form 
an electrostatic interaction with Asp37. This is likely due to the rigidity of the spirocycle 
compared with the ethyl amino group of NMR154L, which did bind. The presence of aromatic 
chlorides may be excluded as a factor as the chloride analogues did not bind. Due to this, it 
would seem that a spirocycle scaffold is unsuitable for binding in the interface pocket of CK2. 
2.7.2. NMR154L analogues 
Elaboration of the NMR154L fragment from the ortho position proved more successful. With 
a second ethyl amino group, the IC50 was improved from 750 μM to 250 μM. Changing the 
benzene core of NMR154L to a naphthalene also produced a compound which bound at the 
interface. Attempts to find a facile way to install a vicinal di(ethyl amino) moiety on to the 
molecule proved unsuccessful. 
2.7.3. Additional interface inhibitors 
While the work in this chapter was being carried out, a series of other elaborations were made 
to NMR154 by substituting the para position of the benzene ring (Figure 2.22). 
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Figure 2.22 A series of mostly biaryl compounds as analogues of NMR154 by para substitution. 
Of these, fragment 123 was the best binder at 150 μM incorporating an ortho-fluorophenyl 
moiety. Additionally, in a screen of compounds to bind in the αD pocket of CK2, the most 
potent inhibitor of CK2 at the interface pocket was discovered with an IC50 of 44 μM. This 
fragment was an analogue of NMR154 with an indole elaboration from the meta position 
(124).68 This suggests that future work on small molecule inhibitors of CK2 at the interface 
pocket be directed towards development of this fragment. 
 
Figure 2.23 The most potent fragment inhibitor of the CK2 interface site. 
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Chapter 3 
3. Spirocyclic fragment libraries
3.1. Introduction 
3.1.1. The need for diversity 
An extremely important factor when searching for new drugs is the variety, or 
diversity, of chemicals available to screen.43 
This Essay is a call to increase chemistry research and investment into the design 
and synthesis of diverse fragment molecules.72 
The concept of chemical diversity is an essential component of the solution to this 
problem [the optimal composition of a screening collection], as it can theoretically 
be shown that a diverse, high-quality collection of compounds should yield more 
leads than, for example, a similar-sized combinatorial library of limited structural 
variation.30 
There are three main considerations in assembling a fragment library. Firstly, the 
properties of the fragments – they… should be as diverse as possible.52 
The above quotes from the literature highlight the need for diversity in compound libraries to 
aid in drug discovery. 
 The hope was that a synthetic strategy could be devised to produce a diverse range of 
compounds—this strategy was developed in 2000 by Stuart Schrieber and has been term 
diversity oriented synthesis (DOS).134 
This begs the questions: what is diversity? How to do we measure it? And how do we make 
diverse libraries? DOS is best understood when it is juxtaposed to its antithesis—target 
oriented synthesis (TOS). In TOS, the chemist has a specific type of compound or compounds 
in mind. The synthesis is usually convergent such that multiple reagents and reactants are 
brought together to form a single compound (or scaffold). The synthesis is usually contrived 
by retrosynthetic analysis with synthesis of the target as the primary goal. In DOS, a starting 
material is grown and modified by multiple reagents to create a collection of different 
molecules which are sufficiently different from one another. In this paradigm forward-
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synthetic analysis is the primary driving force—there is no one target in mind but multiple. 
Synthetic handles and branch points are favoured to maximise the range of reactions that can 
be carried out (Figure 3.1).135 
  
Figure 3.1 The difference between target-oriented synthesis and diversity-oriented synthesis.The grids of the 
right of each scheme depicting the chemical space covered by the TOS and DOS targets respectively.  
TOS will often produce only one compound or a set of structurally similar compounds which 
only exhibit appendage diversity. DOS aims to incorporate:136 
Structural diversity: that is the physical shape of the molecules in space are different. This 
requires synthesis to connect different parts of the starting material in different ways to build 
a variety of skeletal frameworks. 
Stereochemical diversity: easy synthetic access to the different stereochemical orientations a 
scaffold can possess. 
Functional group diversity: the molecules which occupy a wide range of physical space must 
also be able to display a variety of functionality (especially if their purpose be to probe 
biological targets). This means that it is important to incorporate a range of heteroatoms and 
functional groups into the molecule and its scaffold. Synthetically, this means starting 
materials should be selected for their ability to undergo an array of different transformations. 
Appendage diversity: the scaffold of the molecules must allow for the easy addition of moieties. 
These are often important growth vectors in the hit-to-lead optimisation of drug discovery. 
Of these scaffold diversity is perhaps the most important for a DOS library to focus on as it is 
the best way to maximise the three other types of diversity.137–139 
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3.1.2. Measuring diversity 
With the principle of diversity established, the need arises for an appropriate way to measure 
diversity in compound libraries. Structural diversity can be most easily measured as 
numerical output of geometric properties. Advances in computer technology have made the 
measurement of spatial diversity easier. 
One leading method for measuring the spatial diversity of compound libraries is Principle 
Moment of Inertia (PMI) analysis.140–143 In this case the moment of inertia (I) is measured for a 
molecule about its three orthogonal principle axes. This gives each molecule three moments 
of inertia (I1, I2, and I3 in ascending magnitude). Since I3 is always greater than or equal to I1 
and I2 these moments of inertia can be easily normalised by calculating I1/I3 and I2/I3. This 
also allows a spatial descriptor of the molecule to be displayed on a 2D cartesian plot of I1/I3 
vs I2/I3.137 
By considering the three extremes of 3D space: a rod, a disk, and a sphere, we can see that a 
PMI forms an isosceles triangle to represent chemical space. In one corner is (0,1) which are 
the coordinates for a rod (or acetylene chemically speaking), (1,1) are the coordinates for a 
sphere (adamentane), and (0.5,0.5) represent a disk (benzene), Figure 3.2. 
 
Figure 3.2 Graphical representation of a PMI plot showing acetylene, adamantane, and benzene on the three 
extremes of the triangle in which all molecular shapes fall.  
In this way a compound library which is structurally diverse will seek to cover as much of the 
PMI plot as possible (Figure 3.3). 
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Figure 3.3 Comparison of predicted PMI plots of a non-structurally diverse TOS library and a structurally 
diverse DOS library.  
Another useful descriptor of chemical space is the fraction of sp3 centres (Fsp3). This is 
expressed as the number of sp3 carbons hybridised divided by the total carbon count of the 
molecule.25 This is a good indicator of 3-dimensionality and the prevalence of aromatic rings. 
However, while molecules with a high Fsp3 are likely to be more 3-dimensional, it does not 
follow that a low Fsp3 necessarily means a flat molecule. For example, antifungal clotrimazole 
has a Fsp3 count of 0.05, however because its structure is four aromatic rings around a 
quaternary carbon centre it is sphere-like (Figure 3.4). 
 
Figure 3.4 Clotrimazole: low Fsp3 count but highly spherical in nature. 
Another method of analysing diversity (or similarity) of a library is principle component 
analysis (PCA). This allows selection of n molecular descriptors, which can be anything from 
the physico-chemical descriptors found in the RO5 to biological descriptors like data from 
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protein binding studies, to be plotted on a 2D graph. The power of PCA is that by taking linear 
combinations of the n-dimensional space, vectors of the descriptors can be projected onto a 2-
dimentional cartesian axis. The axes are unitless but represent the variance in the data set. 
PCA results will therefore always depend on both the data set and the descriptors chosen, but 
the plots that are produced give useful insights as to how diverse a compound library is 
internally and compared to other libraries (Figure 3.5).144 
 
Figure 3.5 Example of PCA plot comparing a random selection of drugs (red) with a random selection of 
natural products. The principle components chosen were: molecular weight, clogP, hydrogen-bond donors, 
hydrogen-bond acceptors, rotatable bonds, polar surface area, stereogenic centres, nitrogen atoms, and 
oxygen atoms. There is greater variance in the natural product library then the drug library and both libraries 
are different from one another. (Image taken from ref 144).  
3.1.3. Features of a DOS campaign 
Two main synthetic strategies have been developed to enable efficient assembly of DOS 
libraries: a reagent-based approach and a substrate-based approach. 
Reagent-based DOS sees a single starting material transformed into a diverse set of 
compounds by utilising both a large amount of in-built functionality, and pluripotent 
functional groups (i.e. a functional group that can be transformed into many others). These 
vectors are often folded, paired, and branched to generate the library.145–148 
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In the substrate-based approach, common reaction conditions are used on a series of starting 
materials which contain ‘pre-encoded’ skeletal information known as σ-elements which react 
to form a diverse array of scaffolds upon subjugation to the common reaction conditions 
(Figure 3.6).145,149,150 
 
Figure 3.6 The two main strategies to generate DOS libraries: a) Reagent-based DOS wherein a common 
starting material for diverse scaffold from different reagents; and, b) Substrate-based DOS where pre-
encoded starting materials form the DOS library from a common set of reaction conditions. (Image taken 
from ref 139).  
Throughout most DOS strategies, however, a common synthetic plan of build, couple, pair 
(B/C/P) has emerged.148 In this, initial building blocks are synthesised from commercial 
reagents. These are then coupled with each other or additional reagents to give a molecule 
appropriately furnished with orthogonal functionality. Finally, this functionality is utilised in 
the pair stage where different areas of the molecule are connected and folded to yield the 
diverse library (Figure 3.7).139,148 
 
Figure 3.7 An archetypal scheme of the DOS build/couple/pair strategy (Image taken from ref 151).  
3.1.4. Achievements of DOS 
Despite only being conceived of around the millennium, DOS has had a number of successes 
in aiding drug discovery.152–158 
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For example, in the field of generating leads for novel antibacterial activity, DOS libraries have 
yielded some interesting compounds.  
Starting from a reactive and pluripotent diazo ester Wyatt et al. rapidly generated a DOS 
library of 223 unique compounds covering 30 scaffolds.159 Phenotypic screening revealed that 
64 compounds (29% of the library) displayed growth inhibition against methicillin-resistant 
Staphylococcus aureus (MRSA). One of these compounds, Emmacin, was found to be 
particularly potent against methicillin-susceptible Staphylococcus aureus (MSSA) as well as to 
epidemic strains of MRSA, EMRSA-15 and EMRSA-16 (Scheme 3.1).160 
Likewise, another reagent-based DOS campaign discovered a novel antibacterial called, 
Gemmacin. This DOS strategy started from a resin supported phosphoester. Using the B/C/P 
technique a library of 242 compounds with 18 molecular frameworks was built. Gemmacin 
and Gemmacin B (a benzene analogue) were discovered to also show good activity against 
MSSA, EMRSA-15, and EMRSA-16 (Scheme 3.1).160,161 
 
 
Scheme 3.1 Summary of the reagent-based DOS approaches which lead to the discovery of three novel 
antibacterials: emmacin, (–)-gemmacin, and (±)-gemmacin B (Image adapted from ref 151). 
125126127128129  
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3.2. Gaps in fragment libraries 
3.2.1. Expanding fragment space 
DOS campaigns have shown the effectiveness of diversity when confronting complex 
biological problems (section 3.1.4). In addition, FBDD is a powerful technique to optimise the 
success in the hit-to-lead process (section 1.3.2). However, FBDD is only ever going to be as 
good as the fragments it screens. Can DOS provide FBDD with diverse fragment libraries? 
Most fragment libraries lack 3D structural motifs and instead focus on sp2-rich 
heteroaromatics.162 This is not surprising given their commercial ubiquity and inherent 
aromatic stability. In addition, rapid growth in the field of metal-mediated cross coupling 
reactions have allowed researchers unprecedented access to otherwise unknown unsaturated 
scaffolds.25,163 These flat libraries have led to advances in the field of drug discovery,164,165 
however, expanding the scope of fragment libraries would allow access to otherwise 
uncharted areas of chemical space.  
3.2.2. Unsaturated rings in drug discovery 
Rings are ubiquitous in pharmaceuticals with only 5% of marketed drugs not containing any 
kind of ring.163  
Unsaturated ring systems are an effective way of installing complexity and 3-dimentionality 
into compounds. They are axiomatically more 3D than unsaturated (aromatic) ring systems 
and will also carry a higher Fsp3 count. Given that 60% of drugs contain at least one sp3 carbon 
in a ring, evidence exists that this area of chemical space is likely to contain biologically 
relevant compounds. Additionally, research from GSK has suggested that a high aromatic 
ring count negatively affects the prospects of drug-like compounds while hetero-aliphatic 
rings showed more desirable properties such as better solubility and reduced 
lipophilicity.26,166 There is also a suggestion that molecules with a greater proportion of sp3 
atoms are more specific binders and so are less likely to be toxic due to off-target 
interactions.167,168 
However, despite the prevalence of rings in chemistry and biology the number of structures 
explored remains limited. For drugs brought to the market before 2013 only 351 unique ring 
systems were represented across 1197 unique frameworks. However, innovation continues 
with, on average, 28% of new drugs containing a novel ring system.74 The field is ripe for 
exploration especially focusing on 3-dimentionality in ring systems. 
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3.2.3. Spirocycles 
Spirocycles, also known as spiranes, are an important and prominent class of unsaturated ring 
system which contain at least two rings joined at a vertex (via a single carbon atom). The 
presence of a spirocentre in organic compounds may give them some advantages when 
considering their application in pharmaceuticals. The spirocentre can introduce 
conformational rigidity, meaning that there would be a reduced conformational entropy 
penalty upon binding to a protein target. Furthermore, spirocycles have greater inherent 
three-dimensionality than fused (aromatic)ring systems which can prove advantageous over 
flat compounds that tend to have suboptimal physical properties.169 
It should come a no surprise that this structural motif has been utilised in drug discovery.170 
As Figure 3.8 demonstrates, successfully marketed drugs containing spirocycles. 
 
Figure 3.8 Examples of marketed drugs containing spirocycles.The spirocyclic scaffold is highlighted in red.  
Spirocycles may be classified into three different classes.  
Class 1: the isolated spirocyclic system where there is one or more spirocycle in a molecule 
and the molecule does not fall into the following two classes; 
Class 2: the condensed spirocyclic system where by one or more rings containing a spirocentre 
is fused by an edge to another ring;  
Class 3: the bridged spirocyclic system where the two rings in the spirocycle are additionally 
connected by bridging atoms.  
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These classes are demonstrated in Table 3.1. Each of these classes can be further subdivided 
by the number of spirocentres present. 
Table 3.1 The three classes of spirocycle with example. The red bonds show the spirocycles, the green bonds 
show the condensed cycle and the blue bonds show the bridged cycle. 
Class Example skeleton 
Class 1: isolated 
 
Class 2: condensed 
 
Class 3: bridged 
 
 
These spirocycles were analysed at their differing levels of complexity. The most basic level 
on which spirocycles can be analysed is their ring combination (RC). This is simply the size of 
the two or more rings in the spirocyclic system, ignoring all heteroatoms, multiple bonds, and 
appendages. The next level of complexity is the scaffold of the RC (SC[RC]), wherein the rings 
are furnished with their heteroatoms and multiple bonds. Above this in the hierarchy comes 
the scaffold of the compound as a whole (SC[CPD]) and finally the compound itself (CPD) 
(Table 3.2).171 
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Table 3.2 Table indicating the hierarchy of spirocyclic complexity.  
RC SC[RC] SC[CPD] CPD 
  
 
 
 
Recent research on the ChEMBL chemical library has shown that 47,000 spirocycles are 
biologically active against approximately 200 targets.171 Their distribution between the above 
three classes was assessed, alongside the number of spirocentres, and the size of the fused 
rings. 
The researchers found that from their high confidence data series there were only 47 unique 
ring combinations which contained 1 spirocentre and 25 unique ring combinations which 
contained greater than 1 spirocentre. However, these had a combined activity against 548 
targets (Table 3.3). Proving the field is ripe for research. 
Table 3.3 Number of unique ring combinations (RC) for each class of spirocycle and the number of unique 
biological targets in each class. 
Class Unique RC (1 spiro atom) Unique RC (>1 spiro atom) Unique targets 
1 20 3 219 
2 18 8 240 
3 9 14 89 
 
The number of compounds targeted by the spirocycles varied from 1 to 20. These spirocycles 
also possess potent biological activity with over 60% showing a potency of at least 100 nM 
against one or more targets. 
On more drug focused discovery, a range of 3-6 sized spiro rings have proved useful. For 
example, compound AM-5262 a spiro variant of AM-1638, a FFA1 agonist, showed a two-fold 
increase in potency from an EC50 of 0.162 μM to 0.081 μM. It also presented increased off-
target selectivity against a panel of over 100 GPCRs, ion channels, transporters, and enzymes 
(Figure 3.9).172  
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Figure 3.9 FFA1 agonists AM-1638 and AM-5262. 130131 
In terms of the variety of ring sizes, as to be expected, most of the spiro systems contained a 
six-membered ring joined to three to six-membered rings. Very few medium sized seven- or 
eight-membered rings were represented. This gives two interesting areas for research: one, 
seeing what scaffolds frequently occur in biologically active spirocycles and synthesising a 
diverse spirocyclic library based on these cores; and two, making entirely novel spirocyclic 
ring combinations in a diverse fashion. 
3.3. Scope of this project 
This project seeks to establish chemistry for the rapid assembly of diverse spirocyclic libraries 
using the divergent build/couple/pair (B/C/P) algorithm of DOS. The ideal synthetic route 
would allow for the greatest range of rings to be synthesised orthogonally from each other. In 
addition, the spirocycles synthesised should be as ‘fragment-like’ as possible and leave ample 
vectors for synthetic development. 
To affect this, two synthetic routes were approached. The first installed two terminal alkene 
moieties onto a quaternary centre. Ring closing metathesis was used to close a ring between 
the alkenes and a range of other chemistry was used to produce the second ring of the 
spirocycle. 
Secondly, cycloaddition reactions were exploited to form spirocycles. This required the 
synthesis of a ring wherein an exo-cyclic olefin can be easily installed. With this in place, a 
range of pericyclic coupling partners were used to furnish the second ring off the alkene, 
forming the spirocyclic library. 
Finally, computational methods were explored to enumerate the library (finding the greatest 
number of compounds which could feasibly be made from the synthetic precedent) and 
decorate the library—finding which appendages and modifications would enhance the 
library’s properties. A collaboration was also opened up with the Bender Group to perform 
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an in silico screen of the enumerated library, aiding any future in vitro biological testing of the 
molecules. 
3.4. Glycine-based spirocycle library 
3.4.1. Library strategy 
The challenge in constructing a spirocyclic DOS library is finding a starting material which 
can be appropriately furnished to allow two separate ring forming reactions. These functional 
handles must be able to undergo several different reactions to form distinct scaffold ring 
combinations (SC[RC]), and ideally different ring combinations (RC). Hence a system which 
would allow easy divergence in the build stage, and a reagent-based DOS approach in the 
couple and pair stage, so that pluripotent functional handle can form a variety of rings. 
Cheap and easy-to-handle pre-functionalised starting materials are ideal for building a DOS 
library. Due to this, ethyl glycinate hydrochloride (132) was initially selected as a starting 
material. This comes ideally equipped with an amino and ester group for use in the couple 
and pair stage. Additionally, the α-centre in 132 can be difunctionalised, meaning this carbon 
atom will be the vertex at which the two rings will join to form a spirocycle (Scheme 3.2). 
 
Scheme 3.2 Outline of DOS scheme to synthesise diverse spirocyclic library.  133134135 
With the final pair stage requiring a form of amine and ester/ester derivative coupling, 
orthogonal functionalities were chosen for installation in the build stage. Ring closing 
metathesis (RCM) is a robust catalytic technique in the forming of small rings.173 RCM uses a 
metallocarbene catalyst to connect two olefin moieties. Application to the above scheme 
would mean R1 and R2 are terminal alkenes. These were readily installed via SN2 chemistry. 
When installed, a ring can be formed quickly by addition of a RCM catalyst, such as Grubb’s 
second generation catalyst (Grubb’s II).174 This gives scope to vary the RC by adding a range 
of olefin homologues. Having two olefin functionalities to form the second ring also gives 
orthogonal functionality between the two ring-forming steps. 
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With this in mind, a broad synthetic strategy was devised. Ethyl glycinate hydrochloride (132) 
was furnished with two terminal olefins of varying length. Once installed, the first ring was 
formed via RCM, known as the tail. Then a reagent-based approach was used to form the 
second ring between the pendent amine and ester (Scheme 3.3), known as the warhead. This 
strategy allowed for sufficient scope to access a number of novel RCs and SC[RC]s. 
 
Scheme 3.3 General plan to synthesise a spirocyclic DOS library from ethyl glycinate hydrochloride (132) using 
RCM to synthesise the first ring and a variety of reagents to couple the amine and ester. 136137138 
Once the spirocycles were installed, they were modified to make new SC[RC]s and explore 
their appendage diversity. The alkene on the bottom ring offered synthetic orthogonality to 
the top ring, making such processes easier. 
3.4.2. Building the precursor 
Established methodology allows for easy installation of the allyl moiety onto glycine.175 
Firstly, the amino group was simultaneously protected, and the α-carbon is activated, by 
condensation with benzophenone (139). The α-protons of this Schiff base (140) were acidic 
enough to be removed by base. This anion performed an SN2 reaction, giving the alkylated 
product in good yield. It was chosen to install a but-1-enyl group and an allyl group. This 
formed a cyclohexene ring upon exposure to Grubbs II. But-1-enyl was installed first, leaving 
the more reactive allyl bromide electrophile to react with the tertiary anion formed from 141. 
Both reactions proceeded smoothly and the acidic workup in allyl installation readily 
removed the benzophenone to reveal the free amine, 142 (Scheme 3.4). 
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Scheme 3.4 Synthesis of glycine derivative 142.  
This strategy can be easily modified to install olefins of different length and pendent 
functionality onto glycinate ethyl ester. 
3.4.3. Coupling and pairing to form spirocycles 
With precursor 142 in hand, the warhead and tail rings were formed. As only the Grubbs II 
catalysed RCM is used to form the tail, whereas a variety of chemistry was to form a number 
of warheads, it was logical to form the tail ring first. Grubbs II, however, does not tolerate the 
presence of a primary amine in a reactant.176 Therefore 142 was protected before exposure to 
Grubbs II. The tert-butyloxycarbonyl (Boc) protecting group was selected due to its ease of 
addition and removal, and the fact that the resulting carbamate group would tolerate Grubbs 
II. 
Therefore, amine 142 was readily Boc-protected to give diene 143, which was subjected to 
RCM with Grubbs II. This formed the tail ring as a cyclohexene derivative (144). While the 
amine was still Boc-protected, the ester was reduced to alcohol 145 for future warhead 
synthesis. With these reactions complete, the Boc protecting group was removed to reveal 
primary amine 146 as the HCl salt (Scheme 3.5). 
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Scheme 3.5 Scheme showing the building of the cyclohexene tail of the library. 
Due to the relatively low 57% yield in the reduction of ester 144 to alcohol 145, it was seen 
whether reduction of diene 143 to an alcohol followed by RCM would be higher yielding. 
Reduction of diene 143 gave alcohol 147, however in the more disappointing yield of 27% 
(Scheme 3.6). Therefore, RCM followed by reduction was used as the preferred route. 
 
Scheme 3.6 Reduction of diene 143. 
3.4.4. Pairing to make the spirocycles 
Before exploring the chemistry of amino alcohol 146, it was noted that exposure of the Boc-
protected precursor, 145, to base caused internal displacement of the tert-butoxy group from 
the Boc, forming a oxazolidin-2-one spirocycle, 148 (Scheme 3.8). 
 
Scheme 3.7 Synthesis of oxazolidine-2-one spirocycle, 148. 
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Examples of the nitrogen in 148 acting as a nucelophile are well precedented in the 
literature.177 Therefore, it was explored whether cross-coupling straight to an aromatic centre 
would increase the scope of 148 to be grown with a variety of aromatics. The Goldberg 
reaction was first tried. Although its scope was originally confined to aniline derivatives, this 
has recently been expanded to amides, and carbamates.178,179 Thus, it was seen whether the 
nitrogen carbamate on spirocycle 148 would be tolerated. Unfortunately, no product was 
obtained from this reaction; an inseparable complex mixture was returned. A literature 
procedure180 was tried to couple a meta-acetyl phenyl to spirocycle 148; this only returned 
starting material. Finally, conditions were tried to couple para-nitrile bromobenzene to 148 
(Table 3.4).181 One possibility for the failure of these reactions could be steric hindrance due to 
the adjacent spirocentre. Although there is literature for these reactions to be carried out next 
to a quaternary centre,182 there is no precedent for the reaction next to a 3–7 membered 
spirocycle. 
Table 3.4 Table of conditions for Cu mediated arylation of the carbamate nitrogen. 
 
Entry Coupling partner Conditions Yield 
1 
 
CuI (50 mol%), N1,N2-dimethylethane-1,2-diamine, 
Cs2CO3, dioxane, 90 °C, 16 h 
Complex 
mixture 
2 
 
CuI (10 mol%), trishydroxymethyl ethane, K3PO4, 
dioxane, DMF, 110 °C, 72 h 
SM 
3 
 
CuI (5 mol%), N,N-dimethylglycine, K2CO3, DMF, 
120 °C, 16 h 
SM 
 
Warheads derived from amino alcohol 146 were subsequently explored. Multiple reactions 
can be carried out with vicinal amino alcohols to form rings as well as other precursors in the 
synthetic steps to make 146. First of all, 146 was condensed with imidate 150 to give spirocycle 
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151 containing a dihydrooxazole ring (Scheme 3.8). This procedure allows for ready 
substitution of phenyl in 151 or other groups due to the ease of the imidate synthesis from 
nitriles. 
 
Scheme 3.8 Synthesis of dihydrooxazole spirocycle. 149 150 151 
In a similar manner, an amine substituted dihydrooxazole spirocycle was synthesised by 
exposing amino alcohol 146 to cyanogen bromide. This afforded spirocycle 152 (Scheme 3.9). 
This is an interesting motif containing an H-bond donor/acceptor pair similar to DNA base 
adenine, perhaps privileging it in biological interactions. 
 
Scheme 3.9 Synthesis of amino-dihydrooxazole spirocycle 152. 
An X-ray structure of 152 was taken to confirm the desired product was made. 
 
Figure 3.10 Crystal structure of the (S)–152.  
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It was assessed whether the exocyclic NH2 group on 152 could be readily used as a synthetic 
handle. A patent was adapted to see if the biologically-relevant morpholine could be installed 
on the amino group.110 A quick microwave experiment produced a complex mixture from 
which no discernible product was obtained (Scheme 3.10). 
 
Scheme 3.10 Attempted installation of morpholine moiety onto 152. 153 
Following this, 6-membered rings synthesis of morpholine-derivatives was explored. Firstly, 
a few microwave reactions were tested. Amino alcohol 146 was subjected to microwave 
reaction with ethyl benzoylformate and α-chloroacetophenone to form dihydrooxazine-2-one 
(154) and dihydrooxazine (155) rings respectively. These would give an imine and/or ester 
functionality which could be a useful tool for further fragment growth. Unfortunately, neither 
of these techniques proved successful, even with increasing the number of molecular sieves 
used (Scheme 3.11). 
 
Scheme 3.11 Attempted microwave condensations to form spirocycles. 
A stepwise approach was then tried; either first an imine condensation followed by an SN2, or 
an SN2 followed by an internal imine condensation. Starting from Boc-protected amino alcohol 
145, exposure to base and α-chloroacetophenone failed to yield the desired product; the 
fractions isolated by column chromatography being complex mixtures. Reaction of 146 with 
α-chloroacetophenone under Dean-Stark conditions also failed to yield the imine (Scheme 
3.12). 
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Scheme 3.12 Failed stepwise reactions to give spirocycle 155. 156 157 
Finally, it was postulated that synthesising the morpholin-2-one ring could be more fruitful. 
Following a literature procedure,183 146 was submitted to basic conditions and phenyl 2-
bromoacetate. This gave spirocycle 158 with a morpholin-2-one warhead. With 158 in hand, 
this could be transformed in the desired dihydrooxazine-2-one warhead as well as a 
morpholine via reduction. Exposure of 158 to Pb(OAc)4 readily oxidised it to dihydrooxazine-
2-one spirocycle 159. This has the advantage over similar spirocycle 154 in that it lacks the 
phenyl group and so allows greater scope in Cu-mediated nucleophilic addition into the imine 
(Scheme 3.13). 
 
Scheme 3.13 Synthesis of morpholin-2-one spirocycle 158 and its subsequent transformation into spirocycles 
159. 
Additionally, the regio-isomer of 158, a morpholin-3-one spirocycle, was prepared by reacting 
146 initially with chloroacetyl chloride. The more reactive primary amine formed an amide 
bond with the acid chloride, making compound 160. Subsequent exposure to base allowed for 
an SN2 reaction between the deprotonated alcohol and the chloride forming morpholin-3-one 
spirocycle 161 (Scheme 3.14). 
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Scheme 3.14 Synthesis of morpholin-3-one spirocycle 161. 
Attempted reduction of the amide group in 161 to form the morpholine ring was unsuccessful, 
despite literature precedent.184 Spirocycle 161 was reacted with lithium aluminium hydride at 
room temperature overnight. When TLC showed only starting material, the reaction was 
heated under reflux for another day; starting material was returned (Scheme 3.15). 
 
Scheme 3.15 Attempted reduction of morpholin-3-one spirocycle 161 to morpholine spirocycle 162. 
It was also explored whether the amide could be transformed into the dihydrooxazin-3-amine, 
164, to imitate the same imine-amine functional motif as in 152. A literature procedure was 
followed,185 first reacting 161 with phosphorous (V) sulphide to form morpholin-3-thione 
intermediate (163) which, upon exposure to aqueous ammonia, should form the desired 
dihydrooxazin-3-amine, 164. Unfortunately, NMR after the first sulphonation step showed 
only starting material returned. Therefore, it was seen whether Lawesson’s Reagent would 
affect sulphonation. Again, this failed to produce the desired product (Scheme 3.16). 
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Scheme 3.16 Attempted sulphonation of spirocycle 161 in order to form dihydrooxazin-3-amine spirocycle 
164. 
Although there was a need to protect the primary amine before RCM, this need not be done 
with a Boc-protecting group. A group could be installed in the amino moiety of precursor 142 
which itself could be used to produce a ring. In this way, 142 was reacted with ethyl malonyl 
chloride to form diester 165. Exposure to base cyclised this species to form tetramic acid 
derivative 166, which in turn underwent ester hydrolysis-decarboxylation to give tetramic 
acid diene 167. With no offending primary amine present, the two terminal alkenes were 
readily cyclised using Grubbs II to give tetramic acid spirocycle 168 (Scheme 3.17). 
 
Scheme 3.17 Synthesis of tetramic acid spirocycle 168 from amino ester 142. 
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Tetramic acid is known to exist in two tautomeric forms: the keto form as in 168, or the enol 
form 168b.186 NMR confirmed the more common form of tetramic acid (168) was isolated due 
to the presence of two protons between the ketone and amide. This tetramic acid spirocycle 
gives several vectors for elaboration and derivation into new spirocycles. 
It was investigated whether the oxo-group on the tetramic acid ring would undergo Wittig 
chemistry to form a substituted exocyclic olefin. Stabilised Wittig Reagent (169) was initially 
tried. However, no reaction took place, with the reagents re-isolated. It was examined whether 
the reaction would proceed if 169 were made in situ. Unfortunately, starting material was 
returned (Scheme 3.18). 
 
Scheme 3.18 Attempted reaction of 168 with stabilised Wittig reagent 169. 170 171 172 
It was postulated that 169 might be too stable to react with 168, as the literature example 
showed reaction with an unstablilised ylide.182 Therefore, the reaction was repeated with 
unstabilised ylide, methylenetriphenylphosphorane. The methylene group had much less 
steric bulk than the methylene ethyl ester of 169, also hopefully discounting any steric factors. 
Again, starting material was returned (Scheme 3.19). 
 
Scheme 3.19 Attempted functionalisation of 168 using unstabilised ylide methylenetriphenylphosphorane. 
173 
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With both these failures, it was postulated whether tetramic acid exists in the enol tautomer 
(168b) under the basic reaction conditions, rendering it unable to perform Wittig chemistry. 
This enol form of the tetramic acid was trapped out and isolated as an ethyl ether (174).187 This 
‘protected’ version of 168 could be used to explore functionalisation on the nitrogen (Scheme 
3.20). 
 
Scheme 3.20 Synthesis of 174. 
The extent to which 168 could be transformed into a γ-lactam or α,β-unsaturated-γ-lactam 
was then explored. First, exploiting the enol tautomer of 168, triflic anhydride formed the 
triflate enol 175. This triflate functionality could be exploited in cross-coupling reactions as a 
pseudo-halogen. This was demonstrated by Suzuki-Miyaura coupling 175 with para-
methoxyphenyl boronic acid to give β-functionalised α,β-unsaturated-γ-lactam 176. This is a 
very useful functional handle to install a variety of sp2-sp2 or sp2-sp coupled centres (Scheme 
3.21). 
 
Scheme 3.21 Transformation of 168 into β-functionalised α,β-unsaturated-γ-lactam 176. 
X-ray crystallography was used to produce a crystal structure of 176 to assess its geometry 
(Figure 3.11). This showed that the α,β-unsaturated-γ-lactam and the aromatic ring were in 
the same plane and flat with respect to one another.  
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Figure 3.11 Crystal structure of (R)-176. 
In addition to the substituted α,β-unsaturated-γ-lactam, it was seen whether an unsubstituted 
α,β-unsaturated-γ-lactam could be synthesised via elimination. Firstly, conditions were 
repeated that were used in the similar reduction-elimination of 6-chloroindanone (entry 1 in 
Table 3.5). The initial reduction to form alcohol 177 proceeded without issue however 
elimination was not observed. Next, a literature procedure was tried,188 in which the authors 
performed a reduction followed by elimination on a spirocyclic tetramic acid. Unfortunately, 
when this was tried carrying 177 through crude, only 10% of 168 was returned after 
purification. Therefore, the reactions were repeated step-wise as described in the literature. 
Reduction worked smoothly, followed by high-yielding mesylation of the alcohol to give 178. 
Alas, upon subjection to the final elimination conditions, 178 was consumed but no discernible 
product was detected. Finally, conditions were tried from a paper which performed the same 
reduction on a α-N-gem-dimethyl tetramic acid.189 After reduction trifluoroacetic anhydride 
was used to trifluroacetylate both the alcohol and the amide. Exposure to TEA eliminated 
trifluroacetate and reaction with KHCO3 revealed the amide giving 179 in 30% yield (Table 
3.5). 
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Table 3.5 List of conditions to transform tetramic acid spirocycle 168 into α,β-unsaturated-γ-lactam 179. 
 
Entry Conditions Yield 
1 1) NaBH4, MeOH, RT, 1h. 2) TsOH, Tol, reflux, 2h Alcohol 
returned 
2 1) NaBH4, MeOH, RT, 1h. 2) MsCl, TEA, DBU, DCM, RT, 3h 10% of SM 
returned 
3 
NaBH4, MeOH, RT, 1h, gave 177 in 86% yield; then 
MsCl, TEA, DCM, gave 178 in 99% yield; then 
TEA, THF, reflux 
No product 
4 
1) NaBH4, MeOH, RT, 1h. 2) TFA anhydride, reflux, 12 h. 3) 
TEA, DCM, RT, 12 h. 4) KHCO3, MeOH, RT, 2 h.  
30% 
 
Although conditions in entry 3 failed to achieve the desired α,β-unsaturated-γ-lactam, 179, it 
did allow access to γ-lactams 177 and 178.  
The crystal structure of 179 was also obtained for future comparisons with the spatial 
properties of derivative 176 (Figure 3.12). 
 
Figure 3.12 Crystal structure of (S)-179. 
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It was explored whether the amino and ester groups of precursor 142 could be linked in such 
a way so as to form rarer 4- and 3-membered rings. It was decided to pursue these linking 
strategies before RCM of the terminal alkenes, as having the cyclohexene ring may limit 
gyration of the amino and ester appendages in forming rings with bond angles less than the 
preferred 109.5°. 
The synthesis of 4-membered β-lactam was explored. For this to be synthesised it would 
require the homologue of amine or ester to be initially synthesised. Homologation of 
carboxylic acids is known via the Arndt-Eistert reaction.190 This sees a carboxylic acid activated 
to the acid chloride before reaction with diazomethane to form a diazoketone. Exposure to 
silver (I) causes this to undergo the Wolff-rearrangement and form the homologous carboxylic 
acid (Scheme 3.22). 
 
Scheme 3.22 General scheme for the Arndt-Eistert reaction for homologation of carboxylic acids. 
180181182183 
Once the homologous carboxylic acid has been obtained, intra-molecular amide coupling 
reactions may couple the carboxylic acid with the amine to yield a β-lactam. 
Hydrolysis of ester 143 proceeded without issue, giving carboxylic acid 184 (Scheme 3.23). 
Next, it was decided not to use diazomethane as the reagent in the Arndt-Eistert reaction due 
to the high explosion risk. Therefore the more stable analogue, TMS-diazomethane, was 
used.191 The crude result of the Arndt-Eistert reaction (185) was carried through to a DCC 
mediated amide coupling.192 Unfortunately, no product could be isolated. 
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Scheme 3.23 Attempted synthesis of β-lactam 186. 
Finally, it was seen whether a 3-membered aziridine ring could be synthesised. Starting from 
alcohol 147, a literature sequential alcohol-activation, then internal SN2, was tried.193 This 
activated the alcohol by tosylation, however the presence of base did not  result in internal 
cyclisation. Unfortunately, only a crude mixture of alcohol 147 and tosylated alcohol 187 was 
returned (Scheme 3.24). 
 
Scheme 3.24 Attempted synthesis of 188 from 147. 
3.4.5. Summary 
In summary, this strategy (to synthesise a spirocyclic library from ethyl glycinate 
hydrochloride (132) by furnishing it with two terminal olefins to allow orthogonal ring 
formation between these and the amino and ester moieties) has yielded 13 novel spirocycles 
comprising 2 RCs, and 10 SC[RC]s (Scheme 3.25). The longest linear sequence in making a 
spirocycle was 9 steps (synthesis of 161). These fragment scaffolds give ample chemical handle 
for further fragment growth. The warheads are appropriately furnished to allow a variety of 
chemistry to be installed at various points (only a fraction of the possible elaborations are 
shown here). In addition, the tail section of the spirocycle could be modified to allow for 5- or 
7- or larger membered rings. The olefin synthetic handle in the tail is orthogonal to the 
functionality in the warheads allowing for easier synthetic development of this species. 
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Scheme 3.25 Scheme summarising the spirocyclic derivatives of ethyl glycinate 132. 
3.5. Pericyclic spirocycle libraries 
3.5.1. Pericyclic reactions 
Pericyclic reactions proceed via a cyclic aromatic transition state and are a powerful and 
versatile method of forming carbon-carbon bonds. Transformations are often regio-and 
diastereiospecific because of the frontier orbital control of this reaction class. 
The cycloaddition class of pericyclic reactions is defined as:194 
A reaction in which two or more unsaturated molecules (or parts of the same 
molecule) combine with the formation of a cyclic adduct. 
For the synthesis of spirocycles, this requires unsaturation in both coupling partners to form 
the spirocyclic adduct. Practically, this means a ring should be furnished with an exo-cyclic 
double bond and the coupling partner would be a diene or 1,3-dipole. As the interaction is 
controlled by frontier orbitals, this means the reactions are under electronic control. 
The two types of cycloaddition explored in this section will be a [4+2] Diels-Alder 
cycloaddition and a [3+2] 1,3-dipolar cycloaddition. Because these reactions are under orbital 
control, there must be the right electronic match between the coupling partners to ensure the 
reaction proceeds. 
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Diels-Alder reactions can be split into two categories: normal-electron-demand and inverse-
electron-demand. In a normal-demand reaction, an electron-rich diene’s frontier orbital’s 
HOMO is the most similar in energy to a dieneophile’s LUMO. Using a frontier molecular 
orbital (FMO) approach, it can be seen that the molecules combine suprafacially (Figure 3.13). 
 
Figure 3.13 Examples of normal-electron-demand and inverse-electron-demand Diels-Alder reactions. a) 
Examples of electron-rich diene 189 with electron-poor species dieneophile 190 in a normal-demand 
interaction and electron-poor diene 191 with electron-rich dieneophile 192 in an inverse-demand interaction, 
b) Orbital energy diagram of the HOMOs and LUMOs interacting, c) a frontier diagram showing the orbital 
overlap of the HOMOs and LUMOs showing the symmetry dictating the suprafacial nature of the interactions. 
Additionally, due to the orbital control of the reaction there is high regiocontrol on the 
arrangements of the pendent functionality in the adduct. The orbitals with the largest 
coefficients will have the better overlap and so will interact preferentially. Drawing the 
resonance structures can aid in the prediction of which orbitals are likely to interact (Figure 
3.14).  
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Figure 3.14 Diagram showing the origin of selectivity in the Diels Alder reaction: a) the two resonance 
structures of electron-rich diene 189 (189a in blue formed from the blue curly arrows and above 189b in red 
from the red curly arrows). The location of the negative charge shows the location of the orbitals with the 
greatest coefficient in the HOMO. The positive charge on the resonance structure of electron-poor 
dieneophile 190 (190a) shows the location of the largest orbital coefficient on the LUMO; b) the major 
product (193) of the reaction is formed when the orbitals with the most similar coefficient overlap and the 
minor product (194) is formed by the disfavoured dissimilar interaction. 
The same theory can equally be applied to 1,3-dipolar cycloadditions. A 1,3-dipole is a 
functional group with a pair of delocalised electrons shared over three atoms, giving 
resonance structures where one atom has a formal positive charge, and another has a formal 
negative charge. 
An FMO approach of the interaction of 1,3-dipoles with dipolarphiles can also be used to see 
which interactions are favoured. In this case 1,3-dipoles can be divided in three categories: 
Type I, Type II, and Type III (Figure 3.15).  
Type I: This dipole has a high lying HOMO (as most closely resembles an electron-rich diene). 
This mean it will quickly react with electron-poor alkenes but react slowly or not at all with 
electron-rich alkene.195 
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Type II: In this case the HOMO and LUMO of the dipole are so placed that they could readily 
overlap with both electron-rich and electron-poor alkenes.196 
Type III: This dipole has a low energy LUMO (just as the electron-poor diene in the Diels Alder 
reaction) which is positioned to react best with electron-rich alkenes.197 
 
Figure 3.15 Diagram of the three dipole types interacting with dipolarphiles. A Type I dipole interacts best 
with a low energy LUMO from an electron-poor dipolarphile. Type II dipoles have HOMO and LUMO so placed 
that interaction can be made with both electron-rich and electron-poor dipolarphile. Type III dipoles have a 
low lying LUMO which can best interact with a high-energy HOMO from an election-rich dipolarphile. 
3.5.2. Dehydroalanine derived spirocycles 
In the synthesis of the ethyl glycinate series, a variety of chemistry was established to link the 
amine group with ester, or in its reduced form, the alcohol. It was proposed that this chemistry 
could be coupled with another way of making rings other than by RCM of installed terminal 
alkenes. A library could be built from a dehydroalanine derivative. This has the amine group 
and ester group to be exploited as before, but these are gem-disposed on a double bond 
meaning pericyclic reactions at this olefin would produce spirocycles. Thus, a general scheme 
was proposed where L-serine ethyl ester (195) could be transformed into dehydroalanine 
derivative (196) which in turn could be coupled and paired to make a spirocyclic library 
(Scheme 3.26). The order of the coupling and pairing is variable in this case depending on the 
functionality involved and the group which can be synthesised. 
 
Scheme 3.26 An outline of the proposed spirocyclic library constructed from dehydroalanine. 197 198 
Additionally, considering 195 has both alcoholic and ester functionalities, a ring can be 
constructed from this molecule before an alkene is revealed. This could then be subject to 
pericyclic chemistry, constructing the library (Scheme 3.27). 
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Scheme 3.27 A second approach to constructing the pericyclic libraries starting from L-serine. 199 200 
This allows for flexibility in the construction of these libraries which may prove useful if 
certain synthetic paths become fruitless. 
Starting along the dehydroalanine path, L-serinate ethyl ester hydrochloride (195) was readily 
Boc-protected (201) and then eliminated to form N-Boc-dehydroalanate ethyl ester (202). 
Reduction of 202 to alcohol 203 was explored as a potential route to 4-methyleneoxazolidin-
2-one (205). With this in hand it was hoped a variety of pericyclic reactions could be explored. 
The reduction of 202 proved challenging, with alcohol 203 proving unstable (a 1H NMR of 203 
was obtained however by the time 13C and 2D NMR were obtained, the sample had 
decomposed). Thus, alcohol 203 was reacted immediately with KOtBu in an effort to yield 205. 
However, the endo-cyclic alkene isomer 204 was obtained. This was even the case when base 
was limited (Scheme 3.28). 
 
Scheme 3.28 Summary of work to make key intermediate 202 and attempted synthesis of 4-
methyleneoxazolidin-2-one 205.  204 205 
Although it was disappointing that 205 could not be made, the intermediate 202 could be used 
in pericyclic chemistry to generate a ring before the amine and ester are coupled to form the 
spirocycle. 
With the carbamate group being an electron donor into the alkene and the ester group being 
an electron withdrawing from the alkene, the electronic state of the alkene in 202 was 
established by 13C NMR. The chemical shift of a magnetic nucleus (δ) is related to the effective 
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magnetic field it experiences (Beff). This is the product of the external applied field from the 
machine’s magnet (B0) and any induced field from the electronic structure of the molecule 
(Bind). The induced field is opposed to the applied field and is larger the greater the electron 
density around the nucleus. The induced field can be calculated around a given atom from its 
chemical shift. 
Table 3.6 shows clearly that 202 is an electron rich alkene. The molecule was split into its two 
components as an ethyl acrylate moiety (206) and a tert-butyl vinylcarbamate moiety (207). 
The difference in the induced fields about the α and β carbons of each molecule was 
calculated. The results clearly show that 202 is electron-rich at the β carbon (being more 
similar to tert-butyl vinylcarbamate electronically). 
Table 3.6 Table calculating the difference in the induced magnetic field (Bind) between the α and β carbons 
on ethyl acrylate, tert-butyl vinyl carbamate and 202. δ = chemical shift, νnucleus = resonance frequency of the 
13C nucleus, Beff = effective magnetic field experienced by the nucleus, Bind = magnitude of the induced 
magnetic field around the nucleus, Cα – Cβ = the difference in the induced magnetic field between the α and 
β nucleus. 
 
Compound Nucleus δ/ppm νnucleus/MHz Beff/T Bind/T Cα–Cβ/μT 
206 Cα 128.8 100.6257 9.39689 0.034957  
 Cβ 131.3 100.6260 9.39692 0.034928 29.13 
207 Cα 128.6 100.6257 9.39689 0.034953  
 Cβ 95.5 100.6224 9.39658 0.035264 -311.00 
202 Cα 131.5 100.6260 9.39692 0.034926  
 Cβ 104.8 100.6233 9.39667 0.035177 -250.86 
 
Knowing that 202 is an electron rich alkene, it would most likely perform cycloadditions with 
Type II and Type III dipoles as well as inverse-demand dienes. 
Compound 202 was first reacted with a nitrile oxide dipole formed in situ from 
hydroxylimidoyl chloride 209. Because of the electron-rich nature of the alkene in 202, the 
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reaction was expected to proceed via transition state TS210, forming the regioisomer 210. This 
was confirmed by NOESY NMR (Figure 3.16) showing spatial proximity between the ortho-
aromatic protons (H11) and the methylene protons in the isooxazole ring (H8). Compound 
210 was reduced, giving alcohol 211 which was cyclised to give spirocycle 212 (Scheme 3.29). 
A crystal structure was taken of 212 to confirm the regiochemical assignment of 210 (Figure 
3.17). 
 
Scheme 3.29 Synthesis of spirocycle 212.  208 209 210 211 212 
 
Figure 3.16 NOESY NMR of compound 210 showing correlation between protons 11 and 8.  
  
H11 
H12&13 
NH 
H6 
H8 
H11 
H12&13 
NH 
H6 H8 
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Figure 3.17 Crystal structure of spirocycle 212 confirming the isomer synthesised. 
Benzyl azide was also reacted with 202 in an attempt to form a dihydro-1,2,3-triazole 
spirocycle. Initially, following a literature procedure,198 heating the reaction under reflux for 
6 h only gave a mixture of benzyl azide and 202. Repeating the reaction by heating under 
reflux overnight seemed to produce the desired product; however, despite the NMR losing 
the olefin peaks of 202 and gaining aromatic peaks to integral 5, the benzyl methylene peak 
was absent and a valid structure could not be proposed to support the data. Finally, a more 
forcing condition of heating to 100 °C in a sealed vessel for 48 h was tried yet no identifiable 
product was isolated from this reaction (Scheme 3.30).  
 
Scheme 3.30 Attempted synthesis of dihydro-1,2,3-triazole 213. 
The second proposed strategy was then explored: forming a ring, revealing the alkene, and 
then performing the cycloaddition. To minimise the use of protecting groups, it was first tried 
to construct the ring using the already present amine and alcohol functionality in L-serinate 
ethyl ester 195. 
Firstly, a morpholin-3-one was the synthetic target, using similar chemistry as in the synthesis 
of 161. Amino alcohol 195 was reacted with chloroacetyl chloride giving amide 214. Only a 
small amount of the difunctionalised by-product 215 was observed. It was hoped that the 
facile SN2 ring closing between the alcohol and the chloride could produce morpholin-3-one 
216, yet unfortunately this was not the case. Reaction with KOtBu in THF gave an insoluble 
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jelly, suggesting polymerisation had taken place. Switching the solvent to HOtBu produced 
the same product, as did IPA. However, this product was submitted for reduction in the hope 
that some of alcohol 217 could be recovered post-purification. No reaction took place. NMR 
analysis of the jelly seemed to suggest alkene 218 had been the product of the reaction (Scheme 
3.31). 
 
Scheme 3.31 Attempted synthesis of morpholin-3-one precursor for cycloadditions. 
The pre-furnished amino alcohol in 195 allows quicker synthesis of the oxazolidin-2-one ring 
than previously. Reacting 195 with triphosgene joins the amine and the alcohol to form 
oxazolidin-2-one 219. However, despite literature precedent,199 the reduction to 220 could not 
be affected. Despite multiple attempts and the TLC in each case showing a spot-to-spot 
reaction, no material was left post work-up. Thus, this synthetic strategy was abandoned 
(Scheme 3.32). 
 
Scheme 3.32 Synthesis of oxazolidin-2-one ring and attempted reduction. 
Finally, reaction of 195 with ethyl benzimidate (150) yielded dihydrooxazole 221 which was 
subsequently reduced to alcohol 222. In spite of several attempts to eliminate this alcohol it 
was returned by the reaction (Scheme 3.33). 
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Scheme 3.33 Formation of dihydrooxazole ring but failed elimination. 223 
A second approach to forming the ring and revealing the alkene was tried. This time, the free 
alcohol on 195 would be TBS-protected before ring forming reactions then a deprotection-
elimination could reveal the olefin. 
Compound 195 was readily TBS protected (224). Firstly, synthesis of the morpholin-3-one ring 
was re-examined. Chloroacetyl chloride acetylated the free amine giving compound 225 
which was reduced to give alcohol 226 (Scheme 3.34). Again a 6-exo-tet ring closure was 
attempted using the previous conditions to produce morpholin-3-one 227. This produced a 
clean product by NMR, however this was not the desired product (Figure 3.18). The TBS 
group was present however it was one CH2 group short of 227. No structure or reaction 
mechanism could be proposed which satisfied the given NMR. 
 
Scheme 3.34 Synthesis of morpholin-3-one precursor 226. 
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Figure 3.18 1H NMR of reaction of 226 with base. 
Further, the synthesis of the tetramic acid warhead was explored. The same process in the 
synthesis of 168 was repeated. Reaction of TBS-protected serine ethyl ester 224 with ethyl 
malonyl chloride gave compound 228. However, several attempts at repeating the ring 
closure-hydroylsis-decarboxylation to afford tetramic acid derivative 229 failed (Scheme 3.35).  
 
Scheme 3.35 Successful reaction of 224 to give diester 228 however cyclisation to form tetramic acid 
derivative failed.  
With this in mind, a different approach was taken. The literature showed that reaction of 
compound 224 with Bestmann’s ylide formed the enol ether of tetramic acid via internal Wittig 
reaction.200 When this reaction was performed, the expected tetramic acid enol ether with TBS 
protected alcohol was not observed. Instead the more desirable elimination product, 230, was 
isolated. This avoided additional steps to reveal the olefin via elimination. The presence of the 
catalytic amount benzoic acid aided in the deprotection-elimination. The eliminated enol was 
observed as a by-product previously,200 however in this case it was major product of the 
reaction (Scheme 3.36). 
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Scheme 3.36 Synthesis of enol ether tetramic acid derivate 230 via Bestmann’s ylide. 231 
Due to the presence of two alkene moieties in 230, it was decided that deprotection of the enol 
ether to reveal the tetramic acid in ketone form was necessary before the pericyclic reaction to 
ensure selectivity on the olefin. This was initially tried with conc. HCl in THF but the reaction 
returned a complex mixture. However, due to literature precedent of this transformation, it is 
expected to work in slightly different solvents e.g. ether or dioxane.190 
In summary, despite difficulty in forming the exo-cyclic olefin from elimination, a spirocycle 
was formed by pericyclic reaction with N-Boc-dehydroalanine ethyl ester and forays have 
been made toward synthesising tetramic acid with an exocyclic double bond.  
3.5.3. 3-Azetidinone derived spirocycles 
Alongside the synthesis of exo-cyclic olefins from L-serinate ethyl ester hydrochloride, 195, 
pericyclic chemistry was also explored to investigate its application to a range of other exo-
cyclic olefins.  
In this case, the ease of transforming ketones into alkenes via the Wittig reaction was used. 
The ‘build’ stage would see the construction of a ring which possesses a ketone. The ‘couple’ 
stage reacted this ketone with a Wittig reagent to form an alkene. Depending on the Wittig 
reagent used, the subsequent alkene can be furnished with various groups which may change 
its reactivity in the ‘pair’ step. In pairing, various pericyclic coupling partners could be used 
to form the spirocycle. 
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Scheme 3.37 Outline of B/C/P strategy for azetidin-3-one based spirocyclic library. 232233234 
Due to the wide commercial availability of rings possessing ketone functionality, it was 
decided that the ‘build’ stage could be by-passed by purchasing the desired ring. N-Boc-
azetidin-3-one (235) was selected as a starting material. Firstly, due to its commercial 
availability, and secondly, despite effort being directed towards their synthesis201, four 
membered aza-spiro rings are under-represented in spirocyclic space.171 Thirdly, the nitrogen 
in the ring is a useful vector for further elaboration. Therefore, a general scheme was 
proposed; N-Boc-azetidin-3-one (235) would be furnished with an exo-cyclic olefin via the 
Wittig reaction, and then the spirocycle would be formed via a pericyclic reaction using a 
similar method as outlined in section 3.5.2 (Scheme 3.37). 
N-Boc-azetidin-3-one (235) was appropriately furnished with an ethyl acetate substituted 
olefin by Wittig reaction to give compound 236. The ethyl acetate substitution was chosen as 
a versatile synthetic handle for future modification and to ensure the olefin was electron-
deficient to allow for a greater range of pericyclic reactions (Scheme 3.38). 
 
Scheme 3.38 Wittig reaction forming α-β unsaturated ester 236. 
Compound 236 was first reacted with previously synthesised nitrile oxide precursor 209 and 
gave spirocycle 237. In contrast to the synthesis of 210, which took an hour to complete, this 
reaction was complete within minutes and the yield of the product diminished if the reaction 
was left for a long time (Scheme 3.39). 
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Scheme 3.39 Cycloaddition with nitrile oxide forming isoazole 237. 
Compound 236 was also reacted with benzyl azide, a reaction which 202 was unable to 
perform. An initial attempt following a literature procedure202 by stirring at 45 °C for 12 h 
without solvent simply returned 236. However, the procedure was adapted, and the mixture 
was heated to 100 °C in a sealed vessel for 48 h. This did produce the desired dihydro-1,2,3-
triazole spirocycle product, 238 (Scheme 3.40). 
 
Scheme 3.40 Cycloaddition with azide forming 1,2,3-triazole 238. 
Next, being an electron deficient alkene, 236 should also be able to perform cycloaddition 
reactions with Type I dipoles and ‘normal demand’ electron-rich dienes. An attempt was 
made to form some bridged cyclic structures using the Diels-alder reaction. Firstly, it was 
attempted to react 236 with furan using a Lewis acid catalyst of zinc iodide.203 After refluxing 
overnight at 40 °C, all of the starting material was returned unreacted. The same result 
occurred when the reaction was repeated in a sealed tube at 50 °C. Therefore, another set of 
conditions was tried. These saw the reaction repeated with Lewis acid catalysis from niobium 
(V) chloride and the reaction carried out –20 °C.204 Again, the starting material was returned 
and spirocycle 239 was not isolated (Scheme 3.41). 
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Scheme 3.41 Diels-Alder reactions between furan and 236. 
Another attempt was made at a Diels-Alder reaction using 2-(trimethylsiloxy)-1,3-
cyclohexadiene with stoichiometric amounts of titanium tetrachloride. Following the 
literature, this was performed at –40 °C.205 Despite the TLC indicating a product had been 
formed, nothing could be isolated from column chromatography (Scheme 3.42).  
 
Scheme 3.42 Attempted Diels-Alder reaction with 2-(trimethylsiloxy)-1,3-cyclohexadiene. 240 
Moving to Type I dipoles, it was decided to move beyond standard 1,3-dipoles and try an 
oxypyrylium zwitterion which could undergo [5+2] cycloaddition with a dipolarphile. The 
precursor to this zwitterion was readily synthesised using literature procedure.206 Furan 241 
was expanded into six-membered hemi-acetal 242 which was acetylated to give oxypyrylium 
zwitterion precursor 243 (Scheme 3.43). 
 
Scheme 3.43 Transformation of (5-formylfuran-2-yl)methyl acetate into oxypyrylium precursor. 
This was submitted to cycloaddition with 236. Unfortunately, in this case only the 
oxypyrylium dimer (244) was observed (Scheme 3.44). 
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Scheme 3.44 Reaction of oxypyrylium zwitterion with 236. 245 
3.5.4. 1,4-Oxazepane based library 
7-Membered rings are underrepresented in spirocyclic libraries.171 Therefore increasing their 
representation in these libraries would hopefully allow a greater probing of biologically 
relevant chemical space. 1,4-Oxazepanes were chosen as a 7-membered ring to build a library 
around because of their potential to be synthesised from amino acids. Additionally, they are 
a privileged structure, having many biological effects including antifungal,207 anti-viral,208 
anti-congestive heart failure,209 and acting as apoptotic agents (Figure 3.19).208 
 
Figure 3.19 A selection of biologically active compounds containing a 1,4-oxazepane ring (highlighted in red). 
Amino alcohols were chosen as a good starting material for 1,4-oxazepane synthesis as they 
are easily derived from the large amino acid pool and can carry intrinsic stereochemistry. The 
1,4-oxazepane could then be built by reacting an amino alcohol with a three-carbon linker. 
This could then be furnished with an exo-cyclic olefin on which a range of pericyclic reactions 
could be paired to create the spirocycle library (Scheme 3.45). 
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Scheme 3.45 Outline of DOS 1,4-oxazepane spirocyclic library. R1 represents a range of functionality from 
commercially available amino acids and amino alcohols. X is a functionality that can be manipulated during 
the couple stage to reveal an exo-cyclic olefin. Finally, the range of dienes and dipoles can be used to form 
the spirocycles in the pair stage. 246 247 248 249 
Initially N-Boc-ethanolamine (250) was chosen as a starting material as it lacked the α-pendent 
group found in all other amino alcohols derived from the naturally occurring amino acids. 
This was pre-treated with exactly two equivalents of sodium hydride before reaction to 1,3-
dichloroacetone (251); however, NMR of the crude reaction mixture did not show the desired 
product (252, Scheme 3.46). 
 
Scheme 3.46 Attempted formation of 1,4-oxazepane ring with 1,3-dichloroacetone. 
The same reaction was repeated with L-prolinol (254) to form a condensed spirocycle and to 
explore the amino acid pool as a source for 1,4-oxazepane formation. The prolinol (254) was 
easily synthesised from L-proline (253) via literature reduction.210 Again the 1,4-oxapene 
synthesis was repeated, however this failed to yield the desired product in either DMF or THF 
as solvents (Scheme 3.47). 
 
Scheme 3.47 Repeat of 1,4-oxazepane synthesis with prolinol. 253 254 255 
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Wondering whether the 1,3-dichloroacetone was active enough to react with the amino 
alcohol, it was iodinated to 1,3-diiodoacetone (256) via the Finkelstein reaction. This was then 
reacted with prolinol and N-benzyl-ethanolamine, as the fluorescent benzene ring may aid in 
detection during reaction monitoring and purification. In this case a weaker base, potassium 
carbonate, was used as it was thought that sodium hydride may have been too strong and 
causing enolization of 1,3-dichloroacetone. The reaction with prolinol did not produce the 
desired product (257). However, the reaction with N-benzyl-ethanolamine produced an NMR 
spectrum of the crude product seemed to suggest 1,4-oxazepane 258 had been produced. 
Attempted purification could not get the small quantity of material clean enough to confirm 
its synthesis (Scheme 3.48). 
 
Scheme 3.48 1,4-Oxazepane synthesis with 1,3-diiodoacetone, showing the attempted reaction been prolinol 
and N-Boc-ethanolamine. 
Removal of the ketone from the coupling partner was considered for two reasons. One, the 
presence of base and/or deprotonated alcohols and amines may cause competing enolization; 
two, the ketone itself it susceptible to nucleophilic attack. Therefore, the haloacetones were 
replaced with 1,3-dichloropropanol (259). Upon reaction with N-benzyl-ethanolamine no 
discernible product (260) was seen. However, a small amount (<5%) of 1,4-oxazepane 261 was 
believed to have been identified by NMR spectroscopy; however, like before, this couldn’t be 
isolated cleanly enough or in high enough yield to progress further in the chemistry (Scheme 
3.49). 
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Scheme 3.49 1,4-Oxazepane synthesis with 1,3-dichloroisopropanol, showing the attempted reaction been 
prolinol and N-Boc-ethanolamine. 
Additionally, a TBS-protected analogue of 1,3-dichloropropanol, compound 262, was 
submitted to the same coupling conditions with N-benzyl-ethanolamine in case the presence 
of the free alcohol in 259 prevented coupling. However, this did not yield 263 (Scheme 3.50). 
 
Scheme 3.50 TBS-protection of 1,3-dichloroisopropanol before attempted 1,4-oxazepane. 
It was then examined whether a functional group other than a ketone or alcohol could be used 
in the coupling partners. A terminal alkene could also be used. This might be transformed 
into a ketone via the Lemieux–Johnson oxidation or submitted for pericyclic reactions itself.  
Therefore 1,3-dichloroisobutene (264) was selected as a coupling partner. This was reacted 
with N-Boc-ethanolamine (250) under sodium hydride as a base and DMF solvent. This did 
produce a 1,4-oxazepane ring however, in the process, the nitrogen had its Boc-group 
removed and the olefin isomerised to an endo position within the ring (265, Scheme 3.51). 
 
Scheme 3.51 Synthesis of 1,4-oxazepane with endo-cyclic olefin. 
The reaction was repeated with prolinol under similar conditions with THF as solvent. This 
time a 1,4-oxazepane ring was formed with the desired exo-cyclic olefin (266) albeit in a 
disappointing 38% yield (Scheme 3.52). 
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Scheme 3.52 Synthsis of 1,4-oxazepane, 266, from prolinol and 1,3-dichloroisobutene. 
With the first 1,4-oxazepane in hand, its oxidation was explored to transform the alkene into 
a ketone so that the Wittig reaction could be exploited to allow functionalised alkenes. Initially 
a Lemieux-Johnson oxidation was tried. Unfortunately, this reaction only returned 15% of the 
starting material and no product (Entry 1, Table 3.7). Therefore, the reaction was repeated 
with 20% more catalyst and at a slightly lower concentration. Again, none of the desired 
product (267) was produced (Entry 2, Table 3.7). Finally, the sodium metaperiodate 
equivalents were doubled so that this key oxidising agent was in excess. This did not yield the 
product either (Entry 3, Table 3.7). As can be seen from the 1H NMRs (Figure 3.20), entries 2 
and 3 gave the same product. In both cases, the alkene CH2 peaks were still present as well as 
the other peaks found in the starting material. The new peaks could not be assigned, but all 
appeared in the region of the peaks for the 1,4-oxazepane ring. 
Therefore, a different metallic oxidising agent was tried. A literature-based ruthenium (III) 
chloride oxidation was tried with Oxone acting the co-oxidising agent.211 Finally, the 
ruthenium (III) chloride oxidation was repeated with sodium metaperiodate as the co-oxidant, 
but to no avail.  
 
 
 
 
 
 
 
 
3.5 Pericyclic spirocycle libraries 
103 
 
Table 3.7 Conditions for attempted oxidation of temrinal alkene to ketone. 
 
Entry Conditions Yield 
1 OsO4 (2.5% in tBuOH, 0.5 mol%), NaIO4 (2.0 eq), Dioxane (0.3 M), 
H2O (0.3 M), 18 h, RT 
15% SM 
retuned 
2 OsO4 (2.5% in tBuOH, 0.6 mol%), NaIO4 (2.0 eq), Dioxane (0.25 
M), H2O (0.25 M), 18 h, RT 
21% by mass 
of by-product 
3 OsO4 (2.5% in tBuOH, 0.6 mol%), NaIO4 (4.0 eq), Dioxane (0.25 
M), H2O (0.25 M), 18 h, RT 
27% by mass 
of by-product 
4 RuCl3 (3.5 mol%), Oxone (2.5 eq), NaHCO3 (7.8 eq), MeCN/H2O 
(5:3, 0.02 M), 30 min, RT 
Complex 
mixture 
5 RuCl3 (3.5 mol%), NaIO4 (2.0 eq), DCE/H2O (5:4, 0.1 M), 2H, RT Complex 
mixture 
 
 
Figure 3.20 1H NMR from attempted Lemieux-Johnson oxidation of 266. The red spectrum is the 1H NMR of 
purified 266. The green, blue, and purple spectra are the purified product of entries 1, 2, and 3 respectively 
in Table 3.7. 
266 
Entry 1 
Entry 2 
Entry 3 
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Finally, in an attempt to form a spirocycle with 1,4-oxazepane 266, and questioning the 
reactivity of the alkene through the attempted oxidations, it was decided to react 266 with a 
carbene to undergo a [1+2] carbene insertion into a double bond. Thus, a literature procedure 
of rhodium (II) acetate mediated ethyl diazo acetate carbene generation was used to 
cyclopropanate the olefin in 266. Despite a couple of attempts, only the carbene dimer (diethyl 
maleate) was isolated cleanly enough. 
 
Scheme 3.53 Reaction between 266 and ethyl diazo acetate. 268 269 
Due to the difficulties in constructing the 1,4-oxazepane ring and the problems in 
functionalising the ring when constructed, it was decided to abandon this line of research and 
focus on analysing the libraries already constructed. 
3.6. Expansion and analysis of libraries 
3.6.1. Enumeration and decoration libraries 
The synthesis of the libraries above only represents a proportion of the scope of the chemical 
space the chemistry could probe. The full extent of this space can be appreciated by 
enumerating and decorating the libraries synthesised. In this context, enumeration means the 
combination of chemistry to form different scaffolds. This would be regarded as the SC[CPD] 
in Table 3.2. Decoration is the addition of appendages onto the SC[CPD] after it has been 
synthesised. 
In the glycine-based spirocyclic library, only the six-membered cyclohexene tail ring was 
used. However, work by Attila Sveiczer also synthesised cyclopentene and cycloheptene tail 
rings. Additionally, he performed some double bond modifications (Figure 3.21). 
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Figure 3.21 Summary of the tails and modifications synthesised by Sveiczer. 
It is not necessary to synthesise each of these tails with each of the warheads as the modular 
nature of the chemistry means each can be made independently of one another. Therefore, a 
library can be constructed wherein all the spirocycles could be synthesised. 
A first-generation library (1GLY) was computationally enumerated combining all the 
synthesised warheads (as detailed in section 3.4), with all the tails synthesised by Sveiczer 
(Figure 3.21). This is the library with the highest synthetic confidence.  
A second-generation library was also enumerated (2GLY). This extended the scope of the tails 
by predicting that all the alkene modifications made to the cyclohexene ring would also be 
successful on the cyclopentene and cycloheptene rings. Additionally, a cycloheptene isomer 
with modification was also included in this library (Figure 3.22). 
 
Figure 3.22 A diagram showing the component parts of libraries 1GLY and 2GLY. 1GLY is necessarily a sub-
library of 2GLY. 
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The properties of these two libraries were analysed and compared to indicators of fragment-
likeness (RO3) and likely success in biological screening. 
Table 3.8 Comparison of the two enumerated libraries, 1GLY and 2GLY , showing the average value of the 
properties with the standard deviation in parenthesis. The 3/75 Rule finds that a compound with a clogP < 3, 
and a PSA of < 75 Å2 ia 2.5 times less likely to be toxic at 10 μM. The value in the table is the percentage of 
the library which obey the rule. 
Property Rule of Three71 1GLY 2GLY 
Molecular Weight (gmol–1) < 300 231.42 (73) 242.77 (75.6) 
clogP ≤ 3 0.53 (1.0) 0.52 (1.1) 
Polar Surface Area (Å2) ≤ 60 57.7 (23) 60.7 (23) 
H-Bond Acceptors ≤ 3 3.9 (1.2) 4.1 (1.3) 
H-Bond Donors ≤ 3 1.3 (0.8) 1.3 (0.8) 
Rotatable Bond Count ≤ 3 0.80 (1.1) 0.81 (1.1) 
3/75 Rule23 — 74% 70% 
 
As can been seen from Table 3.8, the mean properties of the libraries broadly fall within the 
RO3. As expected, the mean value of the molecular weight is higher for 2GLY because two 
types of cycloheptene ring were allowed in the enumeration. The two properties which may 
cause some concern are the PSA and H-bond acceptors. These are only just in range or slightly 
violate the RO3. The high PSA is due to the presence of bromides and tosyl groups in some 
compounds. The presence of the tosyl groups also explains the high mean of H-bond 
acceptors. However, as can be seen from Figure 3.23, most of the compound which contributes 
to the high PSA fall outside the RO3 limits on molecular weight and clogP. This indicates that 
the compounds in the libraries either have properties which all generally fall into the RO3 or 
all fall outside the RO3. 
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Figure 3.23 Plot of clogP against molecular weight for libraries 1GLY and 2GLY. The shading of the points also 
indicates the value of the PSA. 
 
  
1GLY plot of clogP vs Mol Weight 
2GLY plot of clogP vs Mol Weight 
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For the next level of enumeration of the glycine-based library, different reagents can be 
explored at key points in the synthesis. This will have a lower confidence level as the proposed 
reactions will not have been tried on the substrates in the laboratory, however, use of the 
literature can guide the viability of the reactions. Examination of the synthesis of glycine 
library can show where enumeration points occur. 
The advantages of this synthetic approach are evident in the multiple vectors of elaboration. 
The modular installation of the terminal alkene moieties allows early substitution on the tail 
ring (Figure 3.24). Consideration here would have to be given to the compatibility of the 
groups with the SN2 installation, acidic removal the benzophenone, and Grubbs II RCM. 
 
Figure 3.24 Installation of five possible vectors for further fragment development by modular installation of 
the alkene moieties. 
Additionally, the warheads leave ample vectors for decoration and elaboration (Figure 3.25). 
 
Figure 3.25 Elaboration vectors on the warheads. The colours represent the possible reactions to elaborate 
the vectors. Red: alkylation/acylation by nucleophilic N. Blue: Addition from nucleophilic enolate formation. 
Green: Metal-mediated cross coupling. Purple: SN2. Yellow: Grignard-type nucleophilic-reduction of ester to 
alcohol. Orange: Imidate condensation. 
A sample of the possible decoration vectors can be explored and assessed computationally. 
Using the open access LLAMA programme,212 the synthesised warheads with a cyclohexene 
tail were decorated with a variety of reliable reactions (see appendix). This gave a decorated 
library GLY-DEC1. This can give an indication about the properties of the chemical space 
around 1GLY and 2GLY. 
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Figure 3.26 Plot of clogP against molecular weight GLY-DEC1 library. The shading of the points also indicated 
the value of the PSA. 
As can be seen from Figure 3.26, the library still has favourable physico-chemical properties 
and most of the molecules are either in RO3 limits or are moving more into lead-like RO5 
space. This is promising for further development of the library. 
Next, the dehydroalanine library was enumerated. This involved the synthesis of intermediate 
202. This was successfully reacted with a nitrile oxide to form a dihydroisoxazole ring, and 
the Boc-protected N and ester were closed to give a carbamate warhead (Scheme 3.54). 
GLY-DEC1 plot of clogP vs Mol Weight 
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Scheme 3.54 Formation of dehydroalanine spirocycle 212. 
This allows for two areas of elaboration: the amino and ester closure, and the pendent group 
on the nitrile oxide. The existence in the literature213 of the dihydroisoxazole ring with a 
geminally disposed primary amine and ester (270) means that there is reasonable confidence 
that the warheads enumerated in the 1GLY library could also be enumerated here (Figure 
3.27). 
 
Figure 3.27 Literature compound 270 gives reasonable confidence to enumerating the warheads from the 
glycine library. 
To complement this, a small range of imidates were chosen as nitrile oxide precursors for 
dihydroisoazole ring formation. These were selected to represent a range of functionalities: 
aromatic, heterocyclic, cyclic, and aliphatic. 
 
Figure 3.28 Chosen imidates as nitrile oxide precursors. 271 272 273 274 
Therefore, a library was enumerated combining the warheads with an isoazole ring 
substituted with the four groups in Figure 3.28. This gave library DEHAL (Figure 3.29). 
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Figure 3.29 Construction of DEHAL library. 
The physico-chemical properties of this library are summarised in Table 3.9 and Figure 3.30. 
Pleasingly, this library seems to be reasonably fragment-like. Unfortunately, this library 
suffers from high PSA and H-bond donors for a fragment collection. This is down to the 
isoazole ring containing two heteroatoms which increases both metrics.  
Table 3.9 Comparison of DEHAL library, showing the average value of the properties with the standard 
deviation in parenthesis. 
Property Rule of Three71 DEHAL 
Molecular Weight (gmol–1) < 300 233.88 (54) 
clogP ≤ 3 1.20 (0.9) 
Polar Surface Area (Å2) ≤ 60 69.7 (17.7) 
H-Bond Acceptors ≤ 3 5.4 (1.0) 
H-Bond Donors ≤ 3 1.2 (0.6) 
Rotatable Bond Count ≤ 3 1.5 (1.1) 
3/75 Rule23 — 75% 
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Figure 3.30 Plot of clogP against molecular weight GLY-DEC1 library. The shading of the points also indicates 
the value of the PSA. 
Finally, a small compound library was constructed from the azetidinone series. This took the 
two key reactions established in the research (the nitrile oxide cycloaddition and the azide 
cycloaddition) and extended them for four nitrile oxide (the ones given in Figure 3.28) and 
four azides (again the same appendages as in Figure 3.28 but a benzyl group in lieu of the 
phenyl one). These were computationally-coupled with two azetidinone derivatives: the α,β-
unsaturated ethyl ester as used in the chemistry, above and the electronically similar  α,β-
unsaturated nitrile. This gave the AZE library. 
 
Figure 3.31 construction of the AZE library. 
As with the DEHAL library, most of the properties are fragment-like yet there is the slight 
problem of the high PSA and number of H-bond acceptors. Perhaps a way to minimise this in 
DEHAL plot of clogP vs Mol Weight 
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these libraries would be to use 1,3-dipoles or dienes with fewer heteroatoms (Table 3.10 and 
Figure 3.32). 
Table 3.10 Comparison of AZE library, showing the average value of the properties with the standard 
deviation in parenthesis. 
Property Rule of Three71 DEHAL 
Molecular Weight (gmol–1) < 300 214.00 (38) 
clogP ≤ 3 -0.03 (1.1) 
Polar Surface Area (Å2) ≤ 60 64.86 (6.4) 
H-Bond Acceptors ≤ 3 5.3 (1.0) 
H-Bond Donors ≤ 3 1.3 (0.9) 
Rotatable Bond Count ≤ 3 2.3 (1.6) 
3/75 Rule23 — 88% 
 
 
Figure 3.32 Plot of clogP against molecular weight GLY-DEC1 library. The shading of the points also indicates 
the value of the PSA. 
AZE plot of clogP vs Mol Weight 
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3.6.2. Spatial diversity of libraries 
As well as analysing the raw physico-chemical properties of these libraries, the spatial 
diversity can also be measured by plotting PMI graphs and the diversity of the physico-
chemical data can be measure by PCA graphs. 
Computational analysis of the above libraries was performed using Molecular Operating 
Environment (MOE) software version 2016.0802 from the Chemical Computing Group. 
The computational parameters of the PMI analysis and PCA are given in Appendix C.c 
The above libraries (1GLY, 2GLY, GLY-DEC1, DEHAL, and AZE) were evaluated and 
compared to small molecules in the top 50 selling pharmaceuticals of 2013214 (Structures in 
Appendix C). 
Merck molecular force field 94X (MMFF94x), an all-atom force field parameterised for small 
organic molecules with the Generalised Born solvation model, was used to minimise the 
energy potential of the library members. A Low Mode MD search was employed for the 
conformation generation. 
Since crystal structures were obtained for four of the spirocycles, a visual comparison was first 
performed. The structures are shown in Table 3.11 and are seen to be visually similar. The 
conformationally constrained nature of spirocycles means that computational models are 
more likely to be reliable in predicting conformation.  
 
 
 
 
 
 
 
                                                     
c The procedure followed to carry out PMI analysis and PCA is based on the procedure developed by Dr Feilin 
Nie 
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Table 3.11 Comparison of the computational lowest energy conformation and crystal structures. 
Structure Lowest Energy Confirmation Crystal structure  
 
  
 
 
 
 
 
 
 
  
 
The conformers of each library member were calculated, with the lowest energy conformer 
assigned a relative energy value of 0 kJmol–1. For each conformer, the principle moments of 
inertia (I1, I2, I3) were calculated and then normalised to (I1/I3) and (I2/I3). These values were 
then plotted on a triangle graph, with the three vertices at (0,1), (0.5,0.5), and (1,1) representing 
the three 3D extremes of rod-like, disk-like, and sphere-like respectively. The lowest energy 
conformation is plotted in Figure 3.33. 
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Figure 3.33 PMI plot showing the spatial diversity of compound libraries. Each point on the plot represents a 
compound in the library at its lowest energy conformation as calculated by MOE. 30 top selling drugs (purple), 
168 1GLY library (light blue), 408 2GLY library (red), 61 GLY-DEC1 library (orange), 52 DEHAL library (green), 
16 AZE library (dark blue). x-azis I1/I3, y-axis I2/I3. 
As can be expected, the spirocycles predominantly possess rod-like features, with most 
clustering around the top-left of the PMI plot. Pleasingly, the range of compounds seem to 
have escaped ‘flat-land’, the rod-disk line. By inspection of the plot it seems that the 
appendage decorated library, GLY-1DEC, increased the spatial spread of the spirocycles 
incorporating more sphere properties. 
Fortunately, the cumulative frequency of the compounds can be measured as a function of 
their distance from the rod-disk axis. This allows for easier inspection of how ‘flat’ the library 
is and how much of the chemical space it covers (Figure 3.34). 
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Figure 3.34 Cumulative frequency graph of compound distance from rod-disk axis. This allows easy 
visualisation of the diversity of compound libraries on the PMI plot. The steeper the gradient of the lines, the 
less chemical space the library explores. The maximum distance a compound can be form the rod-disk axis is 
1/√2 ≈ 0.71. 
The least spatially diverse library is AZE, probably due to the second ring being limited to 
either an isoazole to 1,2,3-triazole. Despite allowing for more possible ring combinations 
between 1GLY and 2GLY, the libraries occupy a broadly similar chemical space. The AZE 
library is slightly further from flat land, however the steeper gradient of the line indicates it 
displays less spatial diversity. Finally, and most interestingly, there is a strong similarity 
between the chemical space occupied by GLY-DEC1 and the marketed drugs. The core 
fragment scaffolds being small, appendages can make a large difference to the spatial 
diversity of the library. This simple modification of the library is likely to bring it into 
biologically relevant space. 
The lowest energy conformer is only part of the picture because a molecule’s conformation 
can change in solution or find favourable interactions on a biologically target. Therefore, the 
energy window was expanded to 3 kJmol–1. Since ΔG = –RTln(k) with an energy window of 
ΔG = 3 kJmol–1 k ≈ 0.3, so the top 70% lowest energy conformers are included.  
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Figure 3.35 PMI plots of the conformers of the five compound libraries compared to the drugs reference set. 
a) Energy level cut of at 0 kJmol–1 (lowest energy conformer); b) energy level cut of at 1 kJmol–1; c) energy 
level cut of at 2 kJmol–1; d) energy level cut of at 3 kJmol–1. 
As can be seen in Figure 3.35, as the energy threshold is increased the marketed drugs start to 
cluster along the rod-disk axis, whereas the GLY-DEC1 library pleasingly spreads out and 
occupies more chemical space. The DEHAL and AZE libraries begin to cluster; DEHAL into 
the top left rod-like area and AZE trending more towards disk-like features. The 1GLY and 
2GLY library spread out a reasonable distance from the rod-disk axis. A clearer illustration of 
this comparison can be seen in Figure 3.36 where each component of Figure 3.35d is separated. 
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Figure 3.36 PMI plot of each DOS library at 3 kJmol–1 threshold. 
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Overall, the different spirocyclic libraries integrated a large range of chemical space. Most 
interesting was the GLY-DEC1 library which showed that appendage growth from these 
scaffolds creates spatially diverse compounds. All the libraries avoided ‘flat land’, the region 
of chemical space which seems to be exhausted for novel chemical leads. This gives confidence 
that these libraries possess the necessary spatial qualities for further exploration.  
3.6.3. Principle component analysis of libraries 
For each compound based on its lowest energy conformation, seventeen structural and 
physico-chemical descriptors were selected. These ranged from solubility, weight, H-bond 
acceptors, PSA, etc. Due to the impossibility of visualising these data in 17-dimensions, 
principle component analysis was employed. Each of the 17-dimensional vectors were 
reduced to 2-dimensional vectors by linear transformation. A linear combination of the 
descriptors was calculated to represent as much of the variance in the data as possible. This 
gave seventeen unitless principle components. Each compound represented by a 2-
dimensional vector was plotted on a scatter chart to visualise the extent of chemical space 
spanned by the libraries. To keep 95% of the variance original data set, seven principle 
components were retained (Table 3.12). 
Table 3.12 Standard deviation and contribution of each principle component of variant. a The standard 
deviation of the data along the principle component vector. b Condition number of the covariance matrix if 
the principle component list were terminated at that row. c Percentage of the variance retained if the 
component list were truncated at that row. 
PC# Deviationa Conditionb Proportion of Variance % Variancec 
PC1 2.798 1.000 46.037 46.037 
PC2 1.899 2.170 21.214 67.251 
PC3 1.300 4.629 9.944 77.195 
PC4 1.049 7.116 6.47 83.665 
PC5 0.914 9.378 4.909 88.574 
PC6 0.888 9.916 4.643 93.217 
PC7 0.682 16.810 2.738 95.955 
 
The first three principle components, accounting for 77% of the variance of the data set, were 
plotted onto three scatter graphs (Figure 3.37). 
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Figure 3.37 PCA plots of each spirocyclic library against the drugs data set. a) PC1 v PC2, b) PC1 vPC3, c) PC2 
v PC3.  
Figure 3.37a shows the ‘Drugs’ library occupying a very broad and different range of chemical 
space compared to the spirocyclic libraries. The difference in breadth is likely down to the fact 
that the spirocyclic libraries were restricted to a spirocyclic core and were only fragment-like. 
Again, the differences are highlighted between the 1GLY, 2GLY, and GLY-DEC1 with 
different areas of the grid occupied.  
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In Figure 3.37b, the 1GLY and 2GLY libraries seem to cover approximately the same chemical 
space as in Figure 3.37a. However, this time the libraries are more differentiated. Moving from 
left to right along the x-axis 2GLY gives way to DEHAL and AZE, with AZE further up the y-
axis. Next comes GLY-DEC1, most of whose members are in the positive region of the x-axis. 
Finally, the drugs represent their diversity by scattering about the first quadrant. 
Figure 3.37c again shows the range of chemical space explored by the spirocycles with each 
library integrating different areas of space. 2GLY also demonstrates its larger physcio-
chemical diversity by being represented below the x-axis. Interestingly the DEHAL library is 
quite diverse under these conditions, having components in quadrants I, II, and IV.  
The transformation matrix of the first seven principle components (95% of the total variance) 
is shown in Table 3.13.  This suggests that increasing the number of rings and the number of 
nitrogens the molecular flexibility would shift the molecules in a positive direction along the 
x-axis (more into the chemical space occupied by the drugs).  
The most important contributors to PC2 were the number of H-bond donors and acceptors 
and the number of oxygen atoms. Increasingly these should shift the libraries positively along 
the PC2 axis, whereas increasing the number of rings would have the opposite effect. 
Finally, PC3 indicates that the number of nitrogen atoms, the solubility in water, and the 
number of H-bond acceptors would move the spirocyclic libraries up along the PC3 axis. 
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Table 3.13 Component loadings for the PCA of the six compound libraries. The top six contributing parameters 
to each principle component are highlighted in grey. All values are normalised.  
Descriptor PC1 PC2 PC3 PC4 PC5 PC6 PC7 
ASA_H 0.0011 -0.0011 0.0020 -0.0020 -0.0020 0.0015 0.0030 
ASA_P 0.0004 0.0033 -0.0059 0.0048 0.0059 -0.0051 -0.0076 
KierFlex 0.0708 0.0568 -0.1725 0.1722 -0.0880 0.1523 0.4722 
SlogP 0.0680 -0.1347 -0.1280 0.1404 -0.0639 0.0846 -0.0863 
TPSA 0.0023 0.0108 0.0079 -0.0003 -0.0001 -0.0044 -0.0113 
Weight 0.0015 0.0005 -0.0024 0.0006 0.0005 -0.0009 0.0004 
a_acc 0.0523 0.1495 0.1231 -0.0949 -0.0891 -0.1786 0.1970 
a_aro 0.0280 -0.0229 0.0413 -0.0104 -0.0260 0.0332 -0.1695 
a_don -0.0092 0.1924 0.1552 0.0816 0.1762 0.9748 -0.5035 
a_nN 0.0712 -0.0065 0.3321 0.3013 0.7741 -0.2422 0.2015 
a_nO 0.0326 0.1818 0.0188 -0.1776 -0.3656 -0.1868 -0.1056 
b_rotN 0.0523 0.0192 0.0522 0.1314 -0.0406 0.0575 0.1366 
chiral 0.0261 0.0624 -0.2553 -0.5431 0.4069 0.2576 0.2794 
logS -0.0752 0.0440 0.1579 -0.0122 0.0867 0.0335 0.4598 
mr 0.0633 -0.0119 0.0080 -0.0067 -0.0079 0.0329 0.0467 
rings 0.1077 -0.1095 0.1183 -0.4540 0.3349 -0.3067 -0.3722 
vol 0.0019 -0.0002 0.0000 -0.0002 0.0002 0.0012 0.0027 
 
Principle component analysis has shown that the different libraries integrate different areas 
of physico-chemical space, with the 2GLY library having the broadest reach. This analysis can 
also aid in the further refinement of the libraries to ensure the greatest amount of diversity. 
3.7. Conclusions 
Herein, four synthetic strategies have been employed to synthesise diverse fragment libraries 
based on spirocyclic compounds. The first of these was based upon a tetra-functionalised 
glycine derivative which was subjected to the B/C/P paradigm. A range of chemistry was 
employed to join the amino and ester functionalities to form a ‘warhead’ ring, while RCM 
formed a cyclohexene tail. This approach yielded thirteen novel spirocyclic scaffolds. 
Next, pericyclic chemistry was explored to form spirocycles. Trying to utilise the same amino-
ester couplings as previously, a dehydroalanine derivative was synthesised. A range of 
approaches were used in trying to synthesise spirocycles from this compound. Forming the 
warhead first and then using pericyclic chemistry proved unsuccessful, but direct formation 
of the pericyclic ring on the dehydroalanine did work. This establishing the possibility of 
Spirocyclic fragment libraries 
124 
 
using electron deficient 1,3-dipoles or dienes to form the ‘tail’ and using the established 
amino-ester couplings to form the warhead. 
The use of pericyclic reactions was further explored by attempted Wittig installation of exo-
cyclic olefins onto rare or privileged scaffolds. Azetidinone proved a good starting material 
for the installation of an electron deficient alkene which performed pericyclic reactions. On 
the other hand, 1,4-oxazepanes proved a synthetic challenge to make. 
These libraries were enumerated computationally giving five libraries. The spatical and 
physico-chemical diversity of these libraries were measured and pleasingly they were found 
to possess descriptors which favour successful clinical candidates.
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Chapter 4 
4. Conclusions and future work
4.1. Conclusions 
This project has focused on two key areas of the fragment-based drug discovery (FBDD) 
process: the design of fragments, and the elaboration of fragments to increase potency of 
potential inhibitors of CK2. 
As part of the ongoing research to discover novel non-ATP competitive inhibitors of CK2, a 
lead fragment NMR154L emerged in the literature. Using NMR154L as a lead, this project has 
utilised novel chemistry, X-ray crystallography and computational analysis to improve the 
binding and specificity of the fragment which, in turn, could lead to improved CK2 inhibitors. 
Screening libraries of fragments have historically failed to incorporate sufficient spatial 
diversity in their collections and this could be leading to higher attrition rates along the drug-
discovery process. Methods were developed for the rapid assembly of novel spirocyclic 
fragments. Spirocycles—being two rings joined at a quaternary carbon—are inherently more 
3-dimensional when compared to sp2-rich aromatic ring dominated libraries. 
In the first line of investigation, two terminal alkenes were installed on to glycine ethyl ester. 
Combining ring-closing metathesis and a range of amine and ester coupling, it was 
demonstrated that an initial library of 14 novel spirocycles could be synthesised. Expanding 
this methodology to different ring sizes could lead to a spirocyclic library of 168 novel 
compounds. A second approach demonstrated how pericyclic reactions could be used to 
make spirocycles. This used both amino acids as building blocks as well as rare and privileged 
heterocycles to expand the chemical space. Computational analysis of these libraries showed 
that they possessed the required spatial and physico-chemical properties to make them 
promising fragment libraries for future drug discovery. 
Overall, this work has expanded novel fragment space by demonstrating how fragment hits 
can be improved by analysis of structure activity relationships, and how novel sp3-rich diverse 
spirocyclic libraries can be quickly assembled with promising structural and physical 
properties. 
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4.2. Future work 
4.2.1. CK2 inhibition 
Work in this project and in the wider Spring Group has led to the discovery of the led to the 
discovery CAM187, currently the most active fragment-like interface specific CK2 inhibitor. 
Due to the fragment nature of this molecule, there is ample room for development to improve 
on the compound’s 44 μM IC50. 
4.2.2. Progressing spirocycle libraries 
The novel spirocyclic libraries resulting from these investigations will be screened to 
determine whether there are any promising leads against biological targets. 
Hence, a collaboration has been initiated with the Bender Group at the University of 
Cambridge. They has developed computational methods for screening large libraries against 
a myriad of known biological targets in silico. The libraries 1GLY and 2GLY have already been 
submitted for computational analysis. It is hoped that any leads from this can be tested against 
the biological targets in vitro to establish any tractable leads. These could be developed into 
potent inhibitors. 
In addition to the in silico analysis, the synthesised compounds may be screened against a 
large number of protein crystals at the Diamond synchrotron. This would give crystal 
structures of the spirocycles binding in protein pockets. These data could be applied to the 
identification of new active compounds with the potential of being developed into new 
medicines. 
4.2.3. α-Allyl serine ethyl ester spirocycles 
There is excellent scope to apply synthetic methods employed in the synthesis of the glycine-
based cyclohexene spirocycles and the dehydroalanine spirocycles. Again, this would start 
from the serine ethyl ester. However, instead of using elimination chemistry to install an exo-
cyclic double bond, a fourth orthogonal functionality can be added onto the α-carbon; in this 
case an allyl group. There is established literature chemistry for the diastereoselective 
insertion of the allyl group onto serine (Scheme 4.1).215 
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Scheme 4.1 Previous work installing an allyl group onto L-serine. 275 276 277 278 
This work could be repeated to form compound 278, or the pivaldehyde could be substituted 
with acetaldehyde to decrease the selectivity of the allyl addition so that both enantiomers can 
be synthesised simultaneously. 
With compound 278 in hand, there are three different pairs of combinations of functional 
groups which could be used to make spirocycles (Figure 4.1). 
 
Figure 4.1 The functional groups in 278 may be combined in three pairs to produce novel spirocycles. 
This could lead to the synthesis of a new spirocyclic library exploring more coupling 
chemistry, different ring sizes, and diverse functionality.  
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Chapter 5 
5. Experimental
Reactions For reactions requiring anhydrous conditions, experiments were carried out in 
oven-dried glassware. Unless otherwise stated, all reactions were carried out under 
nitrogen atmosphere. Room temperature (RT) refers to ambient temperature. All 
temperatures below 0 °C are that of the external bath. Temperatures of 0 °C were 
maintained using an ice-water bath. Temperatures of –15 °C were maintained using a salt 
and ice-water bath. Temperatures of –78 °C were maintained using an acetone-cardice bath. 
Solvents and reagents Solvents and commercially available reagents were dried and purified 
before use, where appropriate using standard procedures. Toluene, hexane, diethyl ether, 
ethyl acetate, methanol, THF, and dichloromethane were dried and distilled using 
standard methods from oxygen free from solvent dispenser units under an argon 
atmosphere. 
Chromatography Analytical thin layer chromatography (TLC) was performed using pre-
coated Merck glass backed silica gel plates (Silica gel 60 F254). Flash column 
chromatography was undertaken on Fluka or Material Harvest silica gel (230–400 mesh) 
under a positive pressure of nitrogen unless otherwise stated. Visualization was achieved 
using ultraviolet light (254 nm) and chemical staining with basic potassium permanganate 
solution as appropriate. Retention factors (Rf) are quoted to 0.01. 
Infrared spectra Infrared (IR) spectra were recorded on a Perkin Elmer 1FT-IR Spectrometer 
fitted with an ATR sampling accessory as either solids or neat films, either through direct 
application or deposited in CDCl3. Absorption maxima (νmax) are reported in wavenumbers 
(cm–1) with the following abbreviations: w, weak; m, medium; s, strong; br, broad. 
NMR spectra Magnetic resonance spectra were processed using TopSpin v. 3.5 (Bruker). An 
aryl, quaternary, or two or more possible assignments were given when signals could not 
be distinguished by any means. Measured coupling constants (J) are reported for mutually 
coupled signals; coupling constants are labelled apparent in the absence of an observed 
mutual coupling, or multiplet when none can be determined. 
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Proton magnetic resonance spectra were recorded using an internal deuterium lock (at 298 
K unless stated otherwise) on Bruker DPX (400 MHz; 1H-13C DUL probe), Bruker Avance 
III HD (400 MHz; Smart probe), Bruker Avance III HD (500 MHz; Smart probe) and Bruker 
Avance III HD (500 MHz; DCH Cryoprobe) spectrometers. Proton assignments are 
supported by 1H–1H COSY, 1H–13C HSQC or 1H–13C HMBC spectra, or by analogy. 
Chemical shifts (δH) are quoted in ppm to the nearest 0.01 ppm and are referenced to the 
residual non-deuterated solvent peak. Discernible coupling constants for mutually coupled 
protons are reported as measured values in Hertz, rounded to the nearest 0.5 Hz. Data are 
reported as: chemical shift, multiplicity (br = broad; s = singlet; d = doublet; t = triplet; q = 
quartet; qn = quintet; sp = septet; m = multiplet; or a combination thereof), coupling 
constants, number of nuclei, and assignment. Diastereotopic protons are assigned as Xa 
and Xb, where Xb designates the lower-field proton. 
Carbon magnetic resonance spectra were recorded using an internal deuterium lock (at 
298 K unless stated otherwise) on Bruker DPX (101 MHz), Bruker Avance III HD 
(101 MHz) and Bruker Avance III HD (126 MHz) spectrometers with broadband proton 
decoupling. Carbon spectra assignments are supported by DEPT editing, 1H–13C HSQC or 
1H–13C HMBC spectra, or by analogy. Chemical shifts (δC) are quoted in ppm to the nearest 
0.1 ppm and are referenced to the deuterated solvent peak. Data are reported as: chemical 
shift, number of nuclei (if not one), multiplicity (if not a singlet), coupling constants, and 
assignment. 
Fluorine magnetic resonance spectra were recorded on Bruker Avance III (376 MHz; QNP 
Cryoprobe) or Bruker Avance III HD (376 MHz; Smart probe) spectrometers. Chemical 
shifts (F) are quoted in ppm to the nearest 0.1 ppm. Data are reported as: chemical shift, 
number of nuclei (if not one), multiplicity (if not a singlet), coupling constants and 
assignment. 
The numbering of molecules used for 13C and 1H NMR assignments does not conform to 
IUPAC standards. 
Mass spectra High-resolution mass spectra (HRMS) were measured on a Micromass LCT 
Premier spectrometer using electron spray ionization (ESI) techniques. Masses are quoted 
within the 5 ppm error limit. 
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Melting points Melting points were obtained on a Buchi B-545 melting point apparatus and 
are uncorrected. 
Optical rotations Chiral products had their optical rotation recorded on an Anton-Paar MCP 
100 polarimeter. [α]D
20 values are reported in °g–1cm–210–1 at the sodium D-line of 598 nm, 
concentration (c) is given in g(100 mL)–1 in the solvent stated.  
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2,2’-(4,5-Dichloro-1,2-phenylene)bis(ethan-1-aminium) dichloride, 29 
 
Compound 35 (60.6 mg, 0.14 mmol) was stirred in HCl/dioxane (4M, 5 mL) for 1 h. The 
mixture was filtered and the filtrate was washed with cold diethyl ether (5 mL). The isolated 
white crystals were placed in a desiccator overnight to yield the pure white crystalline product 
(39.0 mg, 0.13 mmol, 14% over two steps); IR (thin film) 𝜈/cm–1: 2936 (C-H, m), 1760 (C=O, 
s), 1499 (C=C, m). 1H NMR (400MHz, (CD3)2SO) δ/ppm: 8.26 (s, 6H, NH3) 7.57 (s, 2H, H1) 
3.00 (s, 8H, H4,5). 13C NMR (101 MHz, (CD3)2SO) δ/ppm: 137.3 (C1×2) 131.8 (C2×2) 129.5 
(C3×2) 66.4 (C5×2) 29.2 (C4×2). HRMS (ESI) C10H15N2Cl2 m/z: [M+H]+ 233.0600 (calc. 
233.0607). m.p. 349-350 °C. 
 
2,2’-(4,5-dichloro-1,2-phenylene)diacetonitrile, 30 
 
To a solution of dibromide 31 (1.08 g, 3.24 mmol, 1.0 eq) in ethanol (21 mL) was added sodium 
cyanide (3.98 mg, 8.11 mmol, 2.5 eq) in water (7 mL) at 0 °C. The reaction was refluxed 
overnight. The excess solvent was removed in vacuo before being diluted with ethyl acetate 
(20 mL) and washed with water (20 mL × 2). The aqueous layer was extracted with ethyl 
acetate (30 mL × 3) and the combined organics were washed with brine (50 mL). This was 
dried over MgSO4, filtered, concentrated and purified by column chromatography (25% 
EtOAc in Hexane) to give the pure product as a colourless oil (631 mg, 2.80 mmol, 86%); Rf 
0.50 (40% EtOAc in Hexane); IR (thin film) 𝜈/cm–1: 3029 (C-H, w), 2859 (C-H, w), 2252 (C≡N, 
m), 1481 (C=C, s), 682 (C-Cl, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.58 (s, 2H, H2), 3.74 (s, 
4H, H4). 13C NMR (101 MHz, CDCl3) δ/ppm: 133.8 (C1×2), 131.7 (C2×2), 128.1 (C3×2), 115.5 
(C5×2), 21.1 (C4×2). HRMS (ESI) C10H6N2Cl2Na m/z: [M+Na]+ 246.9793 (calc. 246.9800). 
The physical and spectroscopic data was found to be in agreement with Rosowsky et al.216 
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1,2-Bis(bromomethyl)-4,5-dichlorobenzene, 31 
 
Dialcohol 32 (550 mg, 2.65 mmol, 1.0 eq) was dissolved in diethyl ether (5 mL). Phosphorous 
tribromide (0.6 mL, 6.36 mmol, 2.4 eq) was added dropwise at 0 °C and the reaction was stirred 
overnight at RT. The reaction was poured into ice water (5 mL), the organic phase was 
separated and washed with brine (5 mL). This was dried over MgSO4, filtered, concentrated 
and purified by column chromatography (10% CH2Cl2 in Hexane) to give the pure product as 
off white crystals (761 mg, 2.29 mmol, 86%); Rf 0.39 (10% CH2Cl2 in Hexane); IR (thin film) 
𝜈/cm–1: 1588 (C=C, w), 1473 (C-H, m), 951 (C-Br, s), 683 (C-Cl, s). 1H NMR (400 MHz, CDCl3) 
δ/ppm: 7.82 (s, 2H, H2), 4.80 (s, 4H, H4). 13C NMR (101 MHz, CDCl3) δ/ppm: 138.0 (C1×2), 
133.3 (C2×2), 131.8 (C3×2), 29.6 (C4×2). HRMS (ESI) C8H6Cl2Br2Na m/z: [M+Na]+ 354.8099 
(calc. 354.8088). m.p. 65–66 °C. 
The physical and spectroscopic data was found to be in agreement with Levy et al.217 
 
(4,5-Dichloro-1,2-phenylene)dimethanol, 32 
 
To a suspension of lithium aluminium hydride (600 mg, 15.7 mmol, 2.0 eq) in THF (10 mL) 
was added 34 (2.07 g, 7.9 mmol, 1.0 eq) dissolved in THF at 0 °C. The reaction was warmed to 
RT and stirred for 24 h. Following this, the reaction was cooled to 0 °C and water (0.6 mL), 
15% NaOH (0.6 mL), and water (1.8 mL) were added and the mixture was stirred for 30 min. 
This mixture was filtered and washed with THF (10 mL). The excess solvent of the filtrate was 
removed in vacuo to yield the pure product (1.5043 g, 7.25 mmol, 92%); Rf 0.21 (20% diethyl 
ether/pet. ether); IR (thin film) 𝜈/cm–1: 3265 (O-H, br s), 2901 (C-H, w), 1483 (C=C, m), 1050 
(C-O, s), 732 (C-Cl, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.46 (s, 2H, H2), 4.68 (s, 4H, H4), 
2.65 (s, 2H, H5). 13C NMR (101 MHz, CDCl3) δ/ppm: 139.0 (C1×2), 132.0 (C3×2), 131.1 (C2×2), 
62.9 (C4×2). HRMS (ESI) C8H8O2Cl2Na m/z: [M+Na]+ 228.9786 (calc. 228.9794). 
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The physical and spectroscopic data was found to be in agreement with Di Lauro et al.218 
Dimethyl 4,5-dichlorophthalate, 34 
 
To a solution of 4,5-dichlorophthalic acid (3 g, 12.76 mmol, 1.0 eq) in methanol (25 mL) cooled 
to 0 °C thionyl chloride (2.33 mL, 31.90, 2.5 eq) was added dropwise. The reaction was warmed 
to RT and stirred for 3 days. The mixture was quenched with sat. aq. NaHCO3 and extracted 
with CH2Cl2. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The 
crude material was purified by column chromatography (50% diethyl ether in pet. ether) to 
give the pure product as a translucent crystal (3.0838 g, 11.7 mmol, 92%); IR (thin film) 𝜈/cm–
1: 3097 (C-H, w), 2957 (C-H, w), 1719 (C=O, s), 1592 (C=C, m), 1551 (C=C, m), 1430 (C=C, m), 
1290 (C-O, s), 781 (CCl, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.81 (s, 2H, H2) 3.90 (s, 6H, 
H5). 13C NMR (101 MHz, CDCl3) δ/ppm: 161.0 (C4×2), 135.8 (C1×2), 131.3 (C3×2), 131.0 
(C2×2), 52.3 (C5×2). HRMS (ESI) C10H9O4Cl2 m/z: [M+H]+ 262.9866 (calc. 262.9872). m.p. 48–
49 °C. 
The physical and spectroscopic data was found to be in agreement with Hennessy et al.219  
 
Di-tert-butyl ((4,5-dichloro-1,2-phenylene)bis(ethane-2,1-diyl))dicarbamate, 
35 
 
Sodium borohydride (470.6 mg, 12.44 mmol, 14.0 eq) was added portion wise at 0 °C to a 
mixture of 30 (200 mg, 0.89 mmol, 1.0 eq), NiCl2.6H2O (42.2 mg, 0.18 mmol, 0.2 eq), and di-
tert-butyl dicarbonate (0.82 mL, 3.55 mmol, 4.0 eq) in methanol (10 mL). The reaction was 
stirred at RT for 6 h. The reaction mixture was poured into ice water and the excess solvent 
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was removed in vacuo. This was diluted with ethyl acetate (20 mL) and washed with NaHCO3 
(20 mL). The aqueous was extracted with ethyl acetate (20 mL × 3). The combined organics 
were washed with brine, dried over MgSO4, filtered, concentrated and purified by column 
chromatography (15% ethyl acetate in hexane) to give the pure product which was carried 
straight over to the next reaction; Rf 0.21 (50% Et2O in pet. ether); IR (thin film) 𝜈/cm–1: 3326 
(N-H, m), 2978 (C-H, w), 1678 (C=O, s), 1524 (C=C, s), 1136 (C-O, s), 780 (C-Cl, s). 1H NMR 
(400 MHz, CDCl3) δ/ppm: 7.24 (s, 2H, H2) 3.30 (q, J = 7.0 Hz, 4H, H5) 2.80 (t, J = 7.0 Hz, 4H, 
H4) 1.43 (s, 18H, H8). 13C NMR (101 MHz, CDCl3) δ/ppm: 155.9 (C6×2), 137.6 (C1×2), 131.6 
(C2×2), 130.3 (C3×2), 79.5 (C7×6), 41.1 (C5×2), 32.7 (C4×2), 28.3 (C8×2). HRMS (ESI) 
C20H31N2O4Cl2 m/z: [M+H]+ 433.1644 (calc. 433.1661). 
 
(4,5-Dichloro-1,2-phenylene)dimethanaminium dichloride, 38 
 
Sodium borohydride (1.34 g, 35.353 mmol, 14.0 eq) was added portion wise at 0 °C to a mixture 
of dichlorodicyanobenzene (500 mg, 2.54 mmol, 1.0 eq), NiCl2.6H2O (120.6 mg, 0.51 mmol, 0.2 
eq), and di-tert-butyl dicarbonate (2.33 mL, 10.15 mmol, 4.0 eq) in methanol (25 mL). The 
reaction was stirred at RT for 6h before the reaction was poured into ice. The mixture was 
extracted with ethyl acetate (3 × 20 mL) and washed with sat. aq. NaHCO3 (20 mL) and brine 
(20 mL). This was dried over anh. MgSO4, filtered and concentrated in vacuo. The crude oil 
was dissolved in 4M HCl/Dioxane (5 mL) and stirred for 1h. The reaction was filtered and 
the residue was washed with cold acetone to give the product as white crystals (241.3 mg, 0.87 
mmol, 34%); IR (thin film) 𝜈/cm–1: 2847 (N-H, br s), 1498 (C=C, s), 1116 (C-N, s), 683 (C-Cl, 
m). 1H NMR (400 MHz, (CD3)2SO) δ/ppm: 8.45 (br s, 6H, NH), 8.08–8.07 (m, 2H, H2), 4.21 (s, 
4H, H4). 13C NMR (101 MHz, (CD3)2SO) δ/ppm: 136.7 (C1), 134.6 (C3), 132.0 (C2), 39.9 (C4). 
HRMS (ESI) C8H11Cl2 m/z: [M+H]+ 205.0290 (calc. 205.0294). m.p. 277–278 °C. 
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2-(4-Chloronaphthalen-1-yl)ethan-1-aminium chloride, 39 
 
To a suspension of lithium aluminium hydride (11 mg, 2.5 mmol, 2.0 eq) in diethyl ether (3 
mL) under N2 was added 45 (25 mg, 0.12 mmol, 1.0 eq) dissolved in diethyl ether (2 mL) 
dropwise. The reaction was stirred overnight. Water (25 μL) was added dropwise at 0 °C 
followed by 15% aq. NaOH (25 μL) and water (75 μL). This was warmed to RT and stirred for 
15 min. The resulting mixture was diluted with diethyl ether (5 mL) and washed with brine 
(10 mL). The organics were dried over anh. MgSO4, filtered and concentrated in vacuo to give 
the crude oil. This was stirred with 4M HCl in dioxane (5 mL) for 15 min and then filtered 
giving the residue as pure white-yellow crystalline product (20.1 mg, 0.08 mmol, 69%); IR 
(thin film) 𝜈/cm–1: 3382 (N-H, m), 3029 (C-H, m), 1500 (C=C, m), 758 (C-Cl, s). 1H NMR (400 
MHz, (CD3)2SO) δ/ppm: 8.27–8.21 (m, 2H, H6&9), 7.95 (br s, 3H, NH3+), 7.76–7.71 (m, 2H, 
H7&8), 7.68 (d, J = 7.5 Hz, 1H, H2), 7.43 (d, J = 7.5 Hz, 1H, H3), 3.38–3.34 (m, 2H, H11), 3.10 
(br s, 2H, H12). 13C NMR (101 MHz, (CD3)2SO) δ/ppm: 133.4 (C4), 132.6 (C1), 130.3 (C5), 130.0 
(C10), 127.6 (C7/8), 127.5 (C7/8), 127.4 (C3), 126.2 (C2), 124.6 (C6/9), 124.4 (C6/9), 39.5 (C12), 
30.1 (C11). HRMS (ESI) C12H13ClN m/z: [M]+ 206.0735 (calc. 206.0737). m.p. 270–271 °C. 
 
1-Acetyl-4-chloronaphthalene, 41 
 
Acetyl chloride (2.80 mL, 40.4 mmol, 1.1 eq) was dissolved in CH2Cl2 (150 mL) under N2. 
Aluminium trichloride (5.68 g, 42.6 mmol, 1.16 eq) was added and stirred for 5 min before 1-
chloronaphthalene (5 mL, 36.7 mmol, 1.0 eq) was added dropwise over 10 min. The reaction 
was refluxed for 1 h. The reaction was poured into a mixture of ice and conc. HCl. This was 
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extracted with diethyl ether (3 × 50 mL) and the ethereal layer was washed with brine. The 
combined organics were dried over MgSO4. The mixture was filtered and concentrated in 
vacuo. The crude was purified by column chromatography (10% diethyl ether in pet. ether) to 
give the pure product as a yellow oil (6.0849 g, 29.73 mmol, 81%); Rf 0.28 (20% diethyl ether 
in pet. ether); IR (thin film) 𝜈/cm–1: 3005 (C-H, w), 1674 (C=O, s), 1565 (C=C, s), 1505 (C=C, 
s) 758 (C-Cl, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 8.78–8.75 (m, 1H, H6), 8.36–8.33 (m, 1H, 
H9), 7.64 (d, J = 8.0 Hz, 1H, H2), 7.68–7.63 (m, 2H, H7&8), 7.59 (d, J = 8.0 Hz, 1H, H3), 2.73 (s, 
3H, H12). 13C NMR (101 MHz, CDCl3) δ/ppm: 201.0 (C11), 136.9 (C1), 134.6 (C4), 131.3 (C10), 
131.1 (C5), 128.8 (C8), 128.3 (C2), 127.6 (C7), 126.5 (C6), 124.8 (C3), 124.8 (C9), 30.0 (C12). 
HRMS (ESI) C12H10ClO m/z: [M+H]+ 205.0412 (calc. 205.0415). 
The physical and spectroscopic data was found to be in agreement with Wiley et al.121 
 
4-Chloro-1-naphthoic acid, 42 
 
Compound 41 (6.00 g, 29.32 mmol, 1.0 eq) was dissolved in pyridine (25 mL). To this iodine 
(4.09 g, 32.25 mmol, 1.1 eq) dissolved in pyridine (25 mL) was added dropwise and the 
reaction was refluxed for 40 min. The mixture was cooled to RT and diluted with diethyl ether 
until a brown precipitate formed. The precipitate was filtered and suspended in 6M NaOH. 
The mixture was refluxed for 2 h. Afterwards, it was cooled to RT and acidified with 3M HCl. 
This was extracted with diethyl ether (3 × 30 mL) and the combined organics where washed 
with brine (30 mL). The organics were dried over anh. MgSO4 and the mixture was filtered 
and concentrated in vacuo. This give the pure product as white crystals (3.08 g, 14.90 mmol, 
51%); IR (thin film) 𝜈/cm–1: 2926 (O-H, br s), 1682 (C=O, s), 1509 (C=C, m), 1249 (C-O, s) 761 
(C-Cl, s). 1H NMR (400 MHz, (CD3)2SO) δ/ppm: 13.40 (br s, 1H, OH), 8.97–8.93 (m, 1H, H6), 
8.36–8.28 (m, 1H, H9), 8.11 (d, J = 8.0 Hz, 1H, H2), 7.89 (d, J = 8.0 Hz, 1H, H3), 7.78 (m, 2H, 
H7&8). 13C NMR (101 MHz, (CD3)2SO) δ/ppm: 168.1 (C11), 135.3 (C1), 131.9 (C4), 130.2 (C10), 
129.9 (C2), 128.6 (C8), 127.9 (C7), 127.8 (C5), 126.4 (C6), 125.7 (C3), 124.3 (C9). HRMS (ESI) 
C11H6ClO2 m/z: [M-H]- 205.0062 (calc. 205.0062). m.p. 220-221 °C. 
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The physical and spectroscopic data was found to be in agreement with Wiley et al.121 
 
(4-Chloronaphthalen-1-yl)methanol, 43 
 
Lithium Aluminium Hydride (264 mg, 6.97 mmol, 7.2 eq) was suspended in diethyl ether (2 
mL) under nitrogen. Compound 42 (200 mg, 0.97 mmol, 1.0 eq) dissolved in diethyl ether (4 
mL) was added dropwise. The reaction was refluxed for 3 h then returned to RT and stirred 
for 14 h. Following this water (0.26 mL), 15% aq. NaOH (0.26 mL), and water (0.78 mL) was 
added dropwise. The resulting suspension was filtered and the filtrate was extracted with 
diethyl ether (3 × 10 mL). This was dried over anh. MgSO4 and the mixture was filtered and 
concentrated in vacuo. This give the pure product as white crystals (114.5 g, 0.59 mmol, 61%); 
Rf 0.24 (50% diethyl ether in pet. ether); IR (thin film) 𝜈/cm–1: 3261 (O-H, br s), 2971 (C-H, w), 
2860 (C-H, w), 1508 (C=C, m), 1076 (C-O, m), 752 (C-Cl, m). 1H NMR (400 MHz, CDCl3) 
δ/ppm: 8.36–8.32 (m, 1H, H6), 8.16–8.12 (m, 1H, H9), 7.65–7.60 (m, 2H, H7&8), 7.55 (d, J = 7.5 
Hz, 1H, H2), 7.45 (d, J = 7.5 Hz, 1H, H3), 5.14 (s, 2H, H11). 13C NMR (101 MHz, CDCl3) δ/ppm: 
135.6 (C1), 132.3 (C4), 131.0 (C10), 128.7 (C5), 127.1 (C7/8), 127.0 (C7/8), 125.6 (C2), 125.2 
(C3&6), 124.0 (C9), 63.3 (C11). HRMS (ESI) C11H10ClO m/z: [M+H]+ 193.0420 (calc. 193.0415). 
m.p. 71–72 °C. 
The physical and spectroscopic data was found to be in agreement with Wiley et al.122  
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1-(Bromomethyl)-4-chloronaphthalene, 44 
 
Phosphorus tribromide (58.5 μL, 0.62 mmol, 1.2 eq) was added dropwise at 0 °C to a solution 
of 43 (100 mg, 0.52 mmol, 1.0 eq) in diethyl ether (1 mL). The reaction was stirred overnight at 
RT, before being poured into ice water. The organic layer was separated and washed with 
brine (10 mL), then dried over anh. MgSO4. This was filtered and the filtrate was concentrated 
in vacuo to give a crude oil. This was purified by column chromatography (10% diethyl ether 
in pet. ether) to yield the product as white crystals (93.0 mg, 0.36mmol, 70%); Rf 0.63 (20% 
diethyl ether in pet. ether); IR (thin film) 𝜈/cm–1: 2987 (C-H, s), 2901 (C-H, s), 1568 (C=C, m). 
1H NMR (400 MHz, CDCl3) δ/ppm: 8.36–8.34 (m, 1H, H6), 8.18–8.16 (m, 1H, H9), 7.71–7.64 
(m, 2H, H7&8), 7.52 (d, J = 7.5 Hz, 1H, H2), 7.47 (d, J = 7.5 Hz, 1H, H3), 4.93 (s, 2H, H11). 13C 
NMR (101 MHz, CDCl3) δ/ppm: 133.5 (C4), 132.6 (C1), 132.1 (C5), 131.3 (C10), 127.5 (C3), 
127.4 (C7/8), 127.3 (C7/8), 125.7 (C2), 125.4 (C6), 124.2 (C9), 31.0 (C11). HRMS (ESI) 
C11H9BrCl m/z: [M+H]+ 254.9559 (calc. 254.9571). m.p. 90–91 °C. 
The physical and spectroscopic data was found to be in agreement with Dixon et al.122 
 
2-(4-Chloronaphthalen-1-yl)acetonitrile, 45 
 
Sodium cyanide (23 mg, 0.47 mmol, 1.3 eq) was dissolved in water (0.7 mL) and added 
dropwise at 0 °C to a solution of 44 (92 mg, 0.36 mmol, 1.0 eq) in ethanol (2.4 mL). The reaction 
mixture was refluxed overnight. It was then concentrated in vacuo and diluted with ethyl 
acetate (10 mL). This was washed with water (3 × 10 mL), the aqueous was extracted with 
ethyl acetate (2 × 10 mL), and the combined organics were washed with brine (30 mL). The 
organic layer was dried over anh. MgSO4, filtered and concentrated in vacuo to give the crude 
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product. This was puried by column chromatography (20% diethyl ether in pet. ether) to yield 
the pure product as white crystals (26.7 mg, 0.13 mmol, 37%); Rf 0.21 (20% diethyl ether in pet. 
ether); IR (thin film) 𝜈/cm–1: 2247 (C≡N, w), 1511 (C=C, m), 751 (C-Cl, s). 1H NMR (400 MHz, 
CDCl3) δ/ppm: 8.40–8.37 (m, 1H, H6), 7.91–7.88 (m, 1H, H9), 7.71–7.67 (m, 2H, H7&8), 7.59 (d, 
J = 7.5 Hz, 1H, H3), 7.53 (d, J = 7.5 Hz, 1H, H2), 4.13 (s, 2H, H11). 13C NMR (101 MHz, CDCl3) 
δ/ppm: 133.1 (C4), 131.8 (C10), 131.0 (C5), 127.9 (C7/8), 127.5 (C7/8), 126.4 (C2), 125.7 (C3), 
125.7 (C6), 125.1 (C1), 122.9 (C9), 117.2 (C12), 21.7 (C11). HRMS (ESI) C12H7ClN m/z: [M-H]– 
200.0275 (calc. 200.0272). m.p. 71–72 °C. 
 
Methyl 2-bromo-4-chlorobenzoate, 49 
 
2-Bromo-4-chlorobenzoic acid (2 g, 8.49 mmol, 1.0 eq) was dissolved in methanol (25 mL) and 
cooled to 0 °C before thionyl chloride (2.30 mL, 32.82 mmol, 3.8 eq) was added dropwise. The 
reaction was refluxed for 4 h. The mixture was concentrated in vacuo and was diluted with 
dichloromethane (25 mL). This was washed with water (20 mL), sat. aq. NaHCO3 (20 mL), and 
brine (20 mL). The organic layer wad dried over anh. Na2SO4, filtered and concentrated in 
vacuo to give the crude product. This was purified by column chromatography (15% diethyl 
ether in pet. ether) to give the pure product as a colourless oil (1.46 g, 5.87 mmol, 69%); Rf 0.50  
(15% diethyl ether in pet. ether) IR (thin film) 𝜈/cm–1: 2952 (C-H, w), 1732 (C=O, s), 1581 
(C=C, s), 1100 (C-O, s), 763 (C-Cl, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.76 (d, J = 8.5 Hz, 
1H, H6), 7.67 (d, J = 2.0 Hz, 1H, H3), 7.33 (dd, J = 2.0, 8.5 Hz, 1H, H5), 3.91 (s, 3H, H8). 13C 
NMR (101 MHz, CDCl3) δ/ppm: 165.6 (C7), 138.3 (C4), 134.2 (C6), 132.4 (C3), 130.2 (C1), 127.5 
(C5), 122.6 (C2), 52.6 (C8). HRMS (ESI) C8H7BrClO2 m/z: [M+H]+ 248.9315 (calc. 248.9318). 
The physical and spectroscopic data was found to be in agreement with Sun et al.220  
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Methyl 4-chloro-2-((trimethylsilyl)ethynyl)benzoate, 50 
 
Trimethylsilylacetylene (0.42 mL, 3.01 mmol, 1.5 eq), 49 (500 mg, 2.00 mmol, 1.0 eq), 
bis(triphenylphosphine)palladium(II) dichloride (70.2 mg, 0.10 mmol, 5 mol%), 
triphenylphosphine (13.1 mg, 0.05 mmol, 2.5 mol%), triethylamine (0.42 mL, 3.01 mmol, 1.5 
eq) were dissolved in tetrahydrofuran (8mL) and stirred at RT for 20 min. Copper (I) iodide 
(4.6 mg, 0.024 mmol, 1.2 mol%) was added and the reaction was refluxed for a further 16 h. 
This was concentrated in vacuo and diluted with dichloromethane and was filtered through 
celite. The filtrate was concentrated in vacuo  to give the crude product. This was purified by 
column chromatography (6.25% ethyl acetate in hexane) to gie the pure product as a yellow 
oil (420.5 mg, 1.58 mmol, 79%); Rf 0.31 (6.25% ethyl acetate in hexane); IR (thin film) 𝜈/cm–1: 
2955 (C-H, w), 2163 (C≡C, w), 1736 (C=O, s), 1247 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 
7.86 (d, J = 8.5 Hz, 1H, H6), 7.57 (d, J = 2.0 Hz, 1H, H3), 7.33 (dd, J = 2.0, 8.5 Hz, 1H, H5), 3.91 
(s, 3H, H8), 0.27 (s, 9H, H11). 13C NMR (101 MHz, CDCl3) δ/ppm: 165.9 (C7), 137.8 (C2), 134.2 
(C3), 131.7(C6), 130.7 (C4), 128.5 (C5), 125.0 (C1), 101.9 (C9/10), 101.5 (C9/10), 52.1 (C8), –0.2 
(C11). HRMS (ESI) C13H16ClO2Si m/z: [M+H]+ 267.0619 (calc. 267.0608). 
 
4-Chloro-2-ethynyl benzoic acid, 51 
 
Compound 50 (200 mg, 0.75 mmol, 1.0 eq) was dissolved 3:2 ethanol:dichloromethane (2mL) 
and cooled to 0 °C when 1M NaOH (3 mL, 3.00 mmol, 4.0 eq) was added dropwise over 10 
min. The reaction was warmed to RT and stirred for 4h. The solution was washed with diethyl 
ether (5 mL) and 1M HCl was added dropwise until a precipitate appeared. The precipitate 
was collected by filtration, dissolved in diethyl ether (5 mL) and washed with water (5 mL). 
The organic layer was dried over Na2SO4 and the excess solvent was removed in vacuo to yield 
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the pure product as yellow crystals (98.6 mg, 0.55 mmol, 73%); IR (thin film) 𝜈/cm–1: 3304 
(C≡C-H, w), 3282 (O-H, m), 2952 (C-H, m), 2113 (C≡C, m), 1686 (C=O, s), 1586 (C=C, s), 1271 
(C-O, s), 777 (C-Cl, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 13.29 (s, 1H, OH), 7.85 (d, J = 8.5 
Hz, 1H, H6), 7.67 (d, J = 2.0 Hz, 1H, H3), 7.57 (dd, J = 2.0, 8.5 Hz, 1H, H5), 4.51 (s, 1H, H9). 13C 
NMR (101 MHz, CDCl3) δ/ppm: 166.2 (C7), 136.3 (C2), 133.7 (C3), 132.6 (C4), 131.8 (C6), 129.1 
(C5), 123.6 (C1), 87.0 (C9), 80.8 (C8). HRMS (ESI) C9H4ClO2 m/z: [M-H]– 178.9903 (calc. 
178.9905). 
 
Hydroxycarbonimidic dibromide, 70 
 
Glyoxylic acid (5.00 g, 54.32 mmol, 1.0 eq) and hydroxylamine hydrochloride (3.77 g, 54.32 
mmol, 1.0 eq) were stirred in water (150mL) for 24 h. NaHCO3 (9.13 g, 108.60mmol, 2.0 eq) 
was added and stirred with CH2Cl2 (200 mL). The mixture was cooled to 6 °C and stirred 
vigorously. Bromine (5.43 mL, 108.60 mmol, 2.0 eq) was added dropwise over 20 min and 
stirred for 3 h. The organic layer was separated, the aqueous was extracted with CH2Cl2 (100 
mL × 3), and the combined organic layers were dried over MgSO4. The salt was filtered and 
the remaining organic layer was concentrated in vacuo to give the product as a white crystal 
(6.7510 g, 33.29 mmol, 61%): Rf 0.45 (20% Et2O in pet. ether); IR (thin film) 𝜈/cm–1: 3290 (O-
H, br s), 1580 (C=N, m), 890 (C-Br, s). 1H NMR (400 MHz, (CD3)2SO) δ/ppm: 12.74 (s, 1H, 
OH). 13C NMR (101 MHz, CDCl3) δ/ppm: 96.7. HRMS (ESI) CH2NOBr2 m/z: [M+H]+ 200.8425 
(calc. 200.8433). 
The physical and spectroscopic data was found to be in agreement with Soleimani et al.221 
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tert-Butyldimethyl(prop-2-yn-1-yloxy)silane, 72 
 
Propargylic alcohol (3.00 mL, 51.5 mmol, 1.0 eq) and imidazole (5.26 g, 77.3 mmol, 1.5 eq) were 
dissolved in CH2Cl2 (150 mL). The mixture was cooled to 0 °C TBSCl (11.7 g, 77.3 mmol, 1.5 
eq) was added and stirred for 90 min. The reaction was quenched with sat. aq. NH4Cl (50 mL), 
extracted with diethyl ether (20 mL × 3), and washed with brine (50 mL). The organic layer 
was dried over MgSO4, the salt was filtered and the remaining organic layer was concentrated 
in vacuo. The crude oil was purified by column chromatography (20% diethyl ether in pet. 
ether) to give the product as a colourless oil (6.2657 g, 36.79 mmol, 71%); Rf 0.70 (20% diethyl 
ether in pet. ether); IR (thin film) 𝜈/cm–1: 2970 (C-H, s), 2901 (C-H, s), 2125 (C≡C, w), 1253 (C-
Si, m), 1087 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 4.29 (d, J = 2.5 Hz, 2H, H3), 2.36 (t, J 
= 2.5 Hz, 1H, H1), 0.89 (s, 9H, H6), 0.10 (s, 6H, H4). 13C NMR (101 MHz, CDCl3) δ/ppm: 82.4 
(C2), 72.8 (C1), 51.5 (C3), 25.8 (C6×2), 18.3 (C5), –5.2 (C4×3). HRMS (ESI) C9H19OSi m/z: 
[M+H]+ 171.1195 (calc. 171.1200). 
The physical and spectroscopic data was found to be in agreement with Yatvin et al.222 
 
3-Bromo-5-(((tert-butyldimethylsilyl)oxy)methyl)isoxazole, 73 
 
Alkyne 72 (5.00 g, 29.4 mmol, 4.0 eq) and oxime 70 (1.49 g, 7.34 mmol, 1.0 eq) were dissolved 
in CH2Cl2 (10 mL) refluxed for 18 h. The reaction was cooled to room temperature and poured 
into 1M HCl (10 mL). The organic layer was separated and dried over anh. NaHSO4. This 
mixture was filtered and the excess solvent of the filtrate was removed in vacuo. The crude 
was purified by column chromatography (40% diethyl ether in pet. ether) to give the pure 
product as a yellow oil (1.7948 g, 6.14 mmol, 84%); Rf 0.28 (40% diethyl ether in pet. ether); IR 
(thin film) 𝜈/cm–1: 2955 (C-H, w), 2858 (C-H, w), 1594 (C=C, m), 1258 (N-O, m), 1124 (C-O, 
m). 1H NMR (400 MHz, CDCl3) δ/ppm: 6.30 (t, J = 1.0 Hz, 2H, H4), 4.78 (d, J = 1.0 Hz, 1H, 
H2), 0.94 (s, 9H, H5), 0.14 (s, 6H, H7). 13C NMR (101 MHz, CDCl3) δ/ppm: 174.0 (C1), 140.3 
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(C3), 105.1 (C2), 57.3 (C4), 25.7 (C7×3), 18.2 (C6), –5.5 (C5×2). HRMS (ESI) C10H19O2NBrSi m/z: 
[M+H]+ 292.0351 (calc. 292.0363). 
 
Spiro[indoline-3,4’-piperidin]-1’-ium chloride, 85 
 
A suspension of lithium aluminium hydride (749 mg, 19.7 mmol, 4.75 eq) in glyme (20 mL) 
was cooled to 0 °C and ethanol (1.7 mL) added. The mixture was heated to reflux and 
compound 96 (1.00 g, 4.15 mmol, 1.0 eq) dissolved in glyme (10 mL) was added followed by 
continuing reflux for 72 h. Subsequently the reaction was cooled to 0 °C and water (20 mL) 
was added slowly. Added to this was a conc. solution of Rochelle’s salt (20 mL) and extracted 
with CH2Cl2 (50 mL). The organic layers were dried over anh. MgSO4 which was removed by 
filtration and the excess solvent was evaporated in vacuo. To the residual oil was added 4M 
HCl/Dioxane (5 mL). The insoluble salt produced was isolated by filtration and washed with 
cold acetone (10 mL) to give the product as white crystals (546 mg, 2.09 mmol, 50%); IR (thin 
film) 𝜈/cm–1: 2923 (C-H, s), 2714 (C-H, s), 1596 (C=C, m). 1H NMR (400 MHz, (CD3)2SO) 
δ/ppm: 9.21 (br. s, 2H, NH2), 7.59–7.54 (m, 2H, H3&4), 7.44–7.36 (m, 2H, H2&5), 3.55 (d, J = 
13.5 Hz, 2H, H10a), 3.36 (s, 2H, H7), 3.18 (t, J = 13.5 Hz, 2H, H10b), 2.56–2.51 (m, 2H, H9a), 
2.40–2.33 (m, 2H, H9b). 13C NMR (101 MHz, (CD3)2SO) δ/ppm: 159.2 (C6), 131.3 (C3), 127.2 
(C4), 125.5 (C2), 119.9 (C1), 117.0 (C5), 40.9 (C10×2), 38.9 (C8), 36.9 (C7), 30.2 (C9×2). HRMS 
(ESI) C12H17N2 m/z: [M+H]+ 188.1313 (calc. 188.1319). m.p. 264–265 °C. 
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2,3-Dihydrospiro[indene-1,4’-piperidin]-1’-ium chloride, 86 
 
The 10% Pd on C (384 mg, 0.36 mmol, 0.1 eq) was suspended in ethanol (10 mL) and hydrogen 
gas was bubbled through the mixture. Compound 103 (500 mg, 2.25 mmol, 1.0 eq) was added 
to the reaction and it was stirred for 2 h in an atmosphere of hydrogen. The catalyst was 
remove by filtering through celite and the ethanol was removed in vacuo. The crystals were 
washed with cold acetone (10 mL) to yield product as white crystals (402 mg, 1.80 mmol, 80%); 
IR (thin film) 𝜈/cm–1: 2943 (C-H, s), 2730 (C-H, s), 1595 (C=C, m). 1H NMR (400MHz, 
(CD3)2SO) δ/ppm: 9.71 (d, J = 64.0 Hz, 2H, NH2), 7.30–7.20 (m, 4H, H2–5), 3.55 (d, J = 12.5 Hz, 
2H, H11a), 3.11 (q, J = 11.5 Hz, 2H, H11b), 2.97 (t, J = 7.5 Hz, 2H, H7), 2.35 (td, J = 14.0, 4.0 Hz, 
2H, H10a), 2.07 (t, J = 7.5 Hz, 2H, H8), 1.75 (d, J = 14.0 Hz, 2H, H10b). 13C NMR (101 MHz, 
(CD3)2SO) δ/ppm: 148.5 (C6), 142.4 (C1), 127.6 (C2), 127.0 (C4), 124.8 (C5), 122.7 (C3), 45.2 
(C9), 41.8 (C11×2), 34.6 (C8), 33.2 (C10×2), 29.8 (C7). HRMS (ESI) C13H17N m/z: [M+H]+ 
188.1447 (calc. 188.1439). m.p. 289–290 °C. 
The physical and spectroscopic data was found to be in agreement with Chambers et al.131 
 
tert-Butyl bis(2-chloroethyl)carbamate, 92 
 
Di-tert-butyl dicarbonate (4.6 mL, 20.0 mmol, 1.2 eq) and bis(2-chloroethyl)amine (3.0 g, 16.8 
mmol, 1.0 eq) were dissolved in CH2Cl2 (20 mL). Triethylamine (2.6 mL, 20.1 mmol, 1.2 eq) 
was added dropwise. The mixture was left to stir for an hour before more triethylamine (0.2 
mL, 1.4 mmol, 0.08 eq) was added. The reaction was stirred overnight before TLC showed it 
had gone to completion. Excess solvent was removed in vacuo. The residue was dissolved in 
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diethyl ether (30 mL) and extracted with water (30 mL). The combined ethereal layers were 
dried over anh. MgSO4 and the excess solvent was removed in vacuo. the residue was purified 
via column chromatography (pet. ether/diethyl ether 20%) to give the product as a colourless 
oil (3.10 g, 12.8 mmol, 76%); Rf 0.31 (pet. ether / Et2O (20%)); IR (thin film)  ?̃?/cm–1: 2977 (C-
H, m), 1693 (C=O, s), 1465 (C-H, m), 1405 (C-H, m), 775 (C-Cl, m). 1H NMR (400 MHz, CDCl3) 
δ/ppm: 3.66–3.59 (m, 8H, H1&2), 1.47 (s, 9H, H5). 13C NMR (101 MHz, CDCl3) δ/ppm: 154.9 
(C3), 80.7 (C4), 51.0 (C2x2), 42.1 (C1x2), 28.3 (C5x3). HRMS (ESI) C5H10NO2Cl2 m/z: [M+H–t-
butyl]+ 186.0089 (calc. 186.0094). 
The physical and spectroscopic data was found to be in agreement with Tantry et al.223 
 
4-Cyano-4-(2-fluorophenyl)piperidin-1-ium chloride, 95 
 
Compound 96 (476 mg, 1.57 mmol) was stirred in HCl/dioxane (4M, 5 mL) for 1 h. The 
mixture was filtered and the filtrate was washed with cold diethyl ether (10 mL). The isolated 
white crystals were placed in a desiccator overnight to yield the pure white crystalline product 
(183 mg, 0.76 mmol, 48%); IR (thin film) 𝜈/cm–1: 2925 (C-H, m), 2712 (C-H, m), 2241 (C≡N, 
w), 1597 (C=C, m). 1H NMR (400 MHz, (CD3)2SO) δ/ppm: 9.26–9.20 (m, 2H, NH2), 7.55–7.50 
(m, 2H, H3&5), 7.40–7.25 (m, 2H, H2,4), 3.51 (d, J = 13.5 Hz, 2H, H10), 3.17–3.09 (m, 2H, H10), 
2.52–2.48 (m, 2H, H9), 2.33 (td, J = 13.5, 3.5 Hz, 2H, H9). 13C NMR (101 MHz, (CD3)2SO) 
δ/ppm: 161.8 (C6), 159.4 (C1), 131.7 (C3), 127.5 (C5), 125.9 (C2), 120.3 (C8), 117.3 (C4), 41.2 
(C10×2), 37.3 (C7), 30.6 (C9×2). HRMS (ESI) C12H14FN2 m/z: [M+H]+ 205.1130 (calc. 205.1136). 
m.p. 276–277 °C. 
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tert-Butyl 4-cyano-4-(2-fluorophenyl)piperidine-1-carboxylate, 96 
 
2-(2-Fluorophenyl)acetonitrile (1.6 mL, 12.39 mmol, 1.5 eq) was added to a suspension of 
sodium hydride (50% in mineral oil, 3.2 g, 80.95 mmol, 9.8 eq) in dry THF (20 mL) at 5 °C. The 
mixture was warmed to RT and stirred for 30 min. The reaction was cooled to 0 °C and 
compound 92 (2.0 g, 8.26 mmol, 1.0 eq) was added before being heated to reflux for 3 h. After 
the reaction had finished, as shown by TLC, the excess solvent was removed in vacuo, ice water 
(10 mL) was added slowly to the residue before being extracted with diethyl ether (20 mL x 
3). The combined organic layers were dried over MgSO4 and the excess solvent was removed 
in vacuo. The resulting substance was purified by column chromatography (40% diethyl ether 
in pet. ether) to give the product as a white amorphous solid (2.09 g, 6.87 mmol, 83%); Rf 0.34 
(40% diethyl ether in pet. ether); IR (thin film) ?̃?/cm–1: 2979 (C-H, s), 2251 (C≡N, m), 1694 
(C=O, s), 1605 (C=C, m). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.46 (td, J = 8.0, 2.0 Hz, 1H, H4), 
7.37–7.34 (m, 1H, H2), 7.19 (td, J = 7.5, 1.5 Hz, 1H, H3), 7.13 (ddd, J = 12.0, 8.0, 1.0 Hz, 1H, H1), 
4.28 (br. s, 2H, H10a), 3.23 (br. s, 2H, H10b), 2.21–2.06 (m, 4H, H9), 1.48 (s, 9H, H13). 13C NMR 
(101 MHz, CDCl3) δ/ppm: 161.7 (C11), 159.7 (C5×3), 154.4 (C6), 130.4 (C4), 127.0 (C2), 124.7 
(C3), 120.2 (C8), 117.0 (C1), 80.1 (C12), 41.3 (C7), 40.2 (C9×2), 33.8 (C10×2), 28.4 (C13). HRMS 
(ESI) C17H21N2O2FNa m/z: [M+Na]+ 327.1479 (calc. 327.1470). 
The physical and spectroscopic data was found to be in agreement with Xie et al.130 
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N-Benzyl-2-chloro-N-(2-chloroethyl)ethan-1-amine, 98 
 
Benzyl bromide (0.80 mL, 6.75 mmol, 1.0 eq) was added dropwise to a suspension of K2CO3 
(0.93 g, 6.72 mmol, 1.2 eq) and bis(2-chloroethyl)ammonium chloride (1.00 g, 5.60 mmol, 1.0 
eq) in acetonitrile (7 mL). The reaction was refluxed overnight. Afterwards the excess solvent 
was removed in vacuo and the remaining mixture was re-dissolved in diethyl ether (20 mL) 
and extracted with water (20 mL) and brine (20 mL) and the combined aqueous layers were 
extracted with diethyl ether (20 mL × 3). The combined ethereal layers were dried over MgSO4 
and the excess solvent was removed in vacuo. The product was purified via column 
chromatography (100% pet. ether) to give the pure product as a colourless oil (500 mg, 2.15 
mmol, 38%); Rf 0.17 (pet. ether); IR (thin film) 𝜈/cm–1: 2961 (C-H, m), 2809 (C-H, m), 1610 
(C=C, w), 1453 (C-H, m), 742 (C-Cl, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.34–7.25 (m, 5H, 
Ar), 3.75 (s, 2H, H3), 3.50–3.33 (m, 4H, H1), 3.01–2.91 (m, 4H, H2). 13C NMR (101 MHz, CDCl3) 
δ/ppm: 138.8 (C4), 128.6 (C5/6×2), 128.4 (C5/6×2), 127.4 (C7), 59.2 (C3), 56.3 (C2×2), 42.0 
(C1×2). HRMS (ESI) C11H16NCl2 m/z: [M+H]+ 232.0668 (calc. 232.0660). 
The physical and spectroscopic data was found to be in agreement with Chan et al.224 
 
1’-Benzylspiro[indene-1,4’-piperidine], 100 
 
Indene (0.50 mL, 4.31 mmol, 1.0 eq) was dissolved in THF (10 mL) and cooled to 0 °C and 
LHMDS (1M in THF, 8.62 mL, 8.62 mmol, 2.0 eq) was added over 15 min. The mixture was 
stirred for 30 min before compound 98 (1.00 g, 4.31 mmol, 1.0 eq) was added dropwise. The 
reaction was heated to RT and stirred for 2 h. When the reaction had concluded, the solvent 
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was removed in vacuo and the residue was diluted with diethyl ether (20 mL) and washed 
with sat. aq. NH4Cl (20 mL) and brine (20 mL). The combined aqueous layers were extracted 
with diethyl ether (20 mL × 3). The combined ethereal layers were dried over MgSO4 and the 
excess solvent was removed in vacuo. The given oil was purified via column chromatography 
(20% diethyl ether in pet. ether) to give the product as a golden oil (809 mg, 2.94 mmol, 68%); 
Rf 0.11 (20% diethyl ether in pet. ether); IR (thin film) 𝜈/cm–1: 3065 (C-H, m), 2945 (C-H, m), 
2804 (C-H, m), 1454 (C=C, m), 698 (C-H, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.42–7.19 (m, 
9H, Ar), 6.87 (d, J = 5.5 Hz, 1H, H8), 6.75 (d, J = 5.5 Hz, 1H, H7), 3.67 (s, 2H, H12), 3.00 (dt, J = 
12.0, 3.0 Hz, 2H, H10a), 2.39 (td, J = 12.0, 2.5 Hz, 2H, H10b), 2.22 (td, J = 12.5, 3.5 Hz, 2H, H11a), 
1.36 (d, J = 12.0 Hz, 2H, H11b). 13C NMR (101 MHz, CDCl3) δ/ppm: 152.4 (C1), 142.9 (C6), 
141.7 (C8), 138.3 (C13), 129.4 (C14/15/16), 129.3 (C7), 128.3 (C14/15/16), 127.1 (C14/15/16), 
126.8 (C2/3/4/5), 125.2 (C2/3/4/5), 121.8 (C2/3/4/5), 121.3 (C2/3/4/5), 63.7 (C12), 52.2 
(C11×2), 52.1 (C9), 33.9 (C10×2),. HRMS (ESI) C20H22N m/z: [M+H]+ 276.1739 (calc. 276.1747). 
 
1’-Benzyl-2,3-dihydrospiro[indene-1,4’-piperidine], 101 
 
The 10% Pd on C (142 mg, 0.13 mmol, 0.1 eq) was suspended in ethanol (10 mL) and hydrogen 
gas was bubbled through the mixture. Compound 100 (230 mg, 0.84 mmol, 1.0 eq) was added 
to the reaction as a solution in ethanol (5 mL) and it was stirred for 2 h in an atmosphere of 
hydrogen. The catalyst was removed by filtering through celite and the ethanol was removed 
in vacuo. The given oil was purified via column chromatography (5 % methanol in CH2Cl2) to 
give the product as a colourless oil (110 mg, 0.40 mmol, 48%); Rf 0.26 (5 % methanol in 
dichloromethane); IR (thin film) 𝜈/cm–1: 3021 (C-H, m), 2924 (C-H, s), 1602 (C=C, w), 1494 
(C=C, w). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.38–7.13 (m, 9H, Ar), 3.57 (s, 2H, H12), 2.91–
2.85 (m, 4H, H7,11a), 2.20 (t, J = 10.5 Hz, 2H, H11b), 2.02–1.92 (m, 4H, H8,10a), 1.53 (d, J = 13.0 
Hz, 2H, H10b). 13C NMR (101 MHz, CDCl3) δ/ppm: 151.5 (C1), 143.2 (C6), 138.4 (C13), 129.4 
(C2/3/4/5), 128.3 (C2/3/4/5), 127.1 (C2/3/4/5), 126.7 (C2/3/4/5), 126.5 (C14/15/16), 124.6 
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(C14/15/16), 122.7 (C14/15/16), 63.7 (C12), 51.3 (C11), 46.5 (C9), 36.9 (C10), 35.1 (C8), 30.0 
(C7). HRMS (ESI) C20H24N m/z: [M+H]+ 278.1891 (calc. 278.1903). 
 
tert-Butyl spiro[indene-1,4’-piperidine]-1’-carboxylate, 102 
 
Indene (0.10 mL, 0.86 mmol, 1.0 eq) was dissolved in dry THF (2 mL) and cooled to 0 °C. 
LHMDS (288 mg, 1.72 mmol, 2.0 eq) was added dropwise over 15 min. This was left to stir for 
30 min before compound 92 (208 mg, 0.86 mmol, 1.0 eq) was added at 0 °C and stirred for 2 h. 
After the reaction had gone to completion excess solvent was removed in vacuo. This was 
purified via column chromatography (20% diethyl ether in pet. ether) to give the product as a 
yellow oil (203 mg, 0.712 mmol, 83%); Rf 0.28 (20% diethyl ether in pet. ether); IR (thin 
film) 𝜈/cm–1: 3057 (C-H, m), 2976 (C-H, m), 2935 (C-H, m), 2865 (C-H, m), 1687 (C=O, s). 1H 
NMR (400 MHz, CDCl3) δ/ppm: 7.36–7.19 (m, 4H, H2–5), 6.85 (d, J = 5.5 Hz, 1H, H8), 6.79 (d, 
J = 5.5 Hz, 1H, H7), 4.20–4.18 (m, 2H, H11a), 3.13 (t, J = 12.5 Hz, 2H, H11b), 2.01 (td, J = 12.5, 
4.5 Hz, 2H, H10a), 1.51 (s, 9H, H14), 1.34 (d, J = 13.0 Hz, 2H, H10b). 13C NMR (101 MHz, 
CDCl3) δ/ppm: 155.1 (C12), 151.7 (C1), 142.8 (C6), 140.4 (C8), 130.3 (C7), 127.0 (C2/3/4/5), 
125.4 (C2/3/4/5), 121.7 (C2/3/4/5), 121.5 (C2/3/4/5), 79.6 (C13), 77.2 (C11), 52.1 (C9), 33.4 
(C10), 28.5 (C14). HRMS (ESI) C18H24NO2 m/z: [M+H]+ 286.1812 (calc. 286.1811). 
The physical and spectroscopic data was found to be in agreement with Tantry et al.223 
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Spiro[indene-1,4’-piperidin]-1’-ium chloride, 103 
 
Compound 102 (1.78 g, 6.24 mmol) was stirred in HCl/dioxane (4M, 5.00 mL) for 1 h. The 
mixture was filtered and the filtrate was washed with cold diethyl ether (10 mL). The isolated 
white crystals were placed in a desiccator overnight to yield the pure white crystalline product 
(405 mg, 5.23 mmol, 84%); IR (thin film) 𝜈/cm–1: 3361 (N-H, m), 2936 (C-H, m), 2801 (C-H, 
m), 1644 (C=C, m), 1600 (C=C, m). 1H NMR (400 MHz, (CD3)2SO) δ/ppm: 9.92 (d, J = 33.5 Hz, 
2H, NH2), 7.48 (d, J = 7.0 Hz, 1H, H5), 7.37–7.24 (m, 3H, H2–4), 6.87 (d, J = 5.5 Hz, 1H, H7), 
6.74 (d, J = 5.5 Hz, 1H, H8), 3.69 (d, J = 13.0 Hz, 2H, H11a), 3.26 (q, J = 13.0 Hz, 2H, H11b), 2.58 
(td, J = 13.0, 4.0 Hz, 1H, H10a) 1.60 (d, J = 13.0 Hz, 2H, H10b). 13C NMR (101 MHz, (CD3)2SO) 
δ/ppm: 150.0 (C1), 142.3 (C6), 138.1 (C8), 132.1 (C7), 127.7 (C2/3/4), 126.1 (C2/3/4), 122.0 
(C2/3/4), 121.9 (C5), 50.1 (C9), 42.81 (C11×2), 30.4 (C10×2). HRMS (ESI) C13H17N m/z: [M+H]+ 
186.1275 (calc. 186.1277). m.p. 309–310 °C. 
 
tert-Butyl 2-oxo-3,4-dihydroquinoline-1(2H)-carboxylate, 105 
 
3,4-Dihydroquinolin-2(1H)-one (100 mg, 0.68 mmol, 1.0 eq) was dissolved in dry CH2Cl2 (5 
mL) before triethylamine (0.095 mL, 0.68 mmol, 1.0 eq), di-tert-butyl decarbonate (0.19 mL, 
0.82 mmol, 1.2 eq), and 4-dimethylaminopyridine (8.50 mg, 0.07 mmol, 0.1 eq) were added to 
the mixture. The mixture was stirred for 18 h at RT. After the reaction had finished the excess 
solvent was removed in vacuo. To the mixture water (20 mL) was added and the mixture was 
extracted with diethyl ether (10 mL × 3). The combined ethereal layers were washed with 1 
M KHSO4 (20 mL), sat. NaHCO3 (20 mL), and brine (20 mL). The organic layers were dried 
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over Na2SO4 and the excess solvent was removed in vacuo. The resulting substance was 
purified by column chromatography (20% diethyl ether in pet. ether) to give the product as a 
white crystalline solid (154 mg, 0.62 mmol, 92%); Rf 0.17 (20% diethyl ether in pet. ether); IR 
(thin film) 𝜈/cm–1: 2981 (C-H, w), 1755 (C=O, s), 1692 (C=O, s), 1605 (C=C, m). 1H NMR (400 
MHz, CDCl3) δ/ppm: 7.23–7.17 (m, 2H, H6,7), 7.06 (td, J = 7.5,1.0 Hz, 1H, H5), 6.94 (d, J = 8.0 
Hz, 1H, H8), 2.95 (t, J = 7.0 Hz, 2H, H3), 2.68–2.64 (m, 2H, H2), 1.60 (s, 9H, H12). 13C NMR (101 
MHz, CDCl3) δ/ppm: 169.3 (C1), 151.8 (C10), 137.1 (C9), 128.0 (C7), 127.3 (C6), 125.9 (C4), 
124.1 (C5), 117.0 (C8), 85.0 (C11), 32.3 (C2), 27.7 (C12×3), 25.5 (C3). HRMS (ESI) C14H17NO3Na 
m/z: [M+Na]+ 270.1063 (calc. 270.1063). m.p. 68–69 °C. 
The physical and spectroscopic data was found to be in agreement with Evans et al.225 
 
1-(tert-Butyl) 4-ethyl piperidine-1,4-dicarboxylate, 109 
 
Di-tert-butyl dicarbonate (0.17 mL, 0.76 mmol, 1.2 eq) and ethyl piperidine-4-carboxylate (0.10 
mL, 0.64 mmol, 1.0 eq) were dissolved in CH2Cl2 (5 mL). Triethylamine (0.11 mL, 0.76 mmol, 
1.2 eq) was added dropwise and the mixture was left to stir overnight. The excess solvent was 
removed in vacuo and the residue was dissolved in diethyl ether (20 mL) before being 
extracted with water (20 mL × 3). The ethereal layers were dried over MgSO4 and the excess 
solvent was removed in vacuo. The remaining solid was purified via column chromatography 
(20% diethyl ether in pet. ether) to give the product as a colourless oil (162 mg, 0.63 mmol, 
98%); Rf 0.18 (20% diethyl ether in pet. ether); IR (thin film) 𝜈/cm–1: 2978 (C-H, m), 1732 (C=O, 
s), 1692 (C=O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 4.14 (q, J = 7.0 Hz, 2H, H8), 4.01 (d, J = 
13.0 Hz, 2H, H4), 2.83 (t, J = 12.5 Hz, 2H, H4), 2.43 (tt, J = 11.0, 4.0 Hz, 1H, H6), 1.87 (d, J = 13.5 
Hz, 2H, H5), 1.67–1.57 (m, 2H, H5), 1.45 (s, 9H, H1), 1.25 (t, J = 7.0 Hz, 3H, H9). 13C NMR (101 
MHz, CDCl3) δ/ppm: 174.6 (C7), 154.7 (C3), 79.6 (C2), 60.5 (C8), 43.2 (C4×2), 41.2 (C6), 28.4 
(C1×3), 28.0 (C5×2), 14.2 (C9). HRMS (ESI) C13H23NO4Na m/z: [M+Na]+ 280.1535 (calc. 
280.1525). 
The physical and spectroscopic data was found to be in agreement with Ueno et al.226 
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1-(tert-Butyl) 4-ethyl 4-(2-nitrobenzyl)piperidine-1,4-dicarboxylate, 111 
 
A solution of 109 (1.21 g, 4.70 mmol, 1.0 eq) in THF (10 mL) was cooled to –78 °C and NaHMDS 
(1M in THF, 6.58 mL, 6.58 mmol, 1.4 eq) was added dropwise. The reaction was stirred at this 
temperature for 1 h, before 2-nitrobenzyl bromide (1.22 g, 5.64 mmol, 1.2 eq) was added and 
the reaction was warmed to RT and stirred overnight. At completion, the excess solvent was 
removed in vacuo and the residue was extracted between water and ethyl acetate and the 
organic washed with brine. The organic layer was dried over MgSO4 and the solvent was 
removed in vacuo. The crude oil produced was purified via column chromatography (20% 
ethyl acetate in hexane) to give the product as a brown oil (184.6 mg, 0.47 mmol, 10%); Rf 0.26 
(20% ethyl acetate in hexane); IR (thin film) 𝜈/cm–1: 2913 (C-H, w), 2713 (C-H, w), 1652 (C=O, 
s), 1596 (N=O, s), 1401 (N=O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.86 (d, J = 8.0 Hz, 1H, 
H15), 7.48 (td, J = 1.5,11.5 Hz, 1H, H13), 7.40–7.37 (m, 1H, H14), 7.20 (dd, J = 1.5,7.5 Hz, 1H, 
H12) 4.07 (q, J = 7.0 Hz, 2H, H8), 3.67 (br. s, 2H, H4a), 3.31–3.29 (m, 2H, H4b), 2.69 (br. s, 2H, 
H10), 2.07–2.05 (m, 2H, H5a), 1.56 (s, 2H, H5b), 1.42 (s, 9H, H1), 1.18 (t, J = 7.0 Hz, 3H, H9). 13C 
NMR (101MHz, CDCl3) δ/ppm: 174.0 (C7), 154.7 (C3), 150.4 (C16), 133.2 (C12), 132.8 (C13), 
132.2 (C11), 128.0 (C14), 127.9 (C15), 79.6 (C6), 61.0 (C8), 47.6 (C2), 41.7 (C4), 38.4 (C10) 33.3 
(C5), 28.4 (C1), 14.0 (C9). HRMS (ESI) C20H29N2O6 m/z: [M+H]+ 393.2042 (calc. 393.2026). 
 
1-(tert-Butyl) 4-ethyl 4-(2-aminobenzyl)piperidine-1,4-dicarboxylate, 112 
 
Hydrogen gas was bubbled through a suspension of palladium on carbon (10%, 112 mg, 0.10 
mmol, 20 mol %) in ethanol (10 mL) to which 111 (179 mg, 0.46 mmol, 1.0 eq) was added. After 
completion, the reaction was filter through celite and the excess solvent was removed in vacuo. 
The product was purified by column chromatography (10% methanol in CH2Cl2) to give the 
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product as a colourless oil (146 mg, 0.37 mmol, 81%) Rf 0.21 (10% methanol in CH2Cl2); IR 
(thin film) 𝜈/cm–1: 2913 (C-H, w), 2713 (C-H, w), 1652 (C=O, s), 1620 (C=O, s), 1225 (C-N, m). 
1H NMR (400 MHz, CDCl3) δ/ppm: 7.20–7.15 (m, 2H, H12,14) 7.01–6.98 (m, 1H, H13) 6.73 (d, 
J = 8.0 Hz, 1H, H15) 3.72 (q, J = 7.0 Hz, 2H, H8) 3.66–3.61 (m, 2H, H4a) 3.47–3.42 (m, 2H, H4b) 
2.87 (s, 2H, H10) 2.62 (s, 2H, H5) 1.94 (s, 2H, H5) 1.45 (s, 9H, H1) 1.24 (t, J = 3.5 Hz, 3H, H9). 
13C NMR (101 MHz, CDCl3) δ/ppm: 174.7 (C7) 154.8 (C3) 136.3 (C16) 128.6 (C12) 127.7 (C14) 
123.2 (C13) 122.2 (C11) 114.5 (C15) 79.5 (C6) 58.5 (C8) 45.7 (C2) 41.0 (C4) 38.5 (C5) 36.5 (C10) 
28.4 (C1) 18.4 (C9). HRMS (ESI) C20H31N2O4 m/z: [M+H]+ 363.2268 (calc. 363.2278). 
 
6-Chloro-1H-indene, 115 
 
To a solution of 5-chloro-1-indanone (1.00 g, 6.00 mmol, 1.0 eq) in methanol (30 mL) was added 
sodium borohydride (613mg, 16.21mmol, 2.7 eq). The mixture was warmed to RT and stirred 
for 1 h. Next water (10 mL) was added and the reaction was extracted with CH2Cl2 (30 mL × 
3). The organic layer was dried over MgSO4 which was subsequently filtered off and the 
filtrated was concentrated in vacuo to give the crude alcohol. This alcohol was dissolved in 
toluene (30 mL) and p-toluenesulfonic acid monohydrate (34.2 mg, 0.18 mmol, 0.03 eq) was 
added before the reaction was refluxed for 2 h. The reaction was cooled to RT and sat. aq. 
NaHCO3 (30 mL) was added before extraction with ethyl acetate (20 mL × 3). The organic 
layers were washed with brine (50 mL) and dried over MgSO4. This was filtered off and the 
filtrate was concentrated in vacuo. The crude oil was purified via column chromatography 
(100%hexane) to yield the pure product as a colourless oil (615 mg, 4.09 mmol, 68%); Rf 0.45 
(100% hexane); IR (thin film) 𝜈/cm–1: 2988 (C-H, m), 1583 (C=C, m), 818 (C-Cl, s). 1H NMR 
(400 MHz, CDCl3) δ/ppm: 7.47 (s, 1H, H2), 7.33 (d, J = 8.0 Hz, 1H, H5), 7.28–7.26 (m, 1H, H4), 
6.87 (d, J = 5.5 Hz, 1H, H7), 6.58 (dt, J = 5.5,2.0 Hz, 1H, H8), 3.42 (s, 2H, H9). 13C NMR (101 
MHz, CDCl3) δ/ppm: 145.4 (C6), 143.3 (C1), 134.6 (C8), 131.4 (C7), 130.6 (C3), 126.4 (C4), 124.1 
(C5), 121.6 (C2), 39.0 (C9). HRMS (ESI) C9H8Cl m/z: [M+H]+ 151.0309 (calc. 151.0315). 
The physical and spectroscopic data was found to be in agreement with Capkova et al.132 
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tert-Butyl 6-chlorospiro[indene-1,4’-piperidine]-1’-carboxylate, 116 
 
To a solution of 115 (615 mg, 4.08 mmol, 1.0 eq) dissolved in THF (10 mL) cooled to 0 °C was 
added LiHMDS (1M in THF, 8.16 mL, 8.16 mmol, 2.0 eq) over 15 min. The reaction was stirred 
for 30 min before 92 (988 mg, 4.08 mmol, 1.0 eq) was added dropwise. The mixture was stirred 
for 2 h at RT. The excess solvent was removed in vacuo. The residue was diluted with diethyl 
ether (20 mL) and washed with sat. aq. NH4Cl (20 mL). The aqueous was extracted with 
diethyl ether (20 mL × 3). The organic layers were dried over MgSO4 and the excess solvent 
was removed in vacuo to give a crude oil. This was purified by column chromatography (20% 
diethyl ether in pet. ether) to give the pure product as a colourless oil (1.0022 g, 3.13 mmol, 
77%); Rf 0.24 (20% diethyl ether in pet. ether); IR (thin film) 𝜈/cm–1: 2974 (C-H, m), 1686 (C=O, 
s), 1601 C=C, m), 733 (C-Cl, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.30–7.28 (m, 1H, H2), 
7.23–7.16 (m, 1H, H4,5), 6.87 (dd, J = 22.0, 5.5 Hz, 1H, H8), 6.73 (dd, J = 5.5,4.0 Hz, 1H, H7), 
4.18 (br. s, 2H, H11a), 3.10 (t, J = 12.5 Hz, 2H, H11b), 1.97 (td, J = 12.5, 4.5 Hz, 2H, H10a), 1.51 
(s, 9H, H14) 1.35–1.30 (m, 2H, H10b). 13C NMR (101 MHz, CDCl3) δ/ppm: 154.9 (C12), 153.5 
(C6), 149.9 (C3), 144.4 (C1), 141.2 (C8), 129.6 (C7), 127.2 (C5), 125.2 (C4), 122.4 (C2), 79.7 (C13), 
52.4 (C9), 42.1 (C11×2), 33.3 (C10×2), 28.5 (C14). HRMS (ESI) C18H22NO2ClNa m/z: [M+Na]+ 
342.1225 (calc. 342.1231).  
 
6-Chlorospiro[indene-1,4’-piperidin]-1’-ium chloride, 117 
 
A solution of 116 (1.0 g, 3.13 mmol, 1.0 eq) was stirred in 4M HCl/dioxane (10 mL) for 30 min. 
The mixture was filtered and the residue was desiccated to give the product as a white crystal 
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(552 mg, 2.15 mmol, 69%); IR (thin film) 𝜈/cm–1: 2944 (C-H, s), 2730 (C-H, s), 1595 (C=C, m), 
1457 (C=C, m), 1428 (C-H, m), 1072 (C-N, m), 734 (C-Cl, s). 1H NMR (400 MHz, (CD3)2SO) 
δ/ppm: 8.89 (br. s, 2H, NH2), 7.45–7.27 (m, 3H, H2,4,5), 7.20 (dd, J = 24.0, 5.5 Hz, 1H, H7), 6.86 
(t, J = 5.5 Hz, 1H, H8), 3.41–3.38 (m, 2H, H11a), 3.22 (td, J = 3.0,13.0 Hz, 2H, H11b), 2.33–2.22 
(m, 2H, H10a), 1.36–1.30 (m, 2H, H10b). 13C NMR (101 MHz, (CD3)2SO) δ/ppm: 153.6 (C1), 
149.6 (C6), 144.6 (C7), 141.9 (C3), 129.6 (C8), 127.4 (C2/4/5), 125.3 (C2/4/5), 123.0 (C2/4/5), 
50.7 (C9), 41.8 (C11×2), 29.7 (C10×2). HRMS (ESI) C13H15NCl m/z: [M+H]+ 220.0879 (calc. 
220.0888). m.p. 294–296 °C. 
 
6-Chloro-2,3-dihydrospiro[indene-1,4’-piperidin]-1’-ium chloride, 118 
 
Hyrdrogen gas was bubbled through a suspension of Pd on C (10% w/w, 200 mg, 0.19 mmol, 
0.16) in ethanol (10 mL). To this 117 was added and the reaction was stirred for 1 h. The 
catalyst was removed by filtration through celite. The excess solvent of the filtrate was 
removed in vacuo to give the product as white crystals (299 mg, 1.16 mmol, 99%); IR (thin 
film) 𝜈/cm–1: 2953 (C-H, s), 1475 (C=C, m), 1439 (C-H, m), 1073 (C-N, s), 815 (C-Cl, m). 1H 
NMR (400 MHz, (CD3)2SO) δ/ppm: 8.83 (br. s, 2H, NH2), 7.29–7.11 (m, 3H, H2,4,5), 3.27 (d, J 
= 13.0 Hz, 2H, H11a), 3.00 (t, J = 13.0 Hz, 2H, H11b), 2.87 (q, J = 8.0 Hz, 2H, H7), 2.10–1.93 (m, 
4H, H8,10a), 1.62–1.60 (m, 2H, H10b). 13C NMR (101 MHz, (CD3)2SO) δ/ppm: 152.3 (C1), 141.9 
(C6), 131.1 (C3), 127.2 (C2/4/5), 126.5 (C2/4/5), 122.2 (C2/4/5), 45.3 (C9), 41.0 (C11×2), 34.3 
(C8), 32.6 (C10×2), 29.0 (C7). HRMS (ESI) C13H17NCl m/z: [M+H]+ 222.1036 (calc. 222.1044). 
m.p. 300–301 °C. 
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8-Chloro-2-(ethoxycarbonyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-5-ium 
chloride, 121 
 
Ethyl 4-oxopiperidine-1-carboxylate (0.84 mL, 5.59 mmol, 1.0 eq) and (4-chlorophenyl) 
hydrazine (1 g, 5.59 mmol, 1.0 eq) were dissolved in ethanol (10 mL) and refluxed for 3 h 
before being left to stir at room temperature overnight. The residual solid was collected by 
filtration and washed with 1:1 mixture of H2O:EtOH to give the product as a white amorphous 
solid (872.6 mg, 3.14 mmol, 56%); IR (thin film) 𝜈/cm–1: 3414 (N-H, br. s), 2988 (C-H, m), 1658 
(C=O, m), 1050 (C-N, s), 823 (C-Cl, m). 1H NMR (400 MHz, CDCl3) δ/ppm: 11.13 (s, 2H, NH2), 
7.48 (d, J = 2.0 Hz, 1H, H7), 7.29 (d, J = 8.5 Hz, 1H, H4), 7.02 (dd, J = 8.5,2.0 Hz, 1H, H6), 4.56 
(s, 2H, H1), 4.09 (q, J = 7.0 Hz, 2H, H13), 3.74 (t, J = 5.5 Hz, 2H, H11), 2.79 (t, J = 5.5 Hz, 2H, 
H10), 1.21 (t, J = 7.0 Hz, 3H, H14). 13C NMR (101 MHz, CDCl3) δ/ppm: 155.2 (C12), 134.6 (C3), 
134.3 (C8), 126.3 (C9), 123.2 (C5), 120.5 (C6), 116.8 (C7), 112.4 (C4), 105.7 (C2), 61.0 (C13), 40.9 
(C1), 40.2 (C11), 23.0 (C10), 14.7 (C14). HRMS (ESI) C14H16ClN2O2 m/z: [M+H]+ 279.0904 (calc. 
279.0895). 
The physical and spectroscopic data was found to be in agreement with Yin et al.133  
 
8-Chloro-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-2-ium chloride, 122 
 
A mixture of 121 (340 mg, 1.22 mmol, 1.0 eq), 0.8M potassium hydroxide (5 mL, 6.10 mmol, 
5.0 eq) and ethanol (10 mL) was refluxed overnight. After the reaction was cooled to RT it was 
stirred with 4M HCl/dioxane. The mixture was filtered and the residue dried in a desiccator 
to achieve the product as a white crystalline solid (207 mg, 0.85 mmol, 71%); IR (thin film) 
𝜈/cm–1: 2919 (C-H, m), 2727 (C-H, m), 1441 (C=C, m), 790 (C-Cl, s). 1H NMR (400 MHz, 
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(CD3)2SO) δ/ppm: 10.9 (s, 2H, NH2), 7.37 (d, J = 2.0 Hz, 1H, H7), 7.21 (d, J = 8.5 Hz, 1H, H4), 
7.08 (dd, J = 8.5,2.0 Hz, 1H, H6), 4.02 (t, J = 1.5 Hz, 2H, H11), 3.22 (t, J = 5.5 Hz, 2H, H1), 2.77 
(t, J = 5.5 Hz, 2H, H10). 13C NMR (101 MHz, (CD3)2SO) δ/ppm: 135.5 (C3), 133.9 (C8), 126.8 
(C9), 122.8 (C5), 119.9 (C6), 116.5 (C7), 112.1 (C4), 108.3 (C2), 42.9 (C1), 41.5 (C11), 24.1 (C10). 
HRMS (ESI) C11H12N2Cl m/z: [M+H]+ 207.0676 (calc. 207.0684). m.p. 277-279 °C. 
The physical and spectroscopic data was found to be in agreement with Yin et al.133 
 
Ethyl (diphenylmethylene)glycinate, 140 
 
Ethyl glycinate hydrochloride (20 g, 143.3 mmol, 1.0 eq), benzophenone (26.11 g, 143.3 mmol, 
1.0 eq), and diisopropylethylamine (25 mL, 143.3 mmol, 1.0 eq) were dissolved in toluene (90 
mL) and heated with Dean-Stark apparatus until one equivalent of water was observed in the 
trap. The reaction was cooled to RT and diluted with water (50 mL). The aqueous was 
extracted with ethyl acetate (3 × 25 mL) and the combined organics were washed with water 
(50 mL), sat. aq. NaHCO3 (50 mL), and brine (50 mL). The organics were dried over anh. 
MgSO4, filtered, and concentrated in vacuo to give the crude product. This was purified by 
column chromatography (10% ethyl acetate in pet. ether) to yield the pure product as white 
crystals (16.61 g, 62.13 mmol, 43%); Rf 0.14 (10% ethyl acetate in pet. ether); IR (thin film) 
𝜈/cm–1: 2981 (C-H, w), 1749 (C=O, s), 1620 (C=N, m), 1188 (C-O, s). 1H NMR (400 MHz, 
CDCl3) δ/ppm: 7.68–7.65 (m, 2H, Ar), 7.49–7.31 (m, 6H, Ar), 7.20–7.17 (m, 2H, Ar), 4.21 (q, J = 
7.0 Hz, 2H, H2), 4.20 (s, 2H, H4), 1.27 (t, J = 7.0 Hz, 3H, H1). 13C NMR (101 MHz, CDCl3) 
δ/ppm: 171.9 (C5), 170.7 (C3), 139.3 (Ar C), 136.0 (Ar C), 130.5 (Ar C), 128.8 (Ar C), 128.8 (Ar 
C×2), 128.7 (Ar C×2), 128.1 (Ar C×2), 127.7 (Ar C×2), 60.9 (C2), 55.7 (C4), 14.2 (C1). HRMS 
(ESI) C17H17NO2Na m/z: [M+Na]+ 290.1160 (calc. 290.1157). m.p. 51–52 °C. 
The physical and spectroscopic data were found to be in agreement with Mukherjee et al.227 
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Ethyl 2-((diphenylmethylene)amino)hex-5-enoate, 141 
 
Potassium tert-butoxide (3.15 g, 28.06 mmol, 1.5 eq) was dissolved in THF (150 mL) under 
nitrogen at 0 °C. To the mixture was added 140 (5 g, 18.70 mmol, 1.0 eq) and this was stirred 
for 10 min. 4-bromo-1-butene (5.7mL, 56.11 mmol, 3.0 eq) was added to the reaction dropwise 
before it was warmed to RT and left to stir overnight. The excess solvent was removed via a 
rotary evaporator and the residue was diluted with ethyl acetate (50 mL). This was washed 
with sat. aq. NaHCO3 (50 mL). The organic layer was extracted with ethyl acetate (3 × 20 mL) 
before the combined organics were washed with brine (50 mL). The organic layer was dried 
over anh. MgSO4. This was filtered and concentrated in vacuo to yield the pure product as a 
yellow oil (5.7169 g, 17.8 mmol, 95%); IR (thin film) 𝜈/cm–1: 2979 (C-H, w), 1735 (C=O, s), 
1622 (C=C, m), 1238 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.66–7.64 (m, 2H, Ar), 7.45–
7.31 (m, 6H, Ar), 7.19–7.16 (m, 2H, Ar), 5.77–5.67 (m, 1H, H7), 4.98–4.88 (m, 2H, H8), 4.19–4.04 
(m, 3H, H2&4), 2.10–1.96 (m, 4H, H5&6), 1.26 (t, J = 7.0 Hz, 3H, H1). 13C NMR (101 MHz, 
CDCl3) δ/ppm: 172.3 (C9), 170.6 (C3), 139.6 (Ar), 137.8 (C7), 136.5 (Ar), 130.9 (Ar), 128.8 
(Ar×2), 128.6 (Ar), 128.5 (Ar×2), 128.1 (Ar×2), 127.9 (Ar×2), 115.0 (C8), 64.9 (C4), 60.9 (C2), 33.0 
(C5/6), 30.2 (C5/6), 14.2 (C1). HRMS (ESI) C21H23NO2Na m/z: [M+Na]+ 344.1624 (calc. 
344.1626). 
The physical and spectroscopic data were found to be in agreement with Andrei et al.228 
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Ethyl 2-allyl-2-aminohex-5-enoate, 142 
 
Potassium tert-butoxide (6.47 g, 57.76 mmol, 1.5 eq) was dissolved in THF (100 mL) under 
nitrogen at 0 °C. To the mixture was added 141 (12.36 g, 38.4 mmol, 1.0 eq) and was stirred 
for 10 min. Allyl bromide (10.0 mL, 115.32 mmol, 3.0 eq) was added dropwise before the 
reaction was warmed to RT and stirred overnight. This was quenched with 3M HCl (38.4 mL, 
1 mL mmol-1 of 141) and stirred for 5 min. This mixture was diluted with dichloromethane (50 
mL) and water (20 mL). This was extracted with dichloromethane (3 × 30 mL). The combined 
aqueous was basified was Na2CO3 and was extracted with ethyl acetate (3 × 30 mL). These 
organic extractions were dried over MgSO4, filtered and concentrated in vacuo to yield the 
pure product as a yellow oil (6.5392 g, 33.15 mmol, 86%); IR (thin film) 𝜈/cm–1: 3078 (C-H, 
w), 1727 (C=O, s), 1640 (C=C, m), 1199 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 5.82–5.74 
(m, 1H, H7), 5.73–5.64 (m, 1H, H10), 5.15–5.12 (m, 2H, H11), 5.04–4.93 (m, 2H, H8), 4.20–4.15 
(m, 2H, H2), 2.58–2.54 (m, 1H, H9a), 2.28–2.23 (m, 1H, H9b), 2.17–2.09 (m, 1H, H6a), 1.99–1.91 
(m, 1H, H6b), 1.88–1.82 (m, 1H, H5a), 1.67–1.61 (m, 3H, H5b&NH2), 1.29–1.26 (m, 3H, H1). 13C 
NMR (101 MHz, CDCl3) δ/ppm: 176.5 (C3), 137.9 (C7), 132.6 (C10), 119.5 (C11), 114.9 (C8), 
61.0 (C2), 60.4 (C4), 44.3 (C9), 39.1 (C5), 28.4 (C6), 14.8 (C1). HRMS (ESI) C11H19NO2Na m/z: 
[M+Na]+ 220.1313 (calc. 220.1313). 
 
Ethyl 2-allyl-2-((tert-butoxycarbonyl)amino)hex-5-enoate, 143 
 
Compound 142 (4 g, 20.28 mmol, 1.0 eq) was dissolved in THF (100 mL). Boc2O (7 mL, 30.41 
mmol, 1.5 eq) was added dropwise and the reaction was refluxed at 70 °C for 3 hours. The 
excess solvent was removed in vacuo and the crude oil was purified via column 
Experimental 
161 
 
chromatography (100% dichloromethane) to yield the product as a colourless oil (5.1314 g, 
17.25 mmol, 85%); IR (thin film) 𝜈/cm–1: 3430 (N-H, w), 3076 (C-H, w), 1714 (C=O, s), 1642 
(C=C, w). 1H NMR (400 MHz, CDCl3) δ/ppm: 5.80–5.70 (m, 1H, H7), 5.67–5.56 (m, 1H, H10), 
5.51 (br s, 1H, NH2), 5.08–5.05 (m, 2H, H11), 5.01–4.91 (m, 2H, H8), 4.20 (q, J = 7.0 Hz, 2H, H13), 
3.07 (m, 1H, H9a), 2.51–2.45 (m, 1H, H9b), 2.40 (m, 1H, H5a), 2.11–2.01 (m, 1H, H6a), 1.88–1.78 
(m, 2H, H5b&6b), 1.43 (s, 9H, H1), 1.28 (t, J = 7.0 Hz, 3H, H14). 13C NMR (101 MHz, CDCl3) 
δ/ppm: 173.3 (C12), 146.7 (C3), 137.6 (C7), 132.5 (C10), 118.8 (C11), 115.0 (C8), 85.2 (C2), 63.2 
(C4), 61.7 (C13), 39.8 (C9), 34.4 (C5), 28.4 (C6), 27.4 (C1), 14.2 (C14). HRMS (ESI) C16H28NO4 
m/z: [M+H]+ 298.2007 (calc. 298.2018). 
 
Ethyl 1-((tert-butoxycarbonyl)amino)cyclohex-3-ene-1-carboxylate, 144 
 
Compound 143 (1 g, 3.36 mmol, 1.0 eq) was dissolved in dichloromethane (170 mL) and 
Grubbs second generation catalyst (285 mg, 0.34 mmol, 10 mol%) was added. The reaction 
was refluxed at 50 °C for 1 hour under nitrogen. When the reaction had gone to completion 
the excess solvent was removed in vacuo to give the crude product. The was purified via 
column chromatography (50 % ethyl acetate in pet. ether) to yield the pure product as a brown 
oil (709.6 mg, 2.63 mmol, 78%); IR (thin film) 𝜈/cm–1: 3379 (n-H, w), 2975 (C-H, w), 1708 (C=O, 
s), 1163 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 5.74—5.71 (m, 1H, H7), 5.59—5.55 (m, 
1H, H8), 4.78 (br s, 1H, NH), 4.22—4.12 (m, 2H, H11), 2.59—2.53 (m, 1H, H9a), 2.28—2.18 (m, 
2H, H9b&5a), 2.13—2.04 (m, 2H, H6), 1.93—1.86 (m, 1H, H5b), 1.42 (s, 9H, H1), 1.25 (t, J = 2.0 
Hz, 3H, H12). 13C NMR (101 MHz, CDCl3) δ/ppm: 174.1 (C10), 154.9 (C3), 127.1 (C7), 122.5 
(C8), 79.8 (C2), 61.1 (C11), 56.8 (C4), 34.1 (C9), 28.3 (C1), 27.5 (C5), 21.8 (C6), 14.2 (C12). HRMS 
(ESI) C14H23NO4Na m/z: [M+Na]+ 292.1515 (calc. 292.1519). 
The physical and spectroscopic data were found to be in agreement with Fariba et al.229 
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tert-Butyl (1-(hydroxymethyl)cyclohex-3-en-1-yl)carbamate, 145 
 
Compound 144 (660 mg, 2.45 mmol, 1.0 eq) was dissolved in THF (25 mL) and cooled to 0 °C 
before lithium borohydride (267 mg, 12.25 mmol, 5.0 eq) was added and the reaction was 
stirred overnight. This was quenched with sat. aq. NH4Cl (25 mL) and stirred for 10 min. The 
layers were separated and the aqueous was extracted with ethyl acetate (3 × 20 mL). The 
combined organics were washed with sat. aq. NaHCO3 (30 mL) and brine (30 mL) and dried 
over MgSO4 before being filtered and concentrated in vacuo to give a crude oil. This was 
purified via column chromatography (20% ethyl acetate in pet. ether) to yield the product as 
white crystals (319.4 mg, 1.41 mmol, 57%); Rf 0.18 (20% ethyl acetate in pet. ether); IR (thin 
film) 𝜈/cm–1: 3423 (O-H, m), 2889 (C-H, w), 1681 (C=O, s), 1528 (C=C, s). 1H NMR (400 MHz, 
CDCl3) δ/ppm: 5.76–5.74 (m, 1H, H7), 5.59–5.56 (m, 1H, H8), 4.65 (br s, 1H, NH), 4.22 (br s, 
1H, OH), 3.70 (d, J = 6.5 Hz, H10), 2.17–2.00 (m, 5H, H5a&6&9), 1.74–1.69 (m, 1H, H5b), 1.44 
(s, 9H, H1). 13C NMR (101 MHz, CDCl3) δ/ppm: 156.6 (C3), 127.4 (C7), 123.1 (C8), 80.0 (C2), 
69.2 (C10), 55.0 (C4), 34.0 (C9), 28.3 (C1), 27.3 (C5), 22.1 (C6). HRMS (ESI) C12H21NO3Na m/z: 
[M+Na]+ 250.1403 (calc. 250.1414). m.p. 77–78 °C. 
 
1-(Hydroxymethyl)cyclohex-3-en-1-aminium chloride, 146 
 
Compound 145 (151.6 mg, 0.67 mmol) was dissolved in hydrochloric acid (4M in dioxane, 10 
mL) and was left for 1 h. The reaction was concentrated in vacuo to give off white crystals. 
These were washed with cold acetone to yield the pure product as white crystals (108.3 mg, 
0.66 mmol, 99%); IR (thin film) 𝜈/cm–1: 3217 (O-H, m), 2837 (C-H, s), 1628 (C=C, m), 1048 (C-
O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.95 (br s, 3H, NH3+), 5.69–5.66 (m, 1H, H6), 5.57–
5.54 (m, 1H, H5), 5.47 (t, J = 5.0 Hz, 1H, OH), 3.42 (d, J = 5.0 Hz, 2H, H1), 2.14 (br s, 2H, H7), 
2.08–2.06 (m, 2H, H4), 1.81–1.66 (m, 2H, H3). 13C NMR (101 MHz, CDCl3) δ/ppm: 126.2 (C6), 
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122.9 (C5), 62.7 (C1), 55.1 (C2), 30.3 (C7), 26.5 (C3), 21.4 (C4). HRMS (ESI) C7H14NO m/z: [M-
Cl–]+ 128.1071 (calc. 128.1070). m.p. 222–223 °C. 
 
3-Oxa-1-azaspiro[4.5]dec-7-en-2-one, 148 
 
Compound 145 (200 mg, 0.88 mmol, 1.0 eq) was dissolved in THF (10 mL). The mixture was 
cooled to 0oC and potassium tert-butoxide (197 mg, 1.76 mmol, 2.0 eq) was added and the 
reaction was warmed to RT and stirred for 1 h. The reaction was then diluted with sat. aq. 
NH4Cl (10 mL), extracted with dichloromethane (3 × 10 mL), dried over anh. MgSO4, before 
the mixture was filtered and concentrated in vacuo. The crude was purified by column 
chromatography (40% ethyl acetate in pet. ether) to give the product as white crystals (108.0 
mg, 0.71 mmol, 80%); Rf 0.11 (40% ethyl acetate in pet. ether); IR (thin film) 𝜈/cm–1: 3240 (N-
H, w), 2924 (C-H, w), 1730 (C=O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 5.76–5.71 (m, 1H, 
H6), 5.65–5.61 (m, 1H, H7), 5.28 (br s, 1H, NH), 4.15 (d, J = 8.5 Hz, 1H, H2a), 4.12 (d, J = 8.5 Hz, 
1H, H2b), 2.32–2.21 (m, 4H, H5&8), 1.89–1.84 (m, 1H, H4a), 1.74–1.72 (m, 1H, H4b). 13C NMR 
(101 MHz, CDCl3) δ/ppm: 158.5 (C1), 127.0 (C6), 123.7 (C7), 75.5 (C2), 55.9 (C3), 36.8 (C5/8), 
32.2 (C4), 22.5 (C5/8). HRMS (ESI) C8H11NO2Na m/z: [M+Na]+ 176.0690 (calc. 176.0682). m.p. 
107–108°C. 
 
tert-Butyl (4-(hydroxymethyl)octa-1,7-dien-4-yl)carbamate, 147 
 
Compound 143 (2 g, 6.72 mmol, 1.0 eq) was dissolved in THF (50 mL) and cooled to 0 °C under 
nitrogen. Lithium borohydride (2M in THF, 10.1 mL, 20.17 mmol, 3eq) was added dropwise. 
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The reaction was warned to RT and stirred overnight. The reaction was quenched by slow 
addition of sat. aq. NH4Cl. This was extracted with ethyl acetate (3 × 25 mL). The combined 
organics were dried over anh. Na2SO4, filtered and the excess solvent removed in vacuo to give 
the crude product. This was purified via column chromatography (25 % ethyl acetate in pet. 
ether) to yield the product as a colourless oil (463.2 mg, 1.81 mmol, 27%); Rf 0.24 (25% ethyl 
acetate in pet. ether); IR (thin film) 𝜈/cm–1: 3404 (O-H, br w), 2978 (C-H, w), 1683 (C=O, s), 
1640 (C=C, m), 1164 (C-O, s), 1053 (C-OH, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 5.83–5.72 
(m, 2H, H7&10), 5.15–5.11 (m, 2H, H11), 5.04–4.93 (m, 2H, H8), 4.66 (br s, 1H, OH), 4.22 (br s, 
1H, NH2), 3.69–3.60 (m, 2H, H12), 2.38–2.27 (m, 2H, H9), 2.14–1.96 (m, 2H, H6), 1.74–1.59 (m, 
2H, H5), 1.41 (s, 9H, H1). 13C NMR (101 MHz, CDCl3) δ/ppm: 156.2 (C3), 138.1 (C7), 132.8 
(C10), 119.4 (C11), 11408 (C8), 79.9 (C2), 67.8 (C12), 58.7 (C4), 39.0 (C9), 33.6 (C5), 28.3 (C1), 
27.7 (C6). HRMS (ESI) C14H26NO3 m/z: [M+H]+ 256.1908 (calc. 256.1913). 
 
Ethyl benzimidate hydrochloride, 150 
 
To a solution on benzonitrile (5.00 g, 48.49 mmol, 1.0 eq) in ethanol (34 mL, 581.85 mmol, 12.0 
eq), acetyl chloride (27.68 mL, 387.90 mmol, 8.0 eq) was added dropwise. The reaction was 
stirred overnight then concentrated in vacuo to yield the product as white crystals (8.0401 g, 
43.31 mmol, 89%); IR (thin film) 𝜈/cm–1: 2828 (C-H, br s), 1626 (C=N, s), 1451 (C=C, s), 1059 
(C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 12.60 (br s, 1H, NH), 11.91 (br s, 1H, NH), 8.40–
8.38 (m, 2H, H3), 7.76–7.67 (m, 1H, H1), 7.58–7.54 (m, 2H, H2), 4.93 (q, J = 7.0 Hz, 2H, H6), 1.61 
(t, J = 7.0 Hz, 3H, H7). 13C NMR (101 MHz, CDCl3) δ/ppm: 170.9 (C5), 135.6 (C1), 129.7 (C3), 
129.3 (C2), 125.3 (C4), 71.3 (C6), 13.9 (C7). HRMS (ESI) C9H12NO m/z: [M-Cl–]+ 150.0913 (calc. 
150.0913). m.p. 120–121 °C. 
The physical and spectroscopic data were found to be in agreement with Berger et al.230 
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2-Phenyl-3-oxa-1-azaspiro[4.5]deca-1,7-diene, 151 
 
Compound 146 (50 mg, 0.31 mmol, 1.1 eq) and 150 (41.4 mg, 0.28 mmol, 1.0 eq) were dissolved 
in 1,2-dichloroethane (1 mL) and refluxed overnight. The reaction was cooled to RT and 
filtered. The filtrate was concentrated in vacuo and the crude was purified by column 
chromatography (30% ethyl acetate in hexane) to yield the product was white crystals (34.0 
mg, 0.16 mmol, 57%); Rf 0.44 (30% ethyl acetate in hexane); IR (thin film) 𝜈/cm–1: 2905 (C-H, 
w), 1648 (C=N, s), 1581 (C=C, m), 1059 (C-O, m). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.96–
7.92 (m, 2H, H3), 7.48–7.44 (m, 1H, H1), 7.41–7.37 (m, 2H, H2), 5.77–5.73 (m, 1H, H10), 5.69–
5.63 (m, 1H, H11), 4.16 (d, J = 8.5 Hz, 1H, H6a), 4.11 (d, J = 8.5 Hz, 1H, H6b), 2.48–2.43 (m, 1H, 
H12a), 2.36–2.29 (m, 1H, H9a), 2.17–2.08 (m, 2H, H9b&12b), 2.05–1.98 (m, 1H, H8a), 1.75–1.69 
(m, 1H, H8b). 13C NMR (101 MHz, CDCl3) δ/ppm: 162.5 (C5), 131.2 (C1), 128.28 (C3), 128.26 
(C2), 128.1 (C4), 127.2 (C10), 124.4 (C11), 77.6(C6), 69.4 (C7), 37.3 (C12), 33.0 (C8), 22.8 (C9). 
HRMS (ESI) C14H16NO m/z: [M+H]+ 214.1222 (calc. 214.1226). 
 
3-Oxa-1-azaspiro[4.5]deca-1,7-dien-2-amine, 152 
 
Cyanobromide (175 mg, 1.65 mmol, 1.2 eq) was added to a solution of 146 (175 mg, 1.38 mmol, 
1.0 eq) as a free base in ethanol (5 mL) and refluxed overnight. This was concentrated in vacuo 
and dissolved in dichloromethane (10 mL). This was washed with 1M NaOH (10 mL) and the 
aqueous was extracted with dichloromethane (10 mL). The combined organics were 
concentrated in vacuo to yield the product as off-white crystals (122.2 mg, 0.80 mmol, 58%); IR 
(thin film) 𝜈/cm–1: 3437 (N-H, m), 2903 (C-H, m), 1666 (C=N, s), 1650 (C=C, m), 1010 (C-O, s). 
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1H NMR (400 MHz, CDCl3) δ/ppm: 5.72–5.68 (m, 1H, H6), 5.64–5.60 (m, 1H, H7), 4.01 (d, J = 
8.0 Hz, 1H, H2a), 3.97 (d, J = 8.0 Hz, 1H H2b), 2.31–2.21 (m, 2H, H5a&8a), 2.12–2.02 (m, 2H, 
H5b&8b), 1.83–1.78 (m, 1H, H4a), 1.67–1.62 (m, 1H, H4b). 13C NMR (101 MHz, CDCl3) δ/ppm: 
159.2 (C1), 127.0 (C6), 124.6 (C7), 78.6 (C2), 66.6 (C3), 37.9 (C5/8), 33.4 (C4), 23.1 (C5//8). 
HRMS (ESI) C8H13N2O m/z: [M+H]+ 153.1025 (calc. 153.1028). m.p. 198–199 °C 
Crystallographic data for this compound is in Appendix B. 
 
4-Oxa-1-azaspiro[5.5]undec-8-en-3-one, 158 
 
Compound 146 as a free base (150 mg, 0.92 mmol, 1.0 eq) was dissolved in acetonitrile before 
phenyl bromoacetate (216.5 mg, 1.00 mmol, 1.1 eq) and diisopropylethylamine (0.4 mL, 2.29 
mmol, 2.5 eq) were added. The reaction was stirred at RT for 4 h before being concentrated in 
vacuo to give the crude product. This was purified by column chromatography (100% ethyl 
acetate) to yield the pure product as white crystals (20 mg, 0.12 mmol, 13%); IR (thin film) 
𝜈/cm–1: 3317 (N-H, w), 2921 (C-H, w), 1730 (C=O, s), 1215 (C-N, s), 1040 (C-O, s). 1H NMR 
(400 MHz, CDCl3) δ/ppm: 5.74–5.70 (m, 1H, H7), 5.62–5.57 (m, 1H, H8), 4.20 (d, J = 11.0 Hz, 
1H, H3a), 4.13 (d, J = 11.0 Hz, 1H, H3b), 3.68 (s, 2H, H1), 2.17–1.97 (m, 5H, H6&9&NH), 1.80–
1.74 (m, 1H, H5a), 1.67–1.61 (m, 1H, H5b). 13C NMR (101 MHz, CDCl3) δ/ppm: 169.1 (C2), 
126.7 (C7), 123.3 (C8), 76.2 (C3), 48.2 (C4), 44.0 (C1), 33.2 (C6/9), 28.6 (C5), 22.0 (C6/9). HRMS 
(ESI) C9H14NO2 m/z: [M+H]+ 168.1017 (calc. 168.1019). 
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4-Oxa-1-azaspiro[5.5]undeca-1,8-dien-3-one, 159 
 
Compound 158 (100 mg, 0.60 mmol, 1.0 eq), was dissolved in acetonitrile (6 mL) and lead (IV) 
acetate (345 mg, 0.78 mmol, 1.3 eq) was added before the reaction was allowed to stir for 30 
min at RT. This was then diluted with ethyl acetate (10 mL) and filtered through Celite. The 
filtrate was washed with sat. aq. NaHCO3 solution (20 mL) and brine (20 mL) before being 
dried over anh. MgSO4, filtered and concentrated in vacuo. The crude oil was purified by 
column chromatography (20% ethyl acetate in hexane) to give the pure product as a yellow 
oil (91.1 mg, 0.55 mmol, 92%); Rf 0.25 (20% ethyl acetate in hexane); IR (thin film) 𝜈/cm–1: 
2923 (C-H, w), 1737 (C=O, s), 1622 (C=N, m), 1038 (C-O, s). 1H NMR (400 MHz, CDCl3) 
δ/ppm: 7.82 (s, 1H, H1), 5.83–5.77 (m, 1H, H7), 5.71–5.65 (m, 1H, H8), 4.29 (d, J = 11.5 Hz, 1H, 
H3a), 4.25 (d, J = 11.5 Hz, 1H, H3b), 2.31–2.21 (m, 2H, H6a&9a), 2.15–2.03 (m, 2H, H6b&9b), 
2.02–1.95 (m, 1H, H5a), 1.70–1.64 (m, 1H, H5b). 13C NMR (101 MHz, CDCl3) δ/ppm: 154.6 
(C2), 151.0 (C1), 127.0 (C7), 122.9 (C8), 72.0 (C3), 55.8 (C4), 32.6 (C6/9), 30.1 (C5), 22.0 (C6/9). 
HRMS (ESI) C9H11NO2Na m/z: [M+H]+ 188.0681 (calc 188.0682). 
 
2-Chloro-N-(1-(hydroxymethyl)cyclohex-3-en-1-yl)acetamide, 160 
 
Compound 145 (1.19 g, 5.24 mmol, 1.0 eq) was dissolved in THF (50 mL). 3M HCl (17.5 mL, 
0.3M) was added and the mixture was refluxed for 3 h. This was concentrated in vauco and 
the residue was dissolved in dichloromethane (50 mL) before triethylamine (2.2 mL, 15.7 
mmol, 3.0 eq), and chloroacetyl chloride (0.42 mL, 5.24 mmol, 1.0 eq) were added dropwise at 
0 °C. This was stirred for 90 min. The reaction was then diluted with sat. aq. NH4Cl  
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(25 mL) and stirred for 10 min. This was extracted with dichloromethane (3 × 20 mL) and the 
organics were dried over anh. MgSO4 before being filtered and concentrated in vacuo. This 
crude was purified via column chromatography (dichloromethane to 10% diethyl ether in 
dichloromethane) to give the pure product as white crystals (261.2 mg, 1.28 mmol, 24%); Rf 
0.14 (10% diethyl ether in dichloromethane); IR (thin film) 𝜈/cm–1: 3352 (O-H, br m), 3271 (N-
H, m), 3070 (C-H alkene, w), 2938 (C-H, w), 1654 (C=O, s), 1549 (C=C, s), 656 (C-Cl, s). 1H 
NMR (400 MHz, CDCl3) δ/ppm: 6.67 (br s, 1H, N-H), 5.81–5.77 (m, 1H, H6), 5.64–5.60 (m, 1H, 
H7), 4.30 (t, J = 6.5 Hz, 1H, OH), 4.04 (s, 2H, H1), 3.75 (d, J = 6.5 Hz, 2H, H9), 2.27–2.18 (m, 3H, 
H8&5a), 2.11–2.03 (m, 2H, H5b&4a), 1.79–1.73 (m, 1H, H4b). 13C NMR (101 MHz, CDCl3) 
δ/ppm: 166.9 (C2), 127.4 (C6), 122.8 (C7), 68.3 (C9), 57.4 (C3), 42.9 (C1), 33.4 (C8), 27.2 (C4), 
21.8 (C5). HRMS (ESI) C9H15ClNO2 m/z: [M+H]+ 204.0776 (calc. 204.0786). m.p. 86–87 °C. 
 
4-Oxa-1-azaspiro[5.5]undec-8-en-2-one, 161 
 
Compound 145 (260 mg, 1.28 mmol, 1.0 eq) was dissolved in tert-butanol (25 mL) and heated 
to 30 °C before potassium tert-butoxide (158 mg, 1.40 mmol, 1.1 eq) was added and the reaction 
was left to stir for 5 h. It was then diluted with sat. aq. NH4Cl (20 mL) and stirred for 10 min. 
This was extracted with dichloromethane (3 × 20 mL). The organics were dried over anh. 
MgSO4. This was filtered and concentrated in vacuo to yield the pure product as off-white 
crystals (211.9 mg, 1.27 mmol, 99%); Rf 0.28 (10% diethyl ether in dichloromethane); IR (thin 
film) 𝜈/cm–1: 3169 (N-H, m), 3070 (C-H alkene, w), 2924 (C-H alkane, w), 1661 (C=O, s), 1098 
(C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 6.13 (br s, 1H, NH), 5.76–5.73 (m, 1H, H7), 5.62–
5.58 (m, 1H, H8), 4.16 (d, J = 4.5 Hz, 2H, H2), 3.60 (s, 2H, H3), 2.27–2.21 (m, 1H, H9a), 2.18–
2.16 (m, 2H, H6), 2.05–1.99 (m, 1H, H9b), 1.93–1.86 (m, 1H, H5a), 1.70–1.63 (m, 1H, H5b). 13C 
NMR (101 MHz, CDCl3) δ/ppm: 168.7 (C1), 126.9 (C7), 123.0 (C8), 71.8 (C3), 67.2 (C2), 52.4 
(C4), 34.7 (C9), 31.0 (C5), 21.9 (C6). HRMS (ESI) C9H13NO2Na m/z: [M+Na]+ 190.0831 (calc. 
190.0839). m.p. 128–129 °C. 
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Ethyl 2-allyl-2-(3-ethoxy-3-oxopropanamido)hex-5-enoate, 165 
 
Compound 142 (1.0 g, 5.07 mmol, 1.0 eq) was dissolved in dichloromethane (50 mL) at 0 °C 
under nitrogen. Triethylamine (1.52 mL, 10.90 mmol, 2.15 eq) and ethyl malonyl chloride (1.04 
mL, 8.11 mmol, 1.6 eq) were added dropwise. The reaction was warmed to RT and stirred for 
30 min. This was quench with sat. aq. NH4Cl (25 mL) and stirred for a further 10 min. The 
layers were separated and the aqueous was extracted with dichloromethane (2 × 20 mL). The 
combined organics were dried over anh. MgSO4, filtered and concentrated in vacuo to give the 
crude product. This was purified by column chromatography (20% ethyl acetate in pet. ether) 
to yield the pure product as a yellow oil (1.2711 g, 4.08 mmol, 81%); Rf 0.23 (20% ethyl acetate 
in pet. ether); IR (thin film) 𝜈/cm–1: 3337 (N-H, w), 2980 (C-H, w), 1732 (C=O ester, s), 1681 
(C=O amide, m), 1650 (C=C, m), 1221 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.66 (br s, 
1H, NH), 5.77–5.67 (m, 1H, H9), 5.63–5.52 (m, 1H, H12), 5.10–4.90 (m, 4H, H10&13), 4.25–4.18 
(m, 4H, H2&15), 3.28 (s, 2H, H4), 3.24–3.18 (m, 1H, H11a), 2.59–2.47 (m, 2H, H8a&11b), 2.07–
1.99 (m, 1H, H7a), 1.90–1.74 (m, 2H, H8b&7b), 1.30–1.26 (m, 6H, H1&16). 13C NMR (101 MHz, 
CDCl3) δ/ppm: 173.1 (C14), 168.8 (C3), 163.8 (C5), 137.3 (C9), 132.2 (C12), 118.9 (C13), 115.1 
(C10), 64.5 (C6), 61.9 (C2/5), 61.6 (C2/5), 42.6 (C4), 39.4 (C11), 34.0 (C7), 28.5 (C8), 14.2 (C1/16), 
14.1 (C1/16). HRMS (ESI) C16H26NO5 m/z: [M+H]+ 312.1820 (calc. 312.1811). 
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5-Allyl-5-(but-3-en-1-yl)pyrrolidine-2,4-dione, 167 
 
Potassium tert-butoxide (691.9 mg, 6.17 mmol, 1.6 eq) was dissolved in THF (35 mL) and 165 
(1.2 g, 3.85, 1.0 eq) was added dropwise. The reaction was refluxed for 2 hours. It was then 
cooled to RT and diluted with ethyl acetate (20 mL) and 1M HCl (20 mL) before stirred for 5 
min. The layers were separated and the aqueous was washed with ethyl acetate (10 mL). The 
combined organics were dried over MgSO4, filtered, and concentrated in vacuo. This crude 
yellow oil was dissolved in acetonitrile-water mixture (10:1, total volume 35 mL). This was 
refluxed at 100 °C for 1 hour. The reaction was cooled to RT, dried over MgSO4, filtered, and 
concentrated in vacuo. The crude oil was purified via column chromatography (50% ethyl 
acetate in pet. ether) to yield the product as white crystals (147.0 mg, 0.76 mmol, 20%); Rf 0.28 
(50% ethyl acetate in pet. ether); IR (thin film) 𝜈/cm–1: 3197 (N-H, m), 2980 (C-H, w), 1642 
(C=O, s), 1574 (C=C, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 6.34 (br s, 1H, NH), 5.74–5.66 (m, 
2H, H7&10), 5.22–5.14 (m, 2H, H11), 5.06–4.98 (m, 2H, H8), 2.87 (d, J = 3.5 Hz, 2H, H2), 2.45–
2.34 (m, 2H, H9), 2.22–2.14 (m, 1H, H6a), 2.02–1.92 (m, 2H, H6b&5a), 1.75–1.66 (m, 1H, H5b). 
13C NMR (101 MHz, CDCl3) δ/ppm: 209.5 (C3), 170.3 (C1), 136.8 (C7), 130.2 (C10), 121.5 (C11), 
116.1 (C8), 71.2 (C4), 42.1 (C9), 41.5 (C2), 35.6 (C5), 28.3 (C6). HRMS (ESI) C11H15NO2 m/z: [M]+ 
193.1099 (calc. 193.1103). m.p. 99–100 °C. 
 
1-Azaspiro[4.5]dec-7-ene-2,4-dione, 168 
 
Compound 167 (119 mg, 0.62 mmol, 1.0 eq) was dissolved in dichloromethane (31 mL) and 
degassed with nitrogen for 5 min. Grubbs second generation catalyst (52.3 mg, 0.06 mmol, 10 
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mol%) was added and the reaction was refluxed for 1 hour. The reaction was cooled to RT 
and concentrated in vacuo. This was purified via column chromatography (dichloromethane 
then ethyl acetate) to yield the pure product as white crystals (60 mg, 0.36 mmol, 59%); Rf 0.14 
(100% diethyl ether); IR (thin film) 𝜈/cm–1: 3185 (N-H, w), 3035 (C-H, w), 1651 (C=C, s), 1588 
(N-H, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 6.27 (br s, 1H, NH), 5.81–5.78 (m, 1H, H7), 5.72–
5.68 (m, 1H, H8), 3.16 (d, J = 22.0 Hz, 1H, H2a), 3.07 (d, J = 22.0 Hz, 1H, H2b), 2.62–2.54 (m, 
1H, H9a), 2.34–2.29 (m, 1H, H6a), 2.21–2.09 (m, 1H, H6b), 2.06–2.00 (m, 1H, H9b), 1.93–1.85 
(m, 1H, H5a), 1.74–1.68 (m, 1H, H5b)  . 13C NMR (101 MHz, CDCl3) δ/ppm: 209.0 (C3), 169.6 
(C1), 126.5 (C7), 123.2 (C8), 66.0 (C4), 40.1 (C2), 33.3 (C9), 29.3 (C5), 21.3 (C6). HRMS (ESI) 
C9H12NO2 m/z: [M+H]+ 166.0866 (calc. 166.0863). m.p. 187–188°C. 
 
4-Ethoxy-1-azaspiro[4.5]deca-3,7-dien-2-one, 174 
 
Compound 168 (100 mg, 0.61 mmol, 1.0 eq) was dissolved in THF (10 mL) at 0 °C. To this was 
added Potassium bis(trimethylsilyl)amide (0.5 M in toluene, 1.22 mL, 0.61 mmol, 1.0 eq) and 
the reaction was left to stir for 10 min before ethyl bromide (0.09 mL, 0.73 mmol, 1.2 eq) and 
18-crown-6 (176 mg, 0.66 mmol, 1.1 eq) was added. The reaction was warmed to RT and left 
to stir overnight. The reaction was concentrated in vacuo and purified via column 
chromatography (ethyl acetate) to give the product as yellow-white crystals (64.1 mg, 0.33 
mmol, 54%); Rf 0.24 (ethyl acetate); IR (thin film) 𝜈/cm–1: 3188 (N-H, w), 3060 (C-H alkene, 
w), 2933 (C-H alkane, w), 1672 (C=O, s), 1026 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 
5.82–5.80 (m, 1H, H7), 5.72–5.68 (m, 1H, H8), 4.91 (d, J = 1.5 Hz, 1H, H2), 4.01 (q, J = 7.0 Hz, 
2H, H10), 2.64 (m, 1H, H9a), 2.32–2.12 (m, 2H, H6), 1.97–1.85 (m, 2H, H9b&5a), 1.60–1.55 (m, 
1H, H5b), 1.39 (t, J = 7.0 Hz, 3H, H11). 13C NMR (101 MHz, CDCl3) δ/ppm: 180.4 (C1), 173.2 
(C3), 126.5 (C7), 124.1 (C8), 92.1 (C2), 67.1 (C10), 59.9 (C4), 33.6 (C9), 29.2 (C5), 22.5 (C6), 14.1 
(C11). HRMS (ESI) C11H16NO2 m/z: [M+H]+ 194.1181 (calc. 194.1176). m.p. 145–146 °C. 
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2-Oxo-1-azaspiro[4.5]deca-3,7-dien-4-yl trifluoromethanesulfonate, 175 
 
Compound 168 (100mg, 0.61 mmol, 1.0 eq) was dissolved in dichloromethane (5 mL), 
triethylamine (0.25 mL, 1.82 mmol, 3.0 eq) and triflic anhydride (0.3 mL, 1.82 mmol, 3.0 eq) 
were added dropwise at 0 °C, and the reaction was stirred for 1 h. The reaction was 
concentrated in vacuo. This was purified by column chromatography (70% to 90% diethyl ether 
in pet. ether) to give the pure product as white crystals (107.0 mg, 0.36 mmol, 59%); Rf 0.18 
(70% diethyl ether in pet. ether); IR (thin film) 𝜈/cm–1: 3164 (N-H, w), 2926 (C-H, w), 1698 
(C=O, s), 1634 (C=C, s), 1332 (S=O, m), 1131 (C-F, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 6.44 
(br s, 1H, NH), 5.93 (d, J = 2.0 Hz, 1H, H2), 5.86–5.83 (m, 1H, H7), 5.77–5.73 (m, 1H, H8), 2.67–
2.60 (m, 1H, H9a), 2.41–2.33 (m, 1H, H6a), 2.28–2.17 (m, 1H, H6b), 2.02–1.94 (m, 2H, H9a&5a), 
1.71–1.67 (m, 1H, H5b). 13C NMR (101 MHz, CDCl3) δ/ppm: 168.5 (C1/3), 167.9 (C1/3), 126.7 
(C7), 123.1 (C8), 120.0 (C10), 107.3 (C2), 60.8 (C4), 32.6 (C9), 28.6 (C5), 22.4 (C6). 19F NMR (376 
MHz, CDCl3) δ/ppm: -72.5. HRMS (ESI) C10H11F3NO4S m/z: [M+H]+ 298.0361 (calc. 298.0355). 
m.p. 119–120 °C. 
 
4-(4-Methoxyphenyl)-1-azaspiro[4.5]deca-3,7-dien-2-one, 176 
 
Compound 175 (50 mg, 0.17 mmol, 1.0 eq) was dissolved in THF (1.7 mL). (4-
methoxyphenyl)boronic acid (38.3 mg, 0.25 mmol, 1.5 eq) was added and stirred until it was 
dissolved. Tetrakis(triphenylphosphine)palladium(0) (9.7 mg, 0.008 mmol, 5 mol%) was 
added as well as sodium carbonate (39.2 mg, 0.37 mmol, 2.2 eq) dissolved in water (0.2 mL). 
The reaction was stirred for 40 min before being refluxed for 3 h. It was then called to RT, 
filtered through Celite, washed with ethyl acetate, and concentrated in vacuo. The crude was 
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purified via column chromatography (diethyl ether to 50% diethyl ether in ethyl acetate to 
ethyl acetate) to give the pure product as yellow-white crystals (31.5 mg, 0.12 mmol, 73%); Rf 
0.11 (diethyl ether); IR (thin film) 𝜈/cm–1: 3160 (N-H, w), 3035 (alkene C-H, w), 2924 (C-H, 
w), 1680 (C=O, s), 1607 (C=C, m), 1511 (C=C aromatic, m), 1181 (C-O, s). 1H NMR (400 MHz, 
CDCl3) δ/ppm: 7.43 (d, J = 9.0 Hz, 2H, H11), 6.93 (d, J = 9.0 Hz, 2H, H12), 6.35 (br s, 1H, NH), 
6.17 (d, J = 2.0 Hz, 1H, H2), 5.89–5.84 (m, 1H, H7), 5.80–5.75 (m, 1H, H8), 3.84 (s, 3H, H14), 
2.82–2.77 (m, 1H, H9a), 2.35–2.18 (m, 3H, H6&5a), 1.98–1.94 (m, 1H, H9b), 1.73–1.71 (m, 1H, 
H5b). 13C NMR (101 MHz, CDCl3) δ/ppm: 171.9 (C1), 165.4 (C3), 160.6 (C13), 132.1 (C10), 
129.0 (C11), 126.7 (C7), 124.7 (C8), 120.4 (C2), 114.2 (C12), 63.5 (C4), 55.4 (C14), 34.8 (C9), 30.4 
(C5), 23.1 (C6). HRMS (ESI) C16H18NO2 m/z: [M+H]+ 256.1331 (calc. 256.1338). m.p. 196–197 
°C. 
 
4-Hydroxy-1-azaspiro[4.5]dec-7-en-2-one, 177 
 
Compound 168 (200 mg, 1.21 mmol, 1.0 eq) was added to a suspension of sodium borohydride 
(77.9 mg, 2.06 mmol, 1.7 eq) in methanol (5 mL) at 0 °C. The reaction was warmed to RT and 
stirred for 1 h. Water (5 mL) was added dropwise and the mixture was extracted with 
dichloromethane (3 × 10 mL). the combined organic layers were dried over anh. MgSO4, 
filtered, and concentrated in vacuo. The product was purified by column chromatography 
(ethyl acetate) to yield the pure product as white crystals (32 mg, 0.19 mmol, 16%); Rf 0.06 
(ethyl acetate); IR (thin film) 𝜈/cm–1: 3368 (N-H, m), 3194 (O-H, br m), 2950 (C-H, w), 1698 
(C=O, s), 1662 (C=C, s), 1058 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 5.87–5.73 (m, 3H, 
NH, OH, H7), 5.64–5.60 (m, 1H, H8), 4.19 (q, J = 5.55 Hz, 1H, H3), 2.75 (dd, J = 17.0, 7.0 Hz, 
1H, H2a), 2.39 (dd, 1H, J = 17.0, 5.0 Hz, 1H, H2b), 2.31–2.28 (m, 1H, H6a), 2.23–2.09 (m, 2H, 
H6b&9a), 2.03–1.97 (m, 1H, H9b), 1.88–1.82 (m, 1H, H5a), 1.78–1.73 (m, 1H, H5b). 13C NMR 
(101 MHz, CDCl3) δ/ppm: 173.9 (C1), 127.5 (C7), 123.9 (C8), 73.6 (C3), 61.0 (C4), 39.2 (C2), 36.3 
(C9), 26.4 (C5), 22.5 (C6). HRMS (ESI) C9H13NO2Na m/z: [M+Na]+ 190.0841 (calc. 190.0844). 
m.p. 130–131 °C. 
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2-Oxo-1-azaspiro[4.5]dec-7-en-4-yl methanesulfonate, 178 
 
Compound 177 (30 mg, 0.18 mmol, 1.0 eq) was dissolved in dichloromethane (1 mL) before 
mesyl chloride (16 μL, 0.22 mmol, 1.2 eq) and triethylamine (35 μL, 0.25 mmol, 1.4 eq) were 
added dropwise at 0 °C. The reaction was stirred at this temperature for 1 h, before being 
quenched with sat. aq. NaHCO3 (5 mL) and extracted with dicholormethane (3 × 5 mL). The 
combined organics were concentrated in vacuo and the crude was purified by column 
chromatography (ethyl acetate) to give the pure product as a white amorphous solid (54.0 mg, 
0.17 mmol, 94%); Rf 0.24 (ethyl acetate); IR (thin film) 𝜈/cm–1: 3352 (N-H, w), , 2929 (C-H, w), 
1692 (C=O, s), 1643 (C=C, s), 1302 (S=O, m). 1H NMR (400 MHz, CDCl3) δ/ppm: 5.97 (br s, 
1H, Nh), 5.80–5.77 (m, 1H, H7), 5.64–5.61 (m, 1H, H8), 5.02 (dd, J = 7.0, 5.0 Hz, 1H, H3), 3.08 
(s, 3H, H10), 2.92–2.83 (m, 1H, H2a), 2.72–2.60 (m, 1H, H2b), 2.47–2.30 (m, 2H, H6a&9a), 2.20–
2.04 (m, 2H, H6b&9b), 1.90–1.76 (m, 2H, H5). 13C NMR (101 MHz, CDCl3) δ/ppm: 171.9 (C1), 
127.5 (C7), 123.1 (C8), 79.8 (C3), 60.2 (C4), 38.7 (C2), 37.0 (C10), 36.1 (C9), 26.9 (C5), 22.1 (C6). 
HRMS (ESI) C10H16NO4S m/z: [M+H]+ 245.0732 (calc. 245.0722). 
 
1-Azaspiro[4.5]deca-3,7-dien-2-one, 179 
 
Compound 177 (23 mg, 0.14 mmol, 1.0 eq) was dissolved in trifluoroacetic anhydride (67 μL, 
0.48 mmol, 3.5 eq) and refluxed for 12 h. Excess solvent was removed in vacuo and the residue 
was dissolved in dichloromethane (0.25 mL). Triethylamine (24 μL, 0.17 mmol, 1.26 eq) was 
added and the reaction was stirred for a further 12 h. Potassium hydrogen carbonate (36 mg, 
0.36 mmol, 2.63 eq) in methanol (0.25 mL) was added to the reaction and it was allowed to stir 
for a further 2 h. Chloroform (5 mL) was added and the mixture was washed with 1M HCl (5 
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mL), water (5 mL), and brine (5 mL). The organic layer was then dried over anh. MgSO4. The 
mixture was filtered and the filtrated was concentrated in vacuo to give a crude product. This 
was then purified by column chromatography (ethyl acetate) to give the pure product as off-
white crystals (6.3 mg, 0.04 mmol, 30%); Rf 0.18 (ethyl acetate); IR (thin film) 𝜈/cm–1: 3170 (N-
H, m), 3030 (C-H alkene, w), 2926 (C-H alkane, w), 1682 (C=O, s), 1655 (C=C, s). 1H NMR (400 
MHz, CDCl3) δ/ppm: 7.08 (d, J = 5.0 Hz, 1H, H3), 6.15 (br s, 1H, NH), 6.03 (d, J = 5.0 Hz, 1H, 
H2), 5.84–5.79 (m, 1H, H7), 5.76–5.71 (m, 1H, H8), 2.38–2.32 (m, 1H, H9a), 2.27–2.21 (m, 2H, 
H6), 2.10–2.04 (m, 1H, H9b), 1.84–1.77 (m, 1H, H5a), 1.73–1.67 (m, 1H, H5b). 13C NMR (101 
MHz, CDCl3) δ/ppm: 154.6 (C3), 129.1 (C2), 126.7 (C7), 124.2 (C8), 62.2 (C4), 34.3 (C9), 30.9 
(C5), 23.6 (C6). HRMS (ESI) C9H12NO m/z: [M+H]+ 150.0918 (calc. 150.0919). m.p. 75–76 °C. 
 
2-Allyl-2-((tert-butoxycarbonyl)amino)hex-5-enoic acid, 184 
 
Compound 143 (1g, 3.36 mmol, 1.0 eq) was dissolved in methanol (67.25 mL) and 1M NaOH 
(67.25 mL, 67.25 mmol, 20.0 eq) was added dropwise. The reaction was refluxed at 75 °C for 
24 hours. The solvent was removed in vacuo and the residue was diluted with water (20 mL). 
Ice and 0.5 M HCl (135 mL) was added. The precipitate was filtered and washed with cold 
water to yield the product as a colourless oil (383.7 mg, 1.42 mmol, 42%); IR (thin film) 𝜈/cm–
1: 2979 (C-H, w), 1707 (C=O, s), 1642 (C=C, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 10.57 (br s, 
1H, COOH), 5.82–5.74 (m, 1H, H7), 5.72–5.64 (m, 1H, H10), 5.16–5.11 (m, 2H, H11), 5.04–4.95 
(m, 2H, H8) 3.01 (br s, 1H, H9a), 2.64–2.56 (m, 1H, H9b), 2.36 (br s, 1H, H5a), 2.12–2.05 (m, 1H, 
H6a), 1.95–1.89 (m, 2H, H5b&6b), 1.44 (s, 9H, H1). 13C NMR (101 MHz, CDCl3) δ/ppm: 178.0 
(C12), 154.2 (C3), 137.3 (C7), 132.0 (C10), 119.4 (C11), 115.2 (C8), 79.8 (C2), 63.1 (C4), 39.7 (C9), 
34.3 (C5), 28.3 (C1&6). HRMS (ESI) C14H23NO4Na m/z: [M+Na]+ 292.1523 (calc. 292.1519). 
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Ethyl (tert-butoxycarbonyl)-L-serinate, 201 
 
L-serine ethyl ester hydrochloride (5 g, 29.48 mmol, 1.0 eq) and di-tert-butyl decarbonate (6.43 
mL, 28.01 eq, 0.95 mmol) were dissolved in ethyl acetate (40 mL) and water (40 mL). Potassium 
carbonate (6.11 g, 44.22 mmol, 1.5 eq) was added to the reaction and it was left to stir overnight 
at RT. The layers were then separated and the aqueous extracted with ethyl acetate (2 × 30 
mL) and the combined organics were washed with brine (50 mL). This was then dried over 
anh. MgSO4. This mixture was filtered and the filtrate was concentrated in vacuo to give the 
product as a pure colourless oil (6.41 g, 27.49 mmol, 93%); Rf 0.07 (20% ethyl acetate in pet. 
ether); IR (thin film) 𝜈/cm–1: 3383 (O-H, br s), 2978 (C-H, w), 1714 (C=O ester, s), 1692 (C=O 
carbamide, s), 1158 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 5.44 (br s, 1H, NH), 4.36 (br 
s, 1H, H4), 4.24 (q, J = 7.0 Hz, 2H, H7), 3.98–3.89 (m, 2H, H5), 2.30 (br s, 1H, OH), 1.46 (s, 9H, 
H1), 1.30 (t, J = 7.0 Hz, 3H, H8). 13C NMR (101 MHz, CDCl3) δ/ppm: 170.7 (C6), 155.8 (C3), 
80.3 (C2), 63.8 (C5), 61.8 (C7), 55.8 (C4), 28.3 (C1), 14.1 (C8). HRMS (ESI) C10H19NO5Na m/z: 
[M+Na]+ 256.1151 (calc. 256.1155). [𝛂]𝐃
𝟐𝟎 –17.2 (c = 1.0, CHCl3). 
The physical and spectroscopic data were found to be in agreement with Tang et al.231 
 
 Ethyl 2-((tert-butoxycarbonyl)amino)acrylate, 202 
 
Compound 201 (6.4 g, 27.44 mmol, 1.0 eq) was dissolved in dichloromethane (70 mL) at -15 
°C. Mesyl chloride (2.65 mL, 34.30 mmol, 1.25 eq) was added dropwise followed by 
triethylamine (11.41 mL, 82.31 mmol, 3.0 eq). The reaction was stirred for 30 min before being 
warmed to RT and stirred for a further 2 h. Then one third molar HCl (30 mL) was added. The 
mixture was washed with water and the combined organics were dried over anh. MgSO4. This 
mixture was filtered, and the filtrate was concentrated in vacuo to give the crude product. This 
was filtered through Celite with dichloromethane to afford the pure product as a yellow oil 
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(5.5667 g, 25.86 mmol, 94%); Rf 0.60 (20% ethyl acetate in pet. ether); IR (thin film) 𝜈/cm–1: 
3420 (N-H, w), 2980 (C-H, w), 1733 (C=O carbamate, m), 1707 (C=O ester, s), 1638 (C=C, w), 
1152 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.02 (br s, 1H, NH), 6.14 (br s, 1H, H5a), 
5.72 (d, J = 1.5 Hz, 1H, H5b), 4.28 (q, J = 7.0 Hz, 2H, H7), 1.48 (s, 9H, H1), 1.33 (t, J = 7.0 Hz, 
3H, H8). 13C NMR (101 MHz, CDCl3) δ/ppm: 164.0 (C6), 152.6 (C3), 131.5 (C4), 104.8 (C5), 
80.6 (C2), 62.0 (C7), 28.2 (C1), 14.1 (C8). HRMS (ESI) C10H17NO4Na m/z: [M+Na]+ 238.1046 
(calc. 238.1050). 
The physical and spectroscopic data were found to be in agreement with Ramesh et al.232 
 
4-Methyloxazol-2(3H)-one, 204 
 
To a solution of potassium tert-butoxide (181.4 mg, 1.62 mmol, 1.0 eq) in THF (15 mL) was 
added 203 (280 mg, 1.62 mmol, 1.0 eq) at 0 °C and the reaction was stirred for 1h. The reaction 
was diluted with sat. aq. NH4Cl (10 mL) and extracted with dichloromethane (3 × 10 mL). The 
combined organics were dried over anh. MgSO4, filtered, and concentrated in vacuo to give 
the pure product as a white crystalline solid (57.2 mg, 0.58 mmol, 36%); IR (thin film) 𝜈/cm–
1: 3163 (N-H, br s), 1706 (C=O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 9.14 (br s, 1H, NH), 6.53 
(s, 1H, H2), 2.02 (d, J = 1.5 Hz, 3H, H4). 13C NMR (101 MHz, CDCl3) δ/ppm: 157.7 (C1), 124.6 
(C2), 122.7 (C3), 9.2 (C4). HRMS (ESI) C4H6NO2 m/z: [M+H]+ 100.0397 (calc 100.0393). m.p. 50–
51°C. 
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N-Hydroxybenzimidoyl chloride, 209 
 
Benzaldehyde (1.5 g, 14.13 mmol, 1.0eq) was dissolved in diethyl ether (12 mL) and 
hydroxylamine (50% in H2O, 1.73 mL, 28.27 mmol, 2.0 eq) was added. The reaction was stirred 
for 10 min. The reaction was dried with direct addition of anh. MgSO4. The mixture was 
filtered and the filtrate was concentrated in vacuo. The residual oil was dissolved in DMF (12 
mL) and N-chlorosuccinimide (2.08 g, 15.55 mmol, 1.1 eq) was added and the reaction was 
stirred for 30 min. The reaction was diluted with water (10 mL), and extracted with ethyl 
acetate (2 × 10 mL). The combined organics were washed with water (20 mL) and brine (20 
mL) before being dried over anh. Na2SO4. The mixture was filtered and the filtrate was 
concentrated in vacuo to give the crude product as a yellow oil. This was carried through crude 
to the following reactions. (2.17 g, 13.95 mmol, 99%); 1H NMR (400 MHz, CDCl3) δ/ppm: 8.94 
(br s, 1H, OH), 7.89–7.86 (m, 2H, H3), 7.47–7.41 (m, 3H, H4&5).  
The physical and spectroscopic data were found to be in agreement with Castellano et al.233 
 
Ethyl 4-((tert-butoxycarbonyl)amino)-3-phenyl-4,5-dihydroisoxazole-4-
carboxylate, 210 
 
Triethylamine (2.2 mL, 15.80 mmol, 6.8 eq) was added to a mixture of 202 (500 mg, 2.32 mmol, 
1.0 eq) an 209 (2.17 g, 13.94 mmol, 6.0 eq) in dichloromthane (40 mL) and the reaction was 
stirred at RT for 1 h. Water (30 mL) was added and the organic layer was washed with water 
(30 mL) and brine (30 mL). The combined organics were dried over anh. MgSO4. This mixture 
was filtered, and the filtrate was concentrated in vacuo to give the crude product. This was 
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purified by column chromatography (20% diethyl ether in pet. ether) to give the pure product 
as off-white amorphous solid (448.6 mg, 1.34 mmol, 58%); Rf 0.12 (20% diethyl ether in pet. 
ether); IR (thin film) 𝜈/cm–1: 3410 (N-H, m), 2976 (C-H, w), 1741 (C=O, m), 1721 (C=N, s), 
1484 (C=C, s), 1308 (N-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.70–7.66 (m, 2H, H11), 7.43–
7.38 (m, 3H, H12&13), 6.08 (br s, 1H, NH), 4.32 (q, J = 7.0 Hz, 2H, H6), 3.91 (br s, 2H, H8), 1.40 
(s, 9H, H1), 1.32 (t, J = 7.0 Hz, 3H, H7). 13C NMR (101 MHz, CDCl3) δ/ppm: 167.6 (C5), 156.3 
(C9), 153.3 (C3), 130.4 (C12), 129.8 (C10), 128.7 (C13), 126.9 (C11), 92.4 (C4), 81.2 (C2), 63.4 (C6), 
42.7 (C8), 28.2 (C1), 14.0 (C7). HRMS (ESI) C17H23N2O5 m/z: [M+H]+ 335.1591 (calc. 335.1607). 
tert-Butyl (4-(hydroxymethyl)-3-phenyl-4,5-dihydroisoxazol-4-yl)carbamate, 
211 
 
Compound 210 (100 mg, 0.30 mmol, 1.0 eq), was dissolved in an 8:1 THF/methanol mixture 
(1.8 mL). This was colled to 0 °C and sodium borohydride (2.83 mg, 0.07 mmol, 0.25 eq) were 
added. The reaction was stirred for 4 h before further sodium borohydride (8.49 mmol, 0.21 
mmol, 0.75 eq) was added. The reaction was stirred overnight. It was quenched with sat. aq. 
NH4Cl (2 mL), and extracted with dichloromethane (3 × 5 mL). The combined organics were 
then dried over anh. MgSO4. This mixture was filtered, and the filtrate was concentrated in 
vacuo to give the crude product. This was purified via column chromatography (55% ethyl 
acetate in hexane) to give the pure product as a white powder (54.0 mg, 0.18 mmol, 62%); Rf 
0.29 (55% ethyl acetate in hexane); IR (thin film) 𝜈/cm–1: 3408 (N-H, w), 3278 (O-H, w), 2970 
(C-H, w), 1717 (C=O, s), 1545 (C=C, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.66–7.64 (m, 2H, 
H7), 7.40–7.37 (m, 3H, H8&9), 5.74 (br s, 1H, NH), 3.90–3.86 (m, 2H, H10a&11a), 3.77–3.73 (m, 
1H, H11b), 3.30 (d, J = 17.5 Hz, 1H, H10b), 3.05 (br s, 1H, OH), 1.40 (s, 9H, H1). 13C NMR (101 
MHz, CDCl3) δ/ppm: 157.3 (C5), 154.1 (C3), 130.3 (C8), 129.6 (C6), 128.7 (C9), 126.7 (C7), 95.4 
(C4), 80.9 (C2), 66.2 (C11), 40.4 (C10), 28.2 (C1). HRMS (ESI) C15H21N2O4 m/z: [M+H]+ 293.1498 
(calc. 293.1501). 
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3-Phenyl-1,8-dioxa-2,6-diazaspiro[4.4]non-2-en-7-one, 212 
 
To a solution of potassium tert-butoxide (30.7 mg, 0.27 mmol, 2.0 eq) in THF (1.4 mL) at 0 °C 
was added 211 (40 mg, 0.14 mmol, 1.0 eq) and the reaction was stirred for 1 h. This was then 
diluted with sat. aq. NH4Cl (5 mL) and extracted with dichloromethane (3 × 5 mL). The 
combined organics were dried over anh. MgSO4, filtered and concentrated in vacuo to give the 
crude product. This was purified by column chromatography (60% ethyl acetate in hexane) to 
give the pure product as a white powder (17 mg, 0.08 mmol, 56%); Rf 0.16 (60% ethyl acetate 
in hexane); IR (thin film) 𝜈/cm–1: 3226 (N-H, w), 1765 (C=O, s), 1048 (C-O, s). 1H NMR (400 
MHz, CDCl3) δ/ppm: 7.64–7.62 (m, 2H, H7), 7.48–7.41 (m, 3H, H8&9), 5.97 (br s, 1H, NH), 4.77 
(d, J = 10.0 Hz, 1H, H2a), 4.59 (d, J = 10.0 Hz, 1H, H2b), 3.59 (d, J = 18.0 Hz, 1H, H4a), 3.49 (d, 
J = 18.0 Hz, 1H, H4b). 13C NMR (101 MHz, CDCl3) δ/ppm: 156.3 (C5), 156.2 (C1), 131.1 (C8), 
129.1 (C9), 128.2 (C6), 126.6 (C7), 96.1 (C3), 73.9 (C2), 42.8 (C4). HRMS (ESI) C11H10N2O3Na 
m/z: [M+H]+ 241.0576 (calc 241.0584). m.p. 178–179 °C 
Crystallographic data for this compound is in Appendix B. 
 
Ethyl (2-chloroacetyl)-L-serinate, 214 
 
L-Serinate ethyl ester hydrochloride (1 g, 5.90 mmol, 1.0 eq), was dissolved in 
dichloromethane (60 mL) and triethylamine (1.73 mL, 12.38 mmol, 2.1 eq) was added to the 
solution. This was cooled to 0 °C before chloroacetyl chloride (0.47 mL, 5.90 mmol, 1.0 eq) was 
added dropwise and the reaction was stirred for 90 min. After this it was diluted with aq. sat. 
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NH4Cl and stirred for 10 min. The mixture was extracted with dichloromethane. The 
combined organics were dried over anh. MgSO4, filtered and concentrated in vacuo to give the 
crude product. This was purified via  column chromatography (80% ethyl acetate in hexane) 
to yield the pure product as a white crystalline solid (673.8 mg, 3.21 mmol, 54%); Rf 0.31 (80% 
ethyl acetate in hexane); IR (thin film) 𝜈/cm–1: 3500 (O-H, m), 3276 (N-H, m), 2957 (C-H, w), 
1712 (C=O ester, s), 1664 (C=O amide, s),  1555 (N-H, s), 1035 (C-O, s), 781 (C-Cl, m). 1H NMR 
(400 MHz, CDCl3) δ/ppm: 7.43 (br s, 1H, NH), 4.65 (dt, J = 7.5, 3.5 Hz, 1H, H3), 4.28 (q, J = 7.0 
Hz, 2H, H6), 4.10 (s, 2H, H1), 4.07–3.94 (m, 2H, H4), 2.26 (t, J = 5.5 Hz, 1H, OH), 1.32 (t, J = 7.0 
Hz, 3H, H7). 13C NMR (101 MHz, CDCl3) δ/ppm: 169.7 (C5), 166.5 (C2), 63.2 (C4), 62.3 (C6), 
42.4 (C1), 14.1 (C7). HRMS (ESI) C7H13ClNO4Si m/z: [M+H]+ 210.0524 (calc. 210.0528). [𝛂]𝐃
𝟐𝟎 
+41.3 (c = 1.00, CHCl3). 
The physical and spectroscopic data were found to be in agreement with Yoshimura et al.234  
 
Ethyl N,O-bis(2-chloroacetyl)-L-serinate, 215 
 
The title compound was isolated as a by-product from the reaction to synthesise 214. White 
crystalline solid (87.5 mg, 0.42 mmol, 5.2%); Rf 0.13 (60% ethyl acetate in hexane); IR (thin 
film) 𝜈/cm–1: 3268 (O-H, s), 2957 (C-H, w), 1744 (C=O ester, s), 1679 (C=O amide, s), 1540 (N-
H, s), 1194 (C-Cl, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.31 (d, J = 6.5 Hz, 1H, NH), 4.86–
4.82 (m. 1H, H3), 4.60–4.53 (m, 2H, H4), 4.27 (q, J = 7.0 Hz, 2H, H8), 4.08 (s, 2H, H1), 4.06 (s, 
2H, H6), 1.30 (t, J = 7.0 Hz, 3H, H9). 13C NMR (101 MHz, CDCl3) δ/ppm: 168.4 (C7), 166.9 
(C5), 166.1 (C2), 64.9 (C4), 62.6 (C8), 52.0 (C3), 42.3 (C1), 40.4 (C6), 14.1 (C9). HRMS (ESI) 
C9H13Cl2NO5 m/z: [M+H]+ 232.0356 (calc. 232.0353). [𝛂]𝐃
𝟐𝟎 +45.0 (c = 1.00, CHCl3). 
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Ethyl (S)-2-oxooxazolidine-4-carboxylate, 219 
 
Triphosgene (2.73 g, 9.20 mmol, 0.5 eq) and L-serine ethyl ester hydrochloride (3.00 g, 17.69 
mmol, 1.0 eq) were dissolved in THF (180 mL) and refluxed for 1h. The reaction was 
concentrated in vacuo and submitted to column chromatography (80% ethyl acetate in hexane) 
to yield the pure product as off-white crystals (2.7054 g, 17.00 mmol, 96%); Rf 0.27 (80% ethyl 
acetate in hexane); IR (thin film) 𝜈/cm–1: 3264 (N-H, br w), 2998 (C-H, w), 1739 (C=O ester, 
s), 1714 (C=O carbamide, s), 1204 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 6.03 (br s, 1H, 
NH), 4.64–4.59 (m, 1H, H2a), 4.54–4.51 (m, 1H, H2b), 4.41–4.38 (m, 1H, H3), 4.27 (q, J = 7.0 Hz, 
2H, H5), 1.31 (t, J = 7.0 Hz, 3H, H6). 13C NMR (101 MHz, CDCl3) δ/ppm: 170.0 (C4), 158.7 
(C1), 66.7 (C2), 62.4 (C5), 53.3 (C3), 14.1 (C6). HRMS (ESI) C6H10NO4 m/z: [M+H]+ 160.0603 
(calc. 160.0604). [𝛂]𝐃
𝟐𝟎 –14.8 (c = 1.00, CHCl3). 
The physical and spectroscopic data were found to be in agreement with Paz et al.235 
 
Ethyl (S)-2-phenyl-4,5-dihydrooxazole-4-carboxylate, 221 
 
Compound 150 (1.6 g, 10.72 mmol, 1.0 eq) as a free base was dissolved in 1,2-dichloroethane 
(20 mL) and L-serine ethyl ester hydrochloride (2.00 g, 11.79 mmol, 1.1 eq) was added. The 
reaction was refluxed overnight. This was cooled to RT and filtered. The filtrate was 
concentrated in vacuo and the crude oil was purified by column chromatography (30% ethyl 
acetate in hexane) to yield the pure product as a white amorphous solid (1.4862 g, 6.78 mmol, 
63%); Rf 0.33 (30% ethyl acetate in hexane); IR (thin film) 𝜈/cm–1: 2984 (C-H, w), 1726 (C=O, 
s), 1631 (C=N, s), 1201 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.98–7.96 (m, 2H, H3), 
7.50–7.46 (m, 1H, H1), 7.41–7.37 (m, 2H, H2), 4.91 (dd, J = 10.5, 8.0 Hz, 1H, H7), 4.68–4.64 (m, 
1H, H6a), 4.60–4.55 (m, 1H, H6b), 4.30–4.21 (m, 2H, H9), 1.31 (t, J = 7.0 Hz, 3H, H10). 13C NMR 
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(101 MHz, CDCl3) δ/ppm: 171.2 (C8), 166.2 (C5), 131.8 (C1), 128.6 (C3), 128.3 (C2), 127.0 (C4), 
69.6 (C6), 68.8 (C7), 61.8 (C9), 14.2 (C10). HRMS (ESI) C12H14NO3 m/z: [M+H]+ 220.0909 (calc. 
220.0974). [𝛂]𝐃
𝟐𝟎 +122.0 (c = 1.00, CHCl3). 
The physical and spectroscopic data were found to be in agreement with Robertson et al.236 
 
(R)-(2-Phenyl-4,5-dihydrooxazol-4-yl)methanol, 222 
 
Calcium chloride (3.14 g, 28.28 mmol, 4.0 eq) and 221 (1.55 g, 7.07 mmol, 1.0 eq) were dissolved 
in ethanol (125 mL). The mixture was cooled to 0 °C and sodium borohydride (2.14 g, 56.56 
mmol, 8.0 eq) was added portion-wise. The reaction was stirred at 0 °C for a further 5 h. Water 
(100 mL) was added and stirred for 1 h. The resulting mixture was filtered, and the filtrate 
concentrated in vacuo. This was diluted with ethyl acetate (50 mL) and washed with brine (50 
mL), dried over anh. Na2SO4, filtered, and contracted in vacuo. This give the pure product as 
an amorphous white solid (882.6 mg, 4.98 mmol, 70%); IR (thin film) 𝜈/cm–1: 3235 (O-H, br 
w), 2899 (C-H, w), 1644 (C=N, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.85 (d, J = 7.5 Hz, 2H, 
H1), 7.45 (t, J = 7.5 Hz, 1H, H2), 7.35 (t, J = 7.5 Hz, 2H, H3), 4.50–4.32 (m, 3H, H7&8), 3.97 (d, J 
= 9.0 Hz, 1H, H6a), 3.66 (d, J = 9.0 Hz, 1H, H6b), 2.92 (br s, 1H, OH). 13C NMR (101 MHz, 
CDCl3) δ/ppm: 165.6 (C5), 131.6 (C2), 128.3 (C1&3), 127.1 (C4), 69.3 (C8), 68.0 (C7), 63.9 (C6). 
HRMS (ESI) C10H12NO2 m/z: [M+H]+ 178.0861 (calc. 178.0863). 
The physical and spectroscopic data were found to be in agreement with Braga et al.237 
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Ethyl O-(tert-butyldimethylsilyl)-L-serinate, 224 
 
L-serinate ethyl ester hydrochloride (2 g, 11.79 mmol, 1.0 eq) and tert-butyldimethylsilyl 
chloride (3.55 g, 23.58 mmol, 2.0 eq) were dissolved in dichloromethane (150 mL). Imidazole 
(2.41 g, 35.38 mmol, 3.0 eq) was added at 0 °C and the reaction was warmed to RT and stirred 
overnight. This was quenched by the addition of water (100 mL) and extracted with 
dichloromethane (3 × 100 mL) to give the pure product as a colourless oil (2.2867 g, 9.24 mmol, 
78%); IR (thin film) 𝜈/cm–1: 2930 (C-H, w), 1739 (C=O, s), 1095 (C-O, s). 1H NMR (400 MHz, 
CDCl3) δ/ppm: 4.20 (q, J = 7.0 Hz, 2H, H7), 3.94 (dd, J = 9.5, 4.0 Hz, 1H, H2a), 3.83 (dd, J = 9.5, 
4.0 Hz, 1H, H2b), 3.51 (t, J = 4.0 Hz, 1H, H1), 1.70 (br s, 2H, NH2), 1.30 (t, J = 7.0 Hz, 3H, H8), 
0.89 (s, 9H, H5), 0.07 (s, 3H, H3a), 0.06 (s, 3H, H3b). 13C NMR (101 MHz, CDCl3) δ/ppm: 174.1 
(C6), 65.4 (C2), 60.9 (C7), 56.5 (C1), 25.7 (C5), 18.2 (C4), 14.2 (C8), –5.5 (C3a), –5.6 (C3b). HRMS 
(ESI) C11H25NO3SiNa m/z: [M+Na]+ 270.1493 (calc. 270.1501). [𝛂]𝐃
𝟐𝟎 –6.1 (c = 1.00, CHCl3). 
The physical and spectroscopic data were found to be in agreement with Hakimelahi et al.238 
 
Ethyl O-(tert-butyldimethylsilyl)-N-(2-chloroacetyl)-L-serinate, 225 
 
Triethylamine (1.18 mL, 8.49 mmol, 2.1 eq) was added to a solution of 224 (1.00 g, 4.04 mmol, 
1.0 eq) in dichloromethane (40 mL). This was cooled to 0 °C and chloroacetyl chloride (0.32 
mL, 4.04 mmol, 1.0 eq) was added dropwise. The reaction was warmed to RT and stirred for 
90 min. The reaction was then quenched with sat. aq. NH4Cl (20 mL), and stirred for 10 min. 
This mixture was extracted with dichloromethane (2 × 10 mL). The combined organics were 
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dried over anh. MgSO4, filtered and concentrated in vacuo to give the crude product. This was 
purified by column chromatography (20% ethyl acetate in hexane) to yield the pure product 
as a colourless oil (723.6 mg, 2.23 mmol, 55%); Rf 0.20 (20% ethyl acetate in hexane); IR (thin 
film) 𝜈/cm–1: 2932 (C-H, w), 1745 (C=O ester, m), 1679 (C=O amide, s), 1110 (C-O, s), 776 (C-
Cl, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.38 (d, J = 8.0 Hz, 1H, NH), 4.61 (dt, J = 8.0, 3.0 Hz, 
1H, H3), 4.22 (q, J = 7.0 Hz, 2H, H5), 4.12–4.04 (m, 3H, H1&7a), 3.84 (dd, J = 10.0, 3.0 Hz, 1H, 
H7b), 1.28 (t, J = 7.0 Hz, 3H, H6), 0.86 (s, 9H, H6), 0.04 (s, 3H, H8a), 0.02 (s, 3H, H8b). 13C NMR 
(101 MHz, CDCl3) δ/ppm: 169.7 (C4), 165.7 (C2), 63.1 (C7), 61.7 (C5), 54.5 (C3), 42.5 (C1), 25.6 
(C10), 18.1 (C9), 14.2 (C6), –5.6 (C8a), –5.7 (C8b). HRMS (ESI) C13H26ClNO4SiNa m/z: [M+Na]+ 
346.1203 (calc. 346.1212). [𝛂]𝐃
𝟐𝟎 +29.2 (c = 1.00, CHCl3). 
 
(R)-N-(1-((tert-Butyldimethylsilyl)oxy)-3-hydroxypropan-2-yl)-2-
chloroacetamide, 226 
 
Powdered sodium borohydride (37.4 mg, 2.34 mmol, 1.05 eq) was added to a solution of 225 
(305 mg, 2.22 mmol, 1.0 eq) and the reaction was stirred at RT for 2 h. Sat. aq. NH4Cl solution 
was added dropwise and the mixture was stirred for 30 min. This was filtered and the filtrate 
was dried over anh. MgSO4 and filtered and concentrated in vacuo. The crude oil was purified 
by column chromatography (80% ethyl acetate in hexane) to give the pure product as a 
colourless oil (27 mg, 0.10 mmol, 43%); Rf 0.29 (80% ethyl acetate in hexane); IR (thin film) 
𝜈/cm–1: 3243 (O-H, br m), 2927 (C-H, w), 1645 (C=O, s), 1053 (C-O, m), 720 (C-Cl, s). 1H NMR 
(400 MHz, CDCl3) δ/ppm: 7.26 (br s, 1H, NH), 4.09 (d, J = 15.5 Hz, 1H, H1a), 4.05 (d, J = 15.5 
Hz, 1H, H1b), 3.98 (sp, J = 4.0 Hz, 1H, H3), 3.87–3.84 (m, 2H, H4a&5a), 3.78 (dd, J = 10.5, 4.5 
Hz, 1H, H5b), 3.70 (dd, J = 10.5, 4.5 Hz, 1H, H4b), 2.85 (br s, 1H, OH), 0.90 (s, 9H, H8), 0.08 (s, 
6H, H6). 13C NMR (101 MHz, CDCl3) δ/ppm: 166.2 (C2), 63.3 (C4/5), 63.2 (C4/5), 52.0 (C3), 
42.6 (C1), 25.7 (C8), 18.1 (C7), –5.6 (C6). HRMS (ESI) C11H25CLNO3Si m/z: [M+H]+ 281.1210 
(calc. 281.1214). [𝛂]𝐃
𝟐𝟎 +18.7 (c = 1.00, CHCl3). 
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Ethyl O-(tert-butyldimethylsilyl)-N-(3-ethoxy-3-oxopropanoyl)-L-serinate, 
228 
 
Compound 224 (500 mg, 2.02 mmol, 1.0 eq) was dissolved in dichloromethane (20 mL) at 0 
°C. Triethylamine (0.61 mL, 4.35 mmol, 2.15 eq) and ethyl malonyl chloride (0.41 mL, 3.23 
mmol, 1.6 eq) were added dropwise to the reaction which was subsequently warmed to RT 
and stirred for 4h. this was quenched with sat. aq. NH4Cl (20 mL) and stirred for 10 min. This 
mixture was separated and the aqueous was extracted with dichloromethane (2 × 20 mL). The 
combined organics were dried over MgSO4, filtered, and the filtrate was concentrated in vacuo 
to give a crude oil. This was purified via column chromatography (40% ethyl acetate in 
hexane) to give the pure product as a yellow oil (482.8 mg, 1.34 mmol, 66%); Rf 0.29 (40% ethyl 
acetate in hexane); IR (thin film) 𝜈/cm–1: 3337 (N-H, w), 2932 (C-H, w), 1739 (C=O ester, s), 
1679 (C=O amide, m), 1109 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.77 (d, J = 7.5 Hz, 
1H, NH), 4.65 (dt, J = 7.5, 3.0 Hz, 1H, H6), 4.21 (qd, J = 7.0, 3.0 Hz, 4H, H2&8), 4.08 (dd, J = 
10.0, 3.0 Hz, 1H, H10a), 3.84 (dd, J = 10.0, 3.0 Hz, 1H, H10b), 3.35 (s, 2H, H4), 1.28 (td, J = 7.0, 
5.5 Hz, 6H, H1&9), 0.87 (s, 9H, H13), 0.03 (s, 3H, H11a), 0.02 (s, 3H, H11b). 13C NMR (101 MHz, 
CDCl3) δ/ppm: 170.0 (C7), 168.7 (C3), 164.9 (C5), 63.3 (C10), 61.6 (C2/8), 61.5 (C2/8), 54.5 (C6), 
41.4 (C4), 25.7 (C13), 18.1 (C12), 14.2 (C1/9), 14.1 (C1/9), –5.6 (C11a), –5.7 (C11b). HRMS (ESI) 
C16H31NO6SiNa m/z: [M+Na]+ 384.1812 (calc. 384.1818). [𝛂]𝐃
𝟐𝟎 +32.1 (c = 1.00, CHCl3). 
 
4-Ethoxy-5-methylene-1,5-dihydro-2H-pyrrol-2-one, 230 
 
Compound 224 (400 mg, 1.62 mmol, 1.0 eq), Bestmann’s Ylide (489 mg, 1.62 mmol, 1.0 eq), 
benzoic acid (39.5 mg, 0.32 mmol, 0.2 eq) were dissolved in THF (8 mL) and refluxed overnight 
at 65 °C in the dark. The reaction mixture was concentrated in vacuo and purified via column 
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chromatography (diethyl ether) to give the pure product as a yellow oil (139.2 mg, 1.00 mmol, 
62%); Rf 0.28 (diethyl ether) IR (thin film) 𝜈/cm–1: 2980 (C-H, w), 1686 (C=O, s), 1652 (C=C, 
s), 1593 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 6.90 (br s, 1H, NH), 5.09 (s, 1H, H2), 5.00 
(d, J = 1.0 Hz, 1H, H5a), 4.74 (t, J = 1.5 Hz, 1H, H5b), 4.05 (q, J = 7.0 Hz, 2H, H6), 1.42 (t, J = 7.0 
Hz, 3H, H7). 13C NMR (101 MHz, CDCl3) δ/ppm: 171.4 (C1), 165.2 (C4), 139.4 (C3), 93.7 (C2), 
91.8 9C5), 67.1 (C6), 14.1 (C7). HRMS (ESI) C7H10NO2 m/z: [M+H]+ 140.0705 (calc. 140.0705). 
 
tert-Butyl 3-(2-ethoxy-2-oxoethylidene)azetidine-1-carboxylate, 236 
 
Tert-butyl 3-oxoazetidine-1-carboxylate (2.90 g, 16.93 mmol, 1.0 eq) and ethyl 
(triphenylphosphoranylidene)acetate (6.49 g, 18.62 mmol, 1.1 eq) were dissolved in 
dichloromethane (56 mL) and refluxed for 6 h. The reaction was concentrated in vacuo and 
submitted to column chromatography (20% ethyl acetate in hexane) to yield the pure product 
as colourless crystals (3.8496 g, 15.95 mmol, 94%); Rf 0.29 (20% ethyl acetate in hexane); IR 
(thin film) 𝜈/cm–1: 2978 (C-H, w), 1725 (C=O carbamide, s), 1704 (C=O ester, s), 1197 (C-O, s). 
1H NMR (400 MHz, CDCl3) δ/ppm: 5.75 (s, 1H, H7), 4.79 (s, 2H, H6), 4.57 (s, 2H, H4), 4.15 (q, 
J = 7.0 Hz, 2H, H9), 1.43 (s, 9H, H1), 1.26 (t, J = 7.0 Hz, 3H, H10). 13C NMR (101 MHz, CDCl3) 
δ/ppm: 165.2 (C8), 156.2 (C3), 152.6 (C5), 113.7 (C7), 80.0 (C2), 60.4 (C6&9), 57.8 (C4), 28.3 (C1), 
14.3 (C10). HRMS (ESI) C12H19NO4Na m/z: [M+Na]+ 264.1215 (calc. 264.1212). 
The physical and spectroscopic data were found to be in agreement with Collier.239 
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2-(tert-Butyl) 8-ethyl 7-phenyl-5-oxa-2,6-diazaspiro[3.4]oct-6-ene-2,8-
dicarboxylate, 237 
 
Compound 236 (300 mg, 1.24 mmol, 1.0 eq) and 209 (1.16 g, 7.46 mmol, 6.0 eq) were dissolved 
in dichloromethane (20 mL). Triethylamine (1.17 mL, 8.43 mmol, 6.8 eq) was added dropwise 
and the reaction was stirred at RT for 1 h. Water (10 mL) was added and the reaction was 
washed with brine (10 mL). The combined organics were concentrated in vacuo and purified 
by column chromatography (30% ethyl acetate in hexane) to yield the product as an orange 
oil (349.6 mg, 0.97 mmol, 78%); Rf 0.38 (30% ethyl acetate in hexane) IR (thin film) 𝜈/cm–1: 
2978 (C-H, w), 1736 (C=O, s), 1698 (C=N, s), 1392 (N-O, s), 1153 (C-O, s). 1H NMR (400 MHz, 
CDCl3) δ/ppm: 7.68–7.66 (m, 2H, H14), 7.43–7.38 (m, 3H, H15&13), 4.45 (s, 1H, H7), 4.33 (dd, 
J = 10.5, 1.0 Hz, 1H, H4/5a), 4.25–4.14 (m, 4H, H9&4/5b), 4.05 (dd, J = 10.0, 1.0 Hz, 1H, H4b), 
1.45 (s, 9H, H1), 1.19 (t, J = 7.0 Hz, 3H, H10). 13C NMR (101 MHz, CDCl3) δ/ppm:167.0 (C8), 
155.9 (C3), 154.8 9C11), 130.8 (C15), 128.9 (C13), 128.0 (C12), 126.8 (C14), 83.4 (C5), 80.3 (C2), 
64.7 (C4/5), 62.4 9C9), 60.5 (C7), 57.3 (C4/5), 28.3 (C1), 14.0 (C10). HRMS (ESI) C19H25N2O5 
m/z: [M+H]+ 360.6087 (calc. 360.6085). 
 
2-(tert-Butyl) 8-ethyl 7-benzyl-2,5,6,7-tetraazaspiro[3.4]oct-5-ene-2,8-
dicarboxylate, 238 
 
Compound 236 (386 mg, 1.60 mmol, 1.0 eq) was dissolved in benzyl azide (2 mL, 16.0, 10.0 eq) 
and heated in a sealed tube at 100 °C for 48 h. This was purified via column chromatography 
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(30% ethyl acetate in pet. ether) to give the pure compound as a yellow oil (204 mg, 0.54 mmol, 
34%); Rf 0.49 (30% ethyl acetate in pet. ether) IR (thin film) 𝜈/cm–1: 2988 (C-H, w), 1726 (C=O, 
s), 1631 (C=C, m), 1115 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 7.30–7.17 (m, 5H, 
H13,14,15), 5.68 (br s, 2H, H4a&5a), 4.89 (br s, 2H, H4b&5b), 4.41 (q, J = 7.0 Hz, 2H, H9), 2.65 
(br s, 3H, H7&11), 1.42–1.38 (m, 12H, H1&10). 13C NMR (101 MHz, CDCl3) δ/ppm: 154.3 (C8), 
138.1 (C3), 128.9 (C12), 128.2 (C14), 127.6 (C13), 126.8 (C15), 89.5 (c7), 79.8 (C2), 59.0 (C9), 54.8 
(C6), 51.1 (d, J = 12.0 Hz, C4/5), 50.3 (d, J = 20.0 Hz, C4/5), 48.4 (C11), 28.4 (C1), 14.6 (C10). 
HRMS (ESI) C19H26N4O4Na m/z: [M+Na]+ 397.1840 (calc. 397.1846). 
 
(2-Hydroxy-5-oxo-5,6-dihydro-2H-pyran-2-yl)methyl acetate, 242 
 
To a suspension of sodium borohydride (225 mg, 5.95 mmol, 0.5 eq) in ethanol (26 mL) was 
added at 0 °C a solution of (5-acetylfuran-2-yl)methyl acetate (2 g, 11.89 mmol, 1.0 eq) in 
ethanol (34 mL) and the reaction was stirred for 10 min at 0 °C. Acetic acid was added 
dropwise until the sodium borohydride had been quenched. The resulting mixture was 
concentrated in vacuo and dissolved in water (80 mL). To this a solution of bromine (1.9 g, 
11.89 mmol, 1.0 eq) in methanol (6 mL) was added dropwise and the reaction was stirred for 
2 h. Sat. aq. NH4Cl was added dropwise until the mixture had reach pH 5. Brine was added 
and the mixture was extracted with ethyl acetate (3 × 50 mL). The combined organics were 
dried over anh. MgSO4, filtered, and concentrated in vacuo to give the pure product as an 
orange oil (1.3491 g, 7.25 mmol, 61%); IR (thin film) 𝜈/cm–1: 3375 (O-H, br s), 1740 (C=O ester, 
s), 1699 (C=O ketone, s), 1044 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 6.90 (d, J = 10.5 
Hz, 1H, H4), 6.18 (d, J = 10.5 Hz, 1H, H3), 4.61 (d, J = 17.0 Hz, 1H, H1a), 4.46 (d, J = 12.0 Hz, 
1H, H6a), 4.19 (d, J = 17.0 Hz, 1H, H1b), 4.08 (d, J = 12.0 Hz, 1H, H6b), 3.37 (br s, 1H, OH), 2.16 
(s, 3H, H8). 13C NMR (101 MHz, CDCl3) δ/ppm: 194.0 (C2), 171.1 (C7), 144.5 (C4), 128.2 (C3), 
92.2 (C5), 67.6 (C6), 66.5 (C1), 20.8 (C8). HRMS (ESI) C8H10O5Na m/z: [M+Na]+ 209.0416 (calc 
209.0420). 
The physical and spectroscopic data were found to be in agreement with Snider et al.206 
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(2-Acetoxy-5-oxo-5,6-dihydro-2H-pyran-2-yl)methyl acetate, 243 
 
To a solution of 242 (1.34 g, 7.20 mmol, 1.0 eq) in dichloromethane (85 mL) was added acetic 
anhydride (14.4 mL, 152.3 mmol 20.0 eq), 4-dimethylaminopyridine (0.09 mL, 0.72 mmol, 0.1 
eq), and pyridine (7.2 mL, 89.4 mmol, 12.5 eq) at 0 °C. The reaction was stirred for 30 min at 0 
°C. This was then washed with 10% aq. CuSO4 (50 mL), water (50 mL), sat. aq. NaHCO3 (50 
mL), and brine (50 mL). The organic layer was dried over anh. MgSO4, filtered and 
concentrated in vacuo to give the pure product as an amorphous blood-red solid (1.3357 g, 5.85 
mmol, 81%); IR (thin film) 𝜈/cm–1: 1736 (C=O ester ,s), 1699 (c=O ketone, m), 1211 (C-O, s). 
1H NMR (400 MHz, CDCl3) δ/ppm: 7.22 (d, J = 10.5 Hz, 1H, H7), 6.21 (d, J = 10.5 Hz, 1H, H6), 
4.59 (d, J = 17.0 Hz, 1H, H4a), 4.54 (d, J = 11.5 Hz, 1H, H8a), 4.42 (d, J = 11.5 Hz, 1H, H8b), 4.29 
(d, J = 17.0 Hz, 1H, H4b), 2.09 (s, 3H, H1/10), 2.07 (s, 3H, H1/10). 13C NMR (101 MHz, CDCl3) 
δ/ppm: 193.2 (C5), 170.1 (C2/9), 169.3 (C2/9), 143.3 (C7), 128.1 (C6), 97.3 (C3), 68.0 (C4), 65.0 
(C8), 21.2 (C1/10), 20.7 (C1/10). HRMS (ESI) C10H12O6 m/z: [M+Na]+ 251.0519 (calc. 251.0526). 
The physical and spectroscopic data were found to be in agreement with Snider et al.206 
 
10,12-Dioxo-3,11-dioxatricyclo[5.3.1.12,6]dodeca-4,8-diene-4,7-
diyl)bis(methylene) diacetate, 244 
 
The title compound was isolated as a by-product from the reaction to synthesise 245. Dark 
orange oil (30.1 mg, 0.09 mmol, 5%); Rf 0.12 (40% ethyl acetate in hexane); IR (thin film) 𝜈/cm–
1: 2977 (C-H, w), 1742 (C=O ester, s), 1698 (C=O ketone, s), 1223 (C-O, s). 1H NMR (400 MHz, 
CDCl3) δ/ppm: 6.83 (d, J = 10.5 Hz, 1H, H7), 6.30 (d, J = 10.5 Hz, 1H, H8), 4.91 (d, J = 9.0 Hz, 
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1H, H4), 4.80–4.76 (m, 2H, H2&10), 4.44–4.25 (m, 4H, H11&14), 3.27 (dd, J = 7.5, 2.5 Hz, 1H, 
H5), 2.21 (s, 3H, H16), 2.09 (s, 3H, H13). 13C NMR (101 MHz, CDCl3) δ/ppm: 198.3 (C1), 189.0 
(C9), 170.4 (C15), 170.3 (C12), 150.8 (C3), 147.9 (C7), 129.6 (C8), 101.0 (C2), 81.5 (C4), 81.4 (C6), 
75.9 (C10), 66.7 (C14), 61.7 (C11), 48.5 (C5), 20.8 (C13), 20.6 (C16). HRMS (ESI) C16H16O8Na 
m/z: [M+Na]+ 359.0743 (calc. 359.0743). 
The physical and spectroscopic data were found to be in agreement with Lee et al.240 
 
L-(+)-Prolinol, 254 
 
To a suspension of lithium aluminium hydride (2.47 g, 65.14 mmol, 15 eq) in THF (65 mL) was 
added portion-wise L-proline (5 g, 43.43 mmol, 1.0 eq) at 0 °C. The reaction was refluxed under 
nitrogen for 2h. This was cooled to RT and quenched with 20% aq. KOH (6.5 mL) the mixture 
was filtered and the residue was refluxed in THF for 45 min. This was filtered and combined 
to the previous filtrate and dried over MgSO4. This was filtered and concentrated in vacuo to 
give the crude product. This was purified by vacuum distillation (77–78 °C, 5 mbar) to give 
the pure product as a colourless oil (3.95 g, 39.09 mmol, 90%); IR (thin film) 𝜈/cm–1: 3294 (O-
H, br s), 2869 (C-H, s), 1457 (C-H, m), 1047 (C-O, s). 1H NMR (400 MHz, (CD3)2SO) δ/ppm: 
4.40 (br s, 1H, OH), 3.23 (d, J = 6.0 Hz, 2H, H5), 2.99 (qn, J = 6.0 Hz, 1H, H4), 2.80–2.75 (m, 1H, 
H1a), 2.72–2.66 (m, 1H, H1b), 1.71–1.54 (m, 3H, H3a&2), 1.35–1.27 (m, 1H, H3b). 13C NMR (101 
MHz, (CD3)2SO) δ/ppm: 64.7 (C5), 59.7 (C4), 46.0 (C1), 27.9 (C3), 25.2 (C2). HRMS (ESI) 
C9H4ClO2 m/z: [M+H]+ 102.0913 (calc. 102.0913). 
The physical and spectroscopic data was found to be in agreement with Widianti et al.210 
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1,3-Diiodoacetone, 256 
  
Sodium iodide (260.0 mg, 0.87 mmol, 2.2 eq) was dissolved in acetone (5 mL) and 1,3-
dichloroacetone (100 mg, 0.79 mmol, 1.0 eq) was added. The reaction was stirred at RT for 1h 
before being filtered and concentrated to give the pure product as a pure yellow solid (197 
mg, 0.64 mmol, 80%); IR (thin film) 𝜈/cm–1: 1710 (C=O, s). 1H NMR (400 MHz, CDCl3) 
δ/ppm: 4.11 (s, 4H, H1). 13C NMR (101 MHz, CDCl3) δ/ppm: 195.6 (C2), 1.3 (C1). 
The physical and spectroscopic data was found to be in agreement with Voronkov et al.110 
 
tert-Butyl((1,3-dichloropropan-2-yl)oxy)dimethylsilane, 262 
 
1,3-Dichloroisopropanol (2 mL, 11.48 mmol, 1.0 eq) and imidazole (1.17 g, 17.22 mmol, 1.5 eq) 
were dissolved in dichloromethane (35 mL). The mixture was cooled to 0 °C, tert-
butyldimethylsilyl chloride (2.59 g, 17.22 mmol, 1.5 eq) was added, and the reaction was 
stirred overnight at RT. This was quenched by addition of sat. aq. NH4Cl (30 mL). The layers 
were separated and the aqueous was extracted with diethyl ether (3 × 10 mL). The combind 
organics were washed with brine (30 mL), dried over anh. MgSO4, filtered, and the excess 
solvent was removed in vacuo to give the crude product. This was purified by column 
chromatography (10% diethyl ether in pet. ether) to yield the pure product as a colourless oil 
(2.25 g, 9.29 mmol, 81%); Rf 0.76 (10% diethyl ether in pet. ether); IR (thin film) 𝜈/cm–1: 2931 
(C-H, w), 1107 (C-O, m), 775 (C-Cl, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 4.03 (qn, J = 5.5 Hz, 
1H, H2), 3.62 (dd, J = 11.0, 5.5 Hz, 2H, H1a), 3.56 (dd, J = 11.0, 5.5 Hz, 2H, H1b), 0.91 (s, 9H, 
H5), 0.12 (s, 9H, H3). 13C NMR (101 MHz, CDCl3) δ/ppm: 72.2 (C2), 45.9 (C1), 25.7 (C5), 18.1 
(C4), –4.7 (C3). HRMS (ESI) C9H21Cl2SiO m/z: [M+H]+ 243.0730 (calc. 243.0739). 
The physical and spectroscopic data was found to be in agreement with Axenrod et al.241 
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(S)-(+)-4-Methylenehexahydro-1H,3H-pyrrolo[2,1-c][1,4]oxazepane, 266 
  
To a suspension of NaH (53% suspension in mineral oil, 1.86 g, 40.97 mmol, 2.0 eq) in THF 
(100 mL) at 0 °C under nitrogen L-prolinol (2 mL, 20.48 mmol, 1.0) was added dropwise. This 
was warmed to RT and stirred for 1 h. 3-Chloro-2-(chloromethyl)prop-1-ene (2.37 mL, 20.48 
mmol, 1.0 eq) was added dropwise and reaction was stirred for 2 h at 60 °C. Afterwards it was 
cooled to RT and the excess solvent was removed in vacuo. This was diluted with ethyl acetate 
(50 mL) and washed sat. aq. NH4Cl (30 mL). The aqueous was extracted with ethyl acetate (20 
mL). The combined organics were dried over MgSO4, filtered and concentrated in vacuo to 
give the crude product. This was purified by column chromatography (10% methanol in 
dichloromethane) to give the pure product as a colourless oil (1.1813 g, 7.71 mmol, 38%); Rf 
0.35 (10% methanol in dichloromethane); IR (thin film) 𝜈/cm–1: 2935 (C-H, m), 1643 (C=C, w), 
1102 (C-O, s). 1H NMR (400 MHz, CDCl3) δ/ppm: 4.89 (d, J = 14.0 Hz, 2H, H1), 4.34 (d, J = 
14.0 Hz, 1H, H3a), 4.25 (d, J = 14.0 Hz, 1H, H3b), 3.90 (dd, J = 12.0, 2.5 Hz, 1H, H8a), 3.63 (d, J 
= 15.0 Hz, 1H, H9a), 3.27–3.21 (m, 2H, H8b&9b), 3.08–3.03 (m, 1H, H4a), 2.61–2.54 (m, 1H, H7), 
2.43–2.37 (m, 1H, H4b), 1.92–1.68 (m, 3H, H6a&5), 1.40–1.31 (m, 1H, H6b). 13C NMR (101 MHz, 
CDCl3) δ/ppm: 146.9 (C2), 111.8 (C1), 76.5 (C8), 74.9 (C3), 67.8 (C7), 58.5 (C9), 56.2 (C4), 27.2 
(C6), 22.6 (C5). HRMS (ESI) C9H16NO m/z: [M+H]+ 154.1221 (calc. 154.1226). [𝛂]𝐃
𝟐𝟎 +110.0 (c = 
1.00, CHCl3).
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A. Spectra 
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2,2’-(4,5-Dichloro-1,2-phenylene)bis(ethan-1-aminium) dichloride, 29
 
Spectra 
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2,2’-(4,5-Dichloro-1,2-phenylene)diacetonitrile, 30
 
Spectra 
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1,2-Bis(bromomethyl)-4,5-dichlorobenzene, 31
 
Spectra 
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(4,5-Dichloro-1,2-phenylene)dimethanol, 32
 
Spectra 
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Dimethyl 4,5-dichlorophthalate, 34
 
Spectra 
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Di-tert-butyl ((4,5-dichloro-1,2-phenylene)bis(ethane-2,1-diyl))dicarbamate, 
35
  
Spectra 
224 
 
(4,5-Dichloro-1,2-phenylene)dimethanaminium dichloride, 38 
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2-(4-Chloronaphthalen-1-yl)ethan-1-aminium chloride, 39 
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1-Acetyl-4-chloronaphthalene, 41 
 
 
Spectra 
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4-Chloro-1-naphthoic acid, 42 
 
 
Spectra 
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(4-Chloronaphthalen-1-yl)methanol, 43 
 
 
Spectra 
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1-(Bromomethyl)-4-chloronaphthalene, 44 
 
 
Spectra 
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2-(4-Chloronaphthalen-1-yl)acetonitrile, 45 
 
 
Spectra 
231 
 
Methyl 2-bromo-4-chlorobenzoate, 49 
 
 
Spectra 
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Methyl 4-chloro-2-((trimethylsilyl)ethynyl)benzoate, 50 
 
 
Spectra 
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4-Chloro-2-ethynyl benzoic acid, 51 
 
 
Spectra 
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Hydroxycarbonimidic dibromide, 70
 
Spectra 
235 
 
tert-Butyldimethyl(prop-2-yn-1-yloxy)silane, 72
 
Spectra 
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3-Bromo-5-(((tert-butyldimethylsilyl)oxy)methyl)isoxazole, 73
 
 
Spectra 
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Spiro[indoline-3,4’-piperidin]-1’-ium chloride, 85 
 
Spectra 
238 
 
2,3-Dihydrospiro[indene-1,4’-piperidin]-1’-ium chloride, 86 
 
Spectra 
239 
 
tert-Butyl bis(2-chloroethyl)carbamate, 92
  
Spectra 
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4-Cyano-4-(2-fluorophenyl)piperidin-1-ium chloride, 95 
 
Spectra 
241 
 
tert-Butyl 4-cyano-4-(2-fluorophenyl)piperidine-1-carboxylate, 96 
 
Spectra 
242 
 
N-Benzyl-2-chloro-N-(2-chloroethyl)ethan-1-amine, 98 
 
Spectra 
243 
 
1’-Benzylspiro[indene-1,4’-piperidine], 100 
 
Spectra 
244 
 
1’-Benzyl-2,3-dihydrospiro[indene-1,4’-piperidine], 101
  
Spectra 
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tert-Butyl spiro[indene-1,4’-piperidine]-1’-carboxylate, 102
  
Spectra 
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Spiro[indene-1,4’-piperidin]-1’-ium chloride, 103 
 
Spectra 
247 
 
tert-Butyl 2-oxo-3,4-dihydroquinoline-1(2H)-carboxylate, 105 
 
Spectra 
248 
 
1-(tert-Butyl) 4-ethyl piperidine-1,4-dicarboxylate, 109
  
Spectra 
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1-(tert-Butyl) 4-ethyl 4-(2-nitrobenzyl)piperidine-1,4-dicarboxylate, 111
 
Spectra 
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1-(tert-Butyl) 4-ethyl 4-(2-aminobenzyl)piperidine-1,4-dicarboxylate, 112
 
Spectra 
251 
 
6-Chloro-1H-indene, 115
 
Spectra 
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tert-Butyl 6-chlorospiro[indene-1,4’-piperidine]-1’-carboxylate, 116
 
Spectra 
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6-Chlorospiro[indene-1,4’-piperidin]-1’-ium chloride, 117
 
Spectra 
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6-Chloro-2,3-dihydrospiro[indene-1,4’-piperidin]-1’-ium chloride, 118
 
Spectra 
255 
 
8-Chloro-2-(ethoxycarbonyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-5-ium 
chloride, 121
 
Spectra 
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8-Chloro-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-2-ium chloride, 122
  
Spectra 
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Ethyl (diphenylmethylene)glycinate, 140 
 
Spectra 
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Ethyl 2-((diphenylmethylene)amino)hex-5-enoate, 141 
 
 
Spectra 
259 
 
Ethyl 2-allyl-2-aminohex-5-enoate, 142 
 
Spectra 
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Ethyl 2-allyl-2-((tert-butoxycarbonyl)amino)hex-5-enoate, 143 
 
 
Spectra 
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Ethyl 1-((tert-butoxycarbonyl)amino)cyclohex-3-ene-1-carboxylate, 144 
 
 
Spectra 
262 
 
tert-Butyl (1-(hydroxymethyl)cyclohex-3-en-1-yl)carbamate, 145 
 
 
Spectra 
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1-(Hydroxymethyl)cyclohex-3-en-1-aminium chloride, 146 
 
 
Spectra 
264 
 
tert-Butyl (4-(hydroxymethyl)octa-1,7-dien-4-yl)carbamate, 147 
 
Spectra 
265 
 
3-Oxa-1-azaspiro[4.5]dec-7-en-2-one, 148 
 
 
Spectra 
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Ethyl benzimidate hydrochloride, 150 
 
 
Spectra 
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2-Phenyl-3-oxa-1-azaspiro[4.5]deca-1,7-diene, 151 
 
 
Spectra 
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3-Oxa-1-azaspiro[4.5]deca-1,7-dien-2-amine, 152 
 
 
Spectra 
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4-Oxa-1-azaspiro[5.5]undec-8-en-3-one, 158 
 
 
Spectra 
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4-Oxa-1-azaspiro[5.5]undeca-1,8-dien-3-one, 159 
 
 
Spectra 
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2-Chloro-N-(1-(hydroxymethyl)cyclohex-3-en-1-yl)acetamide, 160 
 
 
Spectra 
272 
 
4-Oxa-1-azaspiro[5.5]undec-8-en-2-one, 161 
 
 
Spectra 
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Ethyl 2-allyl-2-(3-ethoxy-3-oxopropanamido)hex-5-enoate, 165 
 
Spectra 
274 
 
5-Allyl-5-(but-3-en-1-yl)pyrrolidine-2,4-dione, 167 
 
 
Spectra 
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1-Azaspiro[4.5]dec-7-ene-2,4-dione, 168 
 
Spectra 
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4-Ethoxy-1-azaspiro[4.5]deca-3,7-dien-2-one, 174 
 
 
Spectra 
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2-Oxo-1-azaspiro[4.5]deca-3,7-dien-4-yl trifluoromethanesulfonate, 175 
 
 
Spectra 
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4-(4-Methoxyphenyl)-1-azaspiro[4.5]deca-3,7-dien-2-one, 176 
 
 
Spectra 
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4-Hydroxy-1-azaspiro[4.5]dec-7-en-2-one, 177 
 
 
Spectra 
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2-Oxo-1-azaspiro[4.5]dec-7-en-4-yl methanesulfonate, 178 
 
 
Spectra 
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1-Azaspiro[4.5]deca-3,7-dien-2-one, 179 
 
 
Spectra 
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2-Allyl-2-((tert-butoxycarbonyl)amino)hex-5-enoic acid, 184 
 
 
Spectra 
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Ethyl (tert-butoxycarbonyl)-L-serinate, 201 
 
 
Spectra 
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Ethyl 2-((tert-butoxycarbonyl)amino)acrylate, 202 
 
 
Spectra 
285 
 
4-Methyloxazol-2(3H)-one, 204 
 
 
Spectra 
286 
 
Ethyl 4-((tert-butoxycarbonyl)amino)-3-phenyl-4,5-dihydroisoxazole-4-
carboxylate, 210 
 
 
Spectra 
287 
 
tert-Butyl (4-(hydroxymethyl)-3-phenyl-4,5-dihydroisoxazol-4-yl)carbamate, 
211 
 
 
Spectra 
288 
 
3-Phenyl-1,8-dioxa-2,6-diazaspiro[4.4]non-2-en-7-one, 212 
 
 
Spectra 
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Ethyl (2-chloroacetyl)-l-serinate, 214 
 
Spectra 
290 
 
Ethyl N,O-bis(2-chloroacetyl)-L-serinate, 215 
 
 
Spectra 
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Ethyl (S)-2-oxooxazolidine-4-carboxylate, 219 
 
 
Spectra 
292 
 
Ethyl (S)-2-phenyl-4,5-dihydrooxazole-4-carboxylate, 221 
 
 
Spectra 
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(R)-(2-Phenyl-4,5-dihydrooxazol-4-yl)methanol, 222 
 
 
Spectra 
294 
 
Ethyl O-(tert-butyldimethylsilyl)-l-serinate, 224 
 
 
Spectra 
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Ethyl O-(tert-butyldimethylsilyl)-N-(2-chloroacetyl)-l-serinate, 225 
 
 
Spectra 
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 (R)-N-(1-((tert-Butyldimethylsilyl)oxy)-3-hydroxypropan-2-yl)-2-
chloroacetamide, 226 
 
 
Spectra 
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Ethyl O-(tert-butyldimethylsilyl)-N-(3-ethoxy-3-oxopropanoyl)-l-serinate, 
228 
 
 
Spectra 
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4-Ethoxy-5-methylene-1,5-dihydro-2H-pyrrol-2-one, 230 
 
 
Spectra 
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tert-Butyl 3-(2-ethoxy-2-oxoethylidene)azetidine-1-carboxylate, 236 
 
 
Spectra 
300 
 
2-(tert-Butyl) 8-ethyl 7-phenyl-5-oxa-2,6-diazaspiro[3.4]oct-6-ene-2,8-
dicarboxylate, 237 
 
 
Spectra 
301 
 
2-(tert-Butyl) 8-ethyl 7-benzyl-2,5,6,7-tetraazaspiro[3.4]oct-5-ene-2,8-
dicarboxylate, 238 
 
Spectra 
302 
 
(2-Hydroxy-5-oxo-5,6-dihydro-2H-pyran-2-yl)methyl acetate, 242 
 
 
Spectra 
303 
 
10,12-Dioxo-3,11-dioxatricyclo[5.3.1.12,6]dodeca-4,8-diene-4,7-
diyl)bis(methylene) diacetate, 244 
 
 
Spectra 
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L-(+)-Prolinol, 254 
 
Spectra 
305 
 
1,3-Diiodoacetone, 256 
 
 
 
Spectra 
306 
 
tert-Butyl((1,3-dichloropropan-2-yl)oxy)dimethylsilane, 262 
 
Spectra 
307 
 
(S)-(+)-4-Methylenehexahydro-1H,3H-pyrrolo[2,1-c][1,4]oxazepane, 266 
 
308 
 
309 
 
Appendix B 
B. Crystallographic Data 
  
Crystallographic Data 
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4-(4-Methoxyphenyl)-1-azaspiro[4.5]deca-3,7-dien-2-one, 176 
Identification code DS_B1_0023  
Empirical formula C16H17NO2  
Formula weight 255.3170 gmol–1  
Temperature 180 (2) K  
Crystal system Triclinic  
Space group P1̅  
Unit cell dimensions a = 5. 9870(3) Å α = 71.715(3)° 
 b = 9.9585(5) Å β = 83.642(3)° 
 c = 11.5405(6) Å γ = 89.345(3)° 
Volume 649.104 Å3  
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1-Azaspiro[4.5]deca-3,7-dien-2-one, 179 
Identification code DS_B1_0024  
Empirical formula C9H11NO  
Formula weight 149.19 gmol–1  
Temperature 180(2) K  
Crystal system Orthorhombic  
Space group Pna22  
Unit cell dimensions a = 10.2930(5) Å α = 90° 
 b = 9.8937(5) Å β = 90° 
 c = 7.6125(4) Å γ = 90° 
Volume 775.25 Å3  
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3-Phenyl-1,8-dioxa-2,6-diazaspiro[4.4]non-2-en-7-one, 212 
Identification code DS_B1_0017  
Empirical formula C11H10N2O3  
Formula weight 218.2120 gmol–1  
Temperature 180(2) K  
Wavelength 1.54178 Å  
Crystal system Triclinic  
Space group P1̅(2)  
Unit cell dimensions a = 5.3405(3) Å α = 78.073(4)° 
 b = 8.0452(5) Å β = 77.997(4)° 
 c = 12.0561(7) Å γ = 81.581(4)° 
Volume 492.828 Å3  
Z 2  
Density (calculated) 1.470 gcm–3  
Absorption coefficient 0.914 mm–1  
F(000) 228  
Crystal size 0.180 × 0.040 × 0.020 mm3  
Theta range for data colletion 3.81–66.58°  
Index ranges –6 ≤ h ≤ 3, –9 ≤ k ≤ 9, –14 ≤ l ≤ 13 
Reflections collected 4038  
Independent reflections 1723  
Completeness to theta = 66.58° 98.7%  
Absorption correction Multi-scan  
Max. and min. transmission 0.7528 and 0.6366  
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 1723/0/149  
Goodness-of-fit F2 1.036  
Final R indices [I > 2σ(I)] R1 = 0.0482, wR2 = 0.1032  
R indices (all data) R1 = 0.0790, wR2 = 0.1153  
Largest diff. peak and hole 0.224 and –0.250 eÅ–3  
Crystallographic Data 
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3-Oxa-1-azaspiro[4.5]deca-1,7-dien-2-amine, 152 
Identification code DS_B1_0020  
Empirical formula C8H12N2O  
Formula weight 152.1970 gmol–1  
Temperature 180(2) K  
Wavelength 1.54056 Å  
Crystal system Monoclinic  
Space group P21/c  
Unit cell dimensions a = 10.3028(8) Å α = 90° 
 b = 7.6579(5) Å β = 91.728(5)° 
 c = 10.3040(8) Å γ = 90° 
Volume 812.593 Å3  
Z 4  
Density (calculated) 1.244 gcm–3  
Absorption coefficient 0.678 mm-1  
F(000) 328  
Crystal size 0.250 × 0.060 × 0.020 mm3  
Theta range for data colletion 4.29–66.73°  
Index ranges –12 ≤ h ≤ 12, –9 ≤ k ≤ 9, –12 ≤ l ≤ 12 
Reflections collected 9075  
Independent reflections 1443  
Completeness to theta = 66.73° 99.9%  
Absorption correction Multi-scan  
Max. and min. transmission 0.987 and 0.849  
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 1443/0/108  
Goodness-of-fit F2 1.094  
Final R indices [I > 2σ(I)] R1 = 0.0465, wR2 = 0.1122  
R indices (all data) R1 = 0.0583, wR2 = 0.1185  
Largest diff. peak and hole 0.189 and –0.184 eÅ–3  
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Appendix C 
C. Computational analysis 
C.1. Reference Set 
The following are the small molecule drugs from the top 50 best-selling drugs of 2013: 
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C.2. Principle Moment of Inertia 
Using MOE 2018.0602 the following parameters were used in conformer searching: 
Table C.1 Conformational search settings. 
Force field MMFF94x 
Solvation Born 
Method LowModeMD 
Rejection Limit 100 
RMS Gradient 0.005 
Iteration Limit 10000 
MM Iteration Limit 500 
RMSD Limit 0.15 
Energy Window 3 
Conformation Limit 200 
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C.3. Principle Component Analysis 
Using MOE 2018.0602 the following structural and physico-chemical parameters were used 
in PCA: 
Table C.2 Structural and physcio-chemical parameters used in PCA. 
Parameter Description 2D or 3D 
ASA_H Total hydrophobic surface area 3D 
ASA_P Total polar surface area 3D 
a_acc Number of hydrogen bond acceptor atoms 2D 
a_aro Number of aromatic rings 2D 
a_don Number of hydrogen bond donor atoms 2D 
a_nN Number of nitrogen atoms 2D 
a_nO Number of oxygen atoms 2D 
b_rotN Number of rotatable bonds 2D 
chiral Number of chiral centres 2D 
KierFlex Molecular flexibility 2D 
logS Log solubility in water 2D 
mr Molar refractivity 2D 
rings Number of rings 2D 
SlogP Log octanol/water partition coefficient 2D 
TPSA Topological polar surface area (Å2) 2D 
vol Van der Waals volume 3D 
weight Molecular weight 2D 
 
The following settings were used in the principle component analysis: 
Table C.3 Principle component settings. 
Weight field None 
Prefix PCA 
Component limit 0 
Minimum variance (%) 95 
Condition limit 1e+006 
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C.4. LLAMA Parameters 
The following reactions were used in the LLAMA program to elaborate the spirocyclic 
scaffolds 
Table C.4 Reactions used in LLAMA elaboration.  
Reductive amination 
Buchwald-Hartwig amination 
Sulfonamide formation 
Urea formation 
Alcohol alkylation 
Carbamate formation 
Secondary amide alkylation 
Esterification 
Secondary amide arylation 
Amide formation 
Alcohol arylation 
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Novel non-ATP competitive small molecules targeting the CK2 α/β interface 
Paul Brear, Andrew North, Jessica Iegre, Kathy Hadje Georgiou, Alexandra Lubin, Laura 
Carro, William Green, Hannah F. Sore, Marko Hyvönen, David R. Spring 
https://doi.org/10.1016/j.bmc.2018.05.011 
 
This paper contains the research the Spring Group has done into elaborating NMR154 and 
NMR154L to find novel non-ATP competitive fragments which inhibit the interface site CK2. 
I was given responsibility to write a publication bringing together all the group’s work in this 
field. This first involved analysing the 144 molecules which had been synthesised to bind at 
the interface. These were then sorted into groups based on the vectors of NMR154 which had 
been elaborated, or if they were not NMR154 based. With the data in hand I wrote the entire 
manuscript, compiled the supplementary information, and synthesised a couple of 
compounds to record missing data. 
 
 
